Official Protocol Title:
NCT number:                [STUDY_ID_REMOVED]
Document Date:            26-Mar-2024             
A Phase 3 Randomized, Active-Controlled, Open-Label 
Clinical Study to Evaluate a Switch to Doravirine/
Islatravir (DOR/ISL) Once-Daily in Participants With 
HIV-[ADDRESS_916776]: MK-8591A  1
PROTOCOL/AMENDMENT NO.: 017-09
MK-8591A -017-09 FINAL PROTOCOL 26-MAR -2024
Title Page
THIS PROTOCOL AMENDMENT AND ALL OF THE INFORMATION RELATING 
TO IT ARE CONFIDENTIAL AND PROPRIETARY PROPERTY OF MERCK 
SHARP & DOHME LLC, RAHWAY, NJ, [LOCATION_003] (MSD) .
Protocol Title: A Phase 3 Randomized, Active -Controlled, Open -Label Clinical Study to 
Evaluate a Switch to Doravirine/Islatravir (DOR/ISL) Once -Daily in Participants With 
HIV-1 Virologically Suppressed on Antiretroviral Therapy
Protocol Number: 017-09
Compound Number: MK-8591A
Sponsor Name:
[CONTACT_19519] & Dohme LLC
(hereafter called the Sponsor or MSD)
Legal Registered Address:
[ADDRESS_916777], NJ [ZIP_CODE] [LOCATION_003]
Regulatory Agency Identifying Number(s):
IND [ADDRESS_916778] 2019- 000586- 20
Approval Date: [ADDRESS_916779]: MK-8591A  2
PROTOCOL/AMENDMENT NO.: 017-09
MK-8591A -017-09 FINAL PROTOCOL 26-MAR -2024
Sponsor Signatory
Typed Name:
[CONTACT_1641]:Date
Protocol -specific Sponsor c ontact information can be found in the Investigator Study
File Binder (or equivalent).
Investigator Signatory
I agree to conduct this clinical study in accordance with the design outlined in this protocol 
and to abide by [CONTACT_19373].
Typed Name:
[CONTACT_1641]:Date
08WCSH
PRODUCT: MK-8591A  3
PROTOCOL/AMENDMENT NO.: 017-[ADDRESS_916780] -treatment management of participants 
with specific decreases in CD4+ T -cell or total lymphocyte counts.
 
Amendment [ADDRESS_916781] -2022 [COMPANY_006] Sharp & Dohme Corp. underwent an entity name [CONTACT_432053] & Dohme LLC, Rahway, NJ, [LOCATION_003]. This conversion resulted only in an entity 
name [CONTACT_26406].
Amendment 0 7 31-MAR -2022 Given the findings of decrease s inCD4+ T-cell andtotal lymphocyte counts in clinical 
studies evaluating ISL , the protocol is being amended to include an optional
plasma/PBMC PK substudy tobe conducted at selected sites in the [LOCATION_002] to 
measure ISL in plasma and ISL -TP in PBMCs to evaluate steady -state levels in 
participants living with HIV, with long -term dosing of ISL .Note: The changes made 
in US country- specific a mendment 07 were not implemented at clinical sites. 
Amendment 06 20-JAN- 2022 Given the findings of decreases in CD4+ T -cell and total lymphocyte counts in clinical 
studies evaluating ISL, the protocol is being amended t o increase the frequency of 
monitoring of CD4+ T -cell and total lymphocyte counts and to specify the 
management of participants who meet protocol -defined decrease sin CD4+ T -cell 
and/or total lymphocyte counts.
CCI
08WCSH
PRODUCT: MK-8591A  4
PROTOCOL/AMENDMENT NO.: 017-09
MK-8591A -017-09 FINAL PROTOCOL 26-MAR -2024
Document Date of Issue Overall Rationale
Amendment 05 07-DEC -2021 To increase frequency of monitoring of CD4+ T -cell counts and lymphocyte counts ,
and to add discontinuation criteria in response to findings of decreases in CD4+ T -cell 
counts (in studies of participants with HIV) and lymphocytes (in studies of participants 
with or without HIV) in ISL clinical studies. Note: The changes made in 
Amendment 05 were not implemented at clinical sites. Amendment 06 supersedes 
Amendment 05.
Amendment 04 02-APR -2021 Additional PK sampling and increased safety monitoring for participants who become 
pregnant and continue study intervention .Increased safety data collection for infants 
born to participants who become pregnant. 
Amendment 03 13-NOV- 2020 The main reasons the protocol was amended were to: (1) permit continued 
administration of study intervention in participants who become pregnant (where 
allowed by [CONTACT_677681]/local standard -
of-care guidelines), (2) add a discontinuation crit erion if a participant chooses to 
breastfeed, and (3) update dose modification instructions.
Amendment 02 08-MAY -2020 The protocol was amended to: (1) allow participants to rescreen one time following 
approval from the Sponsor , and (2) add a scheduled stu dy visit at Week 52 so that 
participants in Group 2 can be monitored 4 weeks after switching to DOR/ISL.
Amendment [ADDRESS_916782]: MK-8591A  5
PROTOCOL/AMENDMENT NO.: 017-09
MK-8591A -017-09 FINAL PROTOCOL 26-MAR -2024
PROTOCOL AMENDMENT SUMMARY OF CHANGES
Amendment: 09
Overall Rationale for the Amendment:
The protocol was amended to revise the post -treatment management of participants with 
specific decreases in CD4+ T -cell or total lymphocyte counts. The recovery criteria were 
revised to account for normal physiologic variability in CD4+ T -cell or total lym phocyte 
counts and the frequency of monitoring was updated to minimize the burden on study 
participants .
Summary of Changes Table
Section Number and 
Name [CONTACT_19522] [IP_ADDRESS] ,
Participants 
Discontinued from Study 
Intervention Due to 
Decreased CD4+ T -cell 
Count and/or Total 
Lymphocyte CountRevised the post -treatment 
management of participants by 
 
[CONTACT_677682] 1 participants who 
discontinued DOR/ISL .
CCI
CCI
08WCSH
PRODUCT: MK-8591A  6
PROTOCOL/AMENDMENT NO.: 017-09
MK-8591A -017-09 FINAL PROTOCOL 26-MAR -2024
Section Number and 
Name [CONTACT_326681] 1.3.4 ,Schedule 
of Activities for 
Participants With
Specified Decreases in 
CD4+ T -cell Counts 
and/or Total 
Lymphocyte CountsSee rationale for Section [IP_ADDRESS]
Section 6.7, Intervention 
After the End of the 
StudyRefer to Section 8.11 .5.2
Section [IP_ADDRESS] ,End of 
Treatment Follow -up
Visit Refer to Section [IP_ADDRESS]
Section [IP_ADDRESS] ,
Participants 
Discontinued from Study 
Intervention For Other 
Reasons AND Have 
Decreases in CD4+ 
T-cell Count and/or 
Total Lymphocyte CountRemoved monitoring details to refer 
to Section [IP_ADDRESS] .Refer to Section [IP_ADDRESS]
Section 10.2, Appendix 
2: Clinical Laboratory 
TestsRemoved frequency of monitoring 
visitsfrom footnote ‘e’ of Table 16Refer to Section [IP_ADDRESS]
Section 10.10 ,Appendix 
10:Summary of Protocol 
Clarification LettersAdded Appendix [ADDRESS_916783]: MK-8591A  7
PROTOCOL/AMENDMENT NO.: 017-09
MK-8591A -017-09 FINAL PROTOCOL 26-MAR -2024
TABLE OF CONTENTS
DOCUMENT HISTORY ........................................................................................................ 3
PROTOCOL AMENDMENT SUMMARY OF CHANGES ............................................... 5
1 PROTOCOL SUMMARY ............................................................................................ 16
1.1 Synopsis ................................................................................................................. 16
1.2 Schema .................................................................................................................. 21
1.3 Schedule of Activities (SoA) ................................................................................ 22
1.3.1 Schedule of Activities .................................................................................. 22
1.3.2 Schedule of Activities – Viremia Confirmation and End of Treatment 
(For All Participants Except Those With Specified Decreases in CD4+ 
T-cell and/or Tota l Lymphocyte Counts) .................................................... 29
1.3.3 Schedule of Activities for Participants Whose Pregnancy or Postpartum 
Visit(s) Extends Beyond Week 96 ............................................................... 31
1.3.4 Schedule of Activities for Participants With Specified Decreases in 
CD4+ T- cell Counts and/or Total Lymphocyte Counts ............................... 33
2 INTRODUCTION .......................................................................................................... 36
2.1 Study Rationale ....................................................................................................36
2.2 Background .......................................................................................................... 36
2.2.1 Islatravir .......................................................................................................36
2.2.2 Doravirine ....................................................................................................37
2.2.3 Doravirine/Islatravir..................................................................................... 37
2.2.4 Information on Other Study -related Therapy .............................................. 38
2.3 Benefit/Risk Assessment ...................................................................................... 38
3 HYPOTHESES, OBJECTIVES, AND ENDPOINTS ................................................ 39
4 STUDY DESIGN ............................................................................................................ 45
4.1 Overall Design ......................................................................................................45
4.2 Scientific Rationale for Study Design ................................................................ .46
4.2.1 Rationale for Endpoints ............................................................................... 46
[IP_ADDRESS] Efficacy Endpoints ............................................................................. 46
[IP_ADDRESS].1 HIV-1 RNA Measurements ..................................................... 46
[IP_ADDRESS].2 Definition of Clinically Significant Confirmed Viremia .........46
[IP_ADDRESS] Safety Endpoints ................................................................................ 47
[IP_ADDRESS] Weight, Laboratory, and Radiological Markers ................................ 47
[IP_ADDRESS] Pharmacokinetic Endpoints ............................................................... 48
[IP_ADDRESS] Patient -reported Outcomes ................................................................ .48
[IP_ADDRESS] Planned Exploratory Biomarker Research .........................................49
[IP_ADDRESS].1 Planned Genetic Analysis ........................................................ 49
[IP_ADDRESS] Future Biomedical Research .............................................................. [ADDRESS_916784]: MK-8591A  8
PROTOCOL/AMENDMENT NO.: 017-09
MK-8591A -017-09 FINAL PROTOCOL 26-MAR -2024
4.2.2 Rationale for the Use of Comparator/Placebo ............................................. 49
4.2.3 Rationale for the Selected Participant Population .......................................50
4.2.4 Rationale for Collecting Race and Ethnicity Data .......................................50
4.2.5 Rationale for Collecting Gender Identity Data ............................................ 51
4.2.6 Rationale for Infant Safety Data Collection ................................................. 51
4.2.7 Rationale for Continuing Study Intervention During Pregnancy ................ 51
4.3 Justification for Dose ........................................................................................... 52
4.4 Beginning and End of Study Definition ............................................................. 53
4.4.1 Clinical Criteria for Early Study Termination ............................................. 53
5 STUDY POPULATION ................................................................................................ 53
5.1 Inclusion Criteria ................................................................................................ .53
5.2 Exclusion Criteria ................................................................................................ 55
5.3 Lifestyle Considerations ...................................................................................... 57
5.4 Screen Failures .....................................................................................................57
5.5 Participant Replacement Strategy ......................................................................57
6 STUDY INTERVENTION ............................................................................................ 57
6.1 Study Intervention(s) Administered ...................................................................57
6.2 Preparation/Handlin g/Storage/Accountability ................................................. 59
6.2.1 Dose Preparation .......................................................................................... 59
6.2.2 Handling, Storage, and Accountability ........................................................ 59
6.3 Measures to Minimize Bias: Randomization and Bl inding .............................. 60
6.3.1 Intervention Assignment.............................................................................. 60
6.3.2 Stratification ................................................................................................ .60
6.3.3 Blinding ........................................................................................................60
6.4 Study Intervention Compliance .......................................................................... 60
6.5 Concomitant Therapy .......................................................................................... 61
6.5.1 Rescue Medications and Supportive Care ................................................... 62
6.6 Dose Modification (Escalation/Titration/Other) ............................................... [ADDRESS_916785]: MK-8591A  9
PROTOCOL/AMENDMENT NO.: 017-09
MK-8591A -017-09 FINAL PROTOCOL 26-MAR -2024
[IP_ADDRESS] General Informed Consent ................................................................ .67
[IP_ADDRESS] Consent and Collection of Specimens for Future Biomedical 
Research ............................................................................................. 68
[IP_ADDRESS] Consent for Postnatal Infant Safety Data Collection Through One 
Year of Age ........................................................................................ 68
[IP_ADDRESS] Consent for Continuation of Study Intervention During 
Pregnancy ........................................................................................... 68
[IP_ADDRESS] Consent to Pa rticipate in the Optional Plasma/PBMC PK 
Substudy (Applicable Only to the [LOCATION_002]) .............................. 68
8.1.2 Inclusion/Exclusion Criteria ........................................................................[ADDRESS_916786] .....................................................................68
8.1.4 Medical History ........................................................................................... 69
8.1.5 Prior and Concomitant Medications Review ............................................... 69
[IP_ADDRESS] Prior Medic ations ............................................................................... 69
[IP_ADDRESS] Concomitant Medications ..................................................................69
8.1.6 Assignment of Screening Number ............................................................... 69
8.1.7 Assignment of Treatment/Randomization Number .....................................69
8.1.8 Study Intervention Administration .............................................................. 70
[IP_ADDRESS] Timing of Dose Administration ......................................................... 70
8.1.9 Discontinuation and Withdrawal ................................................................ .70
[IP_ADDRESS] Withdrawal From Future Biomedical Research ................................ 71
8.1.10 Participant Blinding/Unblinding ..................................................................71
8.1.11 Calibration of E quipment ............................................................................. 71
8.1.12 Administration of Patient Questionnaires .................................................... 72
8.2 Efficacy Assessments ........................................................................................... 72
8.2.1 HIV-1 RNA ..................................................................................................72
8.2.2 Management of Study P articipants With Viremia .......................................72
[IP_ADDRESS] Viremia Confirmation ........................................................................72
[IP_ADDRESS] Participants With Clinically Significant Viremia ( ≥200 
Copi[INVESTIGATOR_014]/mL) ........................................................................................ 73
[IP_ADDRESS] Participants With Low -level Viremia ( ≥50and <200 Copi[INVESTIGATOR_014]/mL) ...73
[IP_ADDRESS] Viral Drug Resistance Testing ........................................................... 73
8.2.3 T-and B -Lymphocyte and Natural Killer Cell Profile (TBNK) .................. 73
8.3 Safety Assessments ............................................................................................... 73
8.3.1 Physical Examinations ................................................................................. 74
[IP_ADDRESS] Weight ................................................................................................ [ADDRESS_916787]: MK-8591A  10
PROTOCOL/AMENDMENT NO.: 017-09
MK-8591A -017-09 FINAL PROTOCOL 26-MAR -2024
8.3.5 Clinical Safety Laboratory Assessments ..................................................... 75
8.3.6 HBV Assessments ........................................................................................ 76
8.3.7 Tobacco and Alcohol Assessments .............................................................. 76
8.4 Adverse Events (AEs), Serious Adverse Events (SAEs), and Other 
Reportable Safety Events .................................................................................... 76
8.4.1 Time Period and Frequency for Collecting AE, SAE, and Other 
Reportable Safety Event Inf ormation .......................................................... 77
8.4.2 Method of Detecting AEs, SAEs, and Other Reportable Safety Events ......80
8.4.3 Follow -up of AE, SAE, and Other Reportable Safety Event Information ...80
8.4.4 Regulatory Reporting Requirements for SAE ............................................. 80
8.4.5 Pregnancy and Exposure During Breastfeeding .......................................... 80
8.4.6 Disease -related Events and/or Disease -related Outcomes Not Qualifying 
as AEs or SAEs ............................................................................................ [ADDRESS_916788] (ECIs) ................................................................ [ADDRESS_916789] and Hip Measurements ......................................................................84
8.8.6 DEXA Assessments ..................................................................................... 84
8.9 Future Biomedical Research Sample Collection ............................................... 85
8.10 Health Economics Medical Resource Utilization and Health Economics .......85
8.11 Visit Requirements ............................................................................................... 85
8.11.1 Screening/Rescreening ................................................................................. 85
8.11.2 Treatment Period .......................................................................................... 86
[IP_ADDRESS] Fasting ................................................................................................ 86
[IP_ADDRESS] Switch ................................................................................................ 86
[IP_ADDRESS] Optional Nurse Visits and Telephone Visits ......................................87
[IP_ADDRESS] End of Study Week 96 Visit .............................................................. 87
8.11.3 Participants Who Discontinue Study Intervention .......................................87
[IP_ADDRESS] Early Discontinuation of Treatment ................................................... 88
[IP_ADDRESS] End of Treatment Follow -up Visit ..................................................... [ADDRESS_916790]: MK-8591A  11
PROTOCOL/AMENDMENT NO.: 017-09
MK-8591A -017-09 FINAL PROTOCOL 26-MAR -2024
8.11.5 Management of Participants with Decreases in CD4+ T -cell Counts 
and/or Total Lymphocyte Counts ................................................................ 89
[IP_ADDRESS] Participants Whose CD4+ T- cell Count and/or Total Lymphocyte 
Count Decreases Meet Criteria for Events of Clinical Interest 
While on Study Intervention .............................................................. 89
[IP_ADDRESS] Participants Discontinued from Study Intervention Due to 
Decreased CD4+ T- cell Count and/or Total Lymphocyte Count ......89
[IP_ADDRESS] Participants Discontinued from Study Intervention For Other 
Reasons AND Have Decreases in CD4+ T -cell Count and/or 
Total Lymphocyte Count ...................................................................90
8.11.6 Clinical Management of Participants Who Become Pregnant ..................... 90
[IP_ADDRESS] Continuing Study Intervention ........................................................... 90
[IP_ADDRESS] Discontinuing Study Intervention ...................................................... 92
[IP_ADDRESS] Participants Who Choose to Breastfeed ............................................. 92
[IP_ADDRESS] Infant Safety Data Collection ............................................................. 92
[IP_ADDRESS].1 Schedule of Activities: Infant Safety Data Collection ............. 93
9 STATISTICAL ANALYSIS PLAN ............................................................................. 93
9.1 Statistical Analysis Plan Summary .....................................................................94
9.2 Responsibility for Analyses/In -house Blinding ................................................. 96
9.3 Hypotheses/Estimation ........................................................................................ 96
9.4 Analysis Endpoints ............................................................................................... 96
9.4.1 Efficacy/Pharmacokinetics Endpoints ......................................................... 96
[IP_ADDRESS] Efficacy Endpoints ............................................................................. 96
[IP_ADDRESS] Pharmacokinetic Endpoint ................................................................ .98
9.4.2 Safety Endpoints .......................................................................................... 98
9.4.3 Patient -reported Outcome Endpoints ........................................................... 99
9.5 Analysis Populations ............................................................................................ 99
9.5.1 Efficacy Analysis Populations .....................................................................99
[IP_ADDRESS] Full Analysis Set ................................................................................ 99
[IP_ADDRESS] Per-Protocol Analysis Set ................................................................ 100
[IP_ADDRESS] Resistance Analysis Subset .............................................................. 100
9.5.2 Safety Analysis Population ........................................................................100
9.6 Statistical Methods ............................................................................................. 101
9.6.1 Statistical Methods for Efficacy Analyses................................................. 101
9.6.2 Statistical Methods for Safety Analyses .................................................... 107
9.6.3 Summaries of Baseline Characteristics, Demographic, and Other 
Analyses .....................................................................................................110
[IP_ADDRESS] Demographic and Baseline Characteristics .....................................[ADDRESS_916791]: MK-8591A  12
PROTOCOL/AMENDMENT NO.: 017-09
MK-8591A -017-09 FINAL PROTOCOL 26-MAR -2024
9.8 Multiplicity ......................................................................................................... 112
9.9 Sample Size and Power Calculations ............................................................... 113
9.9.1 Sample Size and Power for Efficacy Analyses .......................................... 113
[IP_ADDRESS] Futility Criteria ................................................................................. 113
[IP_ADDRESS] Evaluation of the Primary Hypothesis ............................................. 114
9.9.2 Sample Size and Power for Safety Analyses ............................................. 115
[IP_ADDRESS] Evaluation of Adverse Event ........................................................... 115
[IP_ADDRESS] Evaluation of Change from Baseline in Lipid Profiles .................... 116
9.10 Subgroup Analyses ................................ ................................
............................. 118
9.11 Compliance (Medication Adherence) ............................................................... 118
9.12 Extent of Exposure ............................................................................................. 119
10 SUPPORTING DOCUMENTATION AND OPERATIONAL 
CONSIDERATIONS ...................................................................................................120
10.1 Appendix 1: Regulatory, Ethical, and Study Oversight Considerations ......[ADDRESS_916792] for Clinical Trials ........................................................... 120
10.1.2 Financial Disclosure ................................................................................... 122
10.1.3 Data Protection ........................................................................................... 122
[IP_ADDRESS] Confidentiality of Data ....................................................................123
[IP_ADDRESS] Confidentiality of Participant Records ............................................. 123
[IP_ADDRESS] Conf identiality of IRB/IEC Information .......................................... 123
10.1.4 Committees Structure ................................................................................. 123
[IP_ADDRESS] Executive Oversight Committee ...................................................... 123
[IP_ADDRESS] External Data Monitoring Committee ............................................. 124
[IP_ADDRESS] Scientific Advisory Committee (SAC) ............................................ 124
10.1.5 Publication Policy ...................................................................................... 124
10.1.6 Compliance with Study Registration and Results Posting Requirements .124
10.1.7 Compliance with Law, Audit, and Debarment .......................................... 125
10.1.8 Data Quality Assurance ............................................................................. 126
10.1.9 Source Documents ..................................................................................... 126
10.1.10 Study and Site Closure ............................................................................... 127
10.2 Appendix 2: Clinical Laboratory Tests ............................................................ 128
10.3 Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow -up, and Reporting ............................................................. [ADDRESS_916793]: MK-8591A  13
PROTOCOL/AMENDMENT NO.: 017-09
MK-8591A -017-09 FINAL PROTOCOL 26-MAR -2024
10.3.5 Reporting of AEs, SAEs, and Other Reportable Safety Events to the 
Sponsor ...................................................................................................... 140
10.4 Appendix 4: Device Events, Adverse Device Events, and Medical Device 
Incidents: Definitions, Collection, and Documentation ..................................142
10.5 Appendix 5: Contraceptive Guidance .............................................................. 143
10.5.1 Definitions ..................................................................................................143
10.5.2 Contraception Requirements ......................................................................145
10.6 Appendix 6: Collection and Management of Specimens for Future 
Biomedical Research .......................................................................................... 146
10.7 Appendix 7: Country -specific Requirements .................................................. [ADDRESS_916794] for the [LOCATION_002] .........................................151
[IP_ADDRESS] Plasma/PBMC PK Substudy ............................................................ 151
[IP_ADDRESS].1 Consent to Participate in the Optional Plasma/PBMC PK 
Substudy ................................................................................. 152
[IP_ADDRESS].2 Plasma/P BMC PK Substudy Procedures ............................... 152
10.8 Appendix 8: Calculation of Creatinine Clearance .......................................... 154
10.9 Appendix 9: Abbreviations ............................................................................... 155
10.10 Appendix 10: Summary of Protocol Clarification Letter .............................. [ADDRESS_916795]: MK-8591A  14
PROTOCOL/AMENDMENT NO.: 017-[ADDRESS_916796] OF TABLES
Table 1 Laboratory Exclusion Criteria .......................................................................... 56
Table 2 Study Interventions ...................................................................................... 58
Table 3 Prohibited Therapi[INVESTIGATOR_014] ...................................................................................... 62
Table 4 Reporting Time Periods and Time Frames for Adverse Events and Other 
Reportable Safety Events ................................................................................. 79
Table 5 Collection of Population PK Samples .............................................................. 82
Table 6 Collection of Population PK Samples During Pregnancy and Postpartum .....92
Table 7 Definitions of Study Time Points ..................................................................102
Table 8 Analysis Strategy for Key Efficacy Variables ............................................... 107
Table 9 Analysis Strategy for Safety Parameters ........................................................ 110
Table 10 Probability of Passing the Interim Analysis and the Overall Study Power 
for Various Underlying True Response Rates Assuming Futility Assessed 
at 40% Enrollment .................................................................................... 113
Table 11 Power (%) to Establish Non -Inferiority Under Various Response Rate 
Assumptions (289 Participants Per Group) .................................................... 114
Table 12 Estimate of Incidence of AEs and 95% Upper Confidence Bound Based 
on Hypothetical Numbers of Participants With AEs (289 Participants Per 
Group) .................................................................................... 115
Table 13 Difference in Incidence of AEs (Group 1 minus Group 2) That Can Be 
Ruled Out With 289 Participants in Each Group ........................................... 116
Table 14 Power (%) to Establish Superiority in the Mean Change from Baseline in 
LDL- C/non -HDL -C Under Various Assumed Treatment Differences, 
Standard Deviations, and Number of Participants in Each Treatment 
Group .................................................................................... 117
Table 15 Protocol -Required Laboratory Assessments .................................................. 129
Table 16 Blood Volumes .................................................................................... 131
Table 17 Blood Volumes: Participants Whose Pregnancy or Postpartum Visit(s) 
Extends Beyond Week 96 .............................................................................. 133
Table 18 Schedule of Activities for Participants in the Plasma/PBMC PK Substudy ..152
Table 19 Blood Volumes: Plasma/PBMC PK Su bstudy .............................................. [ADDRESS_916797]: MK-8591A  15
PROTOCOL/AMENDMENT NO.: 017-[ADDRESS_916798]: MK-8591A  16
PROTOCOL/AMENDMENT NO.: 017-09
MK-8591A -017-09 FINAL PROTOCOL 26-MAR -2024
1 PROTOCOL SUMMARY
1.1 Syno psis
Protocol Title: A Phase 3 Randomized, Active -Controlled, Open -Label Clinical Study to 
Evaluate a Switch to Doravirine/Islatravir (DOR/ISL) Once -Daily in Parti cipants With HIV -
1 Virologically Suppressed on Antiretroviral Therapy
Short Title: DOR/ISL Open -Label Switch 
Acronym: Not applicable
MK-8591A (hereafter referred to as DOR/ISL) is a novel 2 -drug FDC of DOR and ISL.
Hypotheses, Objectives ,and Endpoints :
Hypotheses are aligned with objectives in the Objectives and Endpoints table.
The following objectives will be evaluated in participants ≥18years of age with HIV-1who 
have been virologically suppressed for ≥3 months on a stable oral 2- drug or 3- drug 
combination (± PK booster) ART.
Primary Objectives Primary Endpoints
-To evaluate the antiretroviral activity following 
switch to DOR/ISL compared to continued 
baseline ART as assessed by [CONTACT_180605] -1 RNA ≥50copi[INVESTIGATOR_014]/mL at 
Week 48.
Hypothesis (H1): DOR/ISL is non- inferior to 
continued baseline ART as measured by [CONTACT_180589] -1 RNA 
≥50copi[INVESTIGATOR_014]/mL at Week 48. A margin of 4 
percentage points is used to define non -
inferiority.-HIV-1 RNA
- To evaluate the safety and tolerability of switch 
to DOR/ISL compared to continued baseline 
ART as assessed by [CONTACT_677683] 48.-Adverse events
-Adverse events leading to 
discontinuation of study intervention
08WCSH
PRODUCT: MK-8591A  17
PROTOCOL/AMENDMENT NO.: 017-09
MK-8591A -017-09 FINAL PROTOCOL 26-MAR -2024
Secondary Objectives Secondary Endpoints
-To evaluate the antiretroviral activity following 
switch to DOR/ISL compared to continued 
baseline ART as assessed by [CONTACT_180605] -1 RNA <40 copi[INVESTIGATOR_014]/mL and 
<50copi[INVESTIGATOR_014]/mL at Week 48.-HIV-1 RNA 
-To evaluate the antiretroviral activity of 
DOR/ISL from Week 48 to Week 96 after 48 
weeks of treatment with DOR/ISL in 
participants who continue baseline ART 
regimen until Week 48 as assessed by [CONTACT_180607] 96:
-  HIV-1 RNA ≥50 copi[INVESTIGATOR_014]/mL
-  HIV-1 RNA <50 copi[INVESTIGATOR_014]/mL
-  HIV-1 RNA <40 copi[INVESTIGATOR_014]/mL-HIV-1 RNA
-To evaluate the sustained antiretroviral activity 
of DOR/ISL from Day 1 to Week 96 in 
participants who switch to DOR/ISL on Day 1
as assessed by [CONTACT_180591] 96:
-  HIV-1 RNA ≥50 copi[INVESTIGATOR_014]/mL
-  HIV-1 RNA <50 copi[INVESTIGATOR_014]/mL
-  HIV-1 RNA <40 copi[INVESTIGATOR_014]/mL-HIV-[ADDRESS_916799] of switch to 
DOR/ISL compared to continued b aseline ART 
as measured by [CONTACT_180592]4+ 
T-cell count at Week 48.-CD4+ T- cell count 
08WCSH
PRODUCT: MK-8591A  18
PROTOCOL/AMENDMENT NO.: 017-[ADDRESS_916800] of DOR/ISL 
at Week 96 as assessed by [CONTACT_677684]4+ 
T-cell count:
-From baseline (Day 1) to Week 96 after 96 
weeks of treatment with DOR/ISL in 
participants who switch to DOR/ISL on Day 1
-From Week 48 to Week 96 after 48 weeks of 
treatment with DOR/ISL in participants who 
switch to DOR/ISL on Day 1
-From Week 48 to Week 96 after 48 weeks of 
treatment with DOR/ ISL in participants who 
continue baseline ART regimen until Week 48-CD4+ T- cell count
-To evaluate the development of viral drug 
resistance to any study intervention in 
participants who switch to DOR/ISL and 
participants who continue baseline ART 
regim en.-Viral resistance -associated 
substitutions
-To evaluate the effect on fasting lipid profiles 
following switch to DOR/ISL compared to 
continued baseline ART by [CONTACT_677685] 
(PI-containing regimens [including PI -+ InSTI -
containing regimens], In STI-based regimens 
[non-PI-containing regimens], and all other 
non-PI-and non -InSTI -containing regimens), as 
measured by [CONTACT_677686] 24 and 48.
If non -inferiority of HIV -1 RNA 
≥50copi[INVESTIGATOR_014]/mL at Week 48 (H1) is met, the 
following hypothesis will be tested for each 
stratum sequentially in the order of PI -
containing regimens, InSTI -containing 
regimens, and all other regimens: 
Hypothesis (H2): DOR/ISL is superior to 
continued baseline ART in each baseline ART 
stratum (PI -containing regimens [including PI -
+ InSTI -containing regimens], InSTI -based 
regimens [non -PI-containing regimens], and all 
other non -PI-and non -InSTI-containing 
regimens) as measured by [CONTACT_677687][INVESTIGATOR_648138] 48.-Fasting low -density lipoprotein 
cholesterol and non -high-density 
lipoprotein cholesterol
08WCSH
PRODUCT: MK-8591A  19
PROTOCOL/AMENDMENT NO.: 017-[ADDRESS_916801] of switch to DOR/ISL 
compared to continued baseline ART of an 
InSTI -based regime n (non -PI-containing 
regimen) on weight, as measured by [CONTACT_677688] 48.-Weight
-To evaluate the safety and tolerability of 
DOR/ISL as assessed by [CONTACT_181773] 96:
-  From baseline (Da y 1) after 96 weeks of 
treatment with DOR/ISL in participants who 
switch to DOR/ISL on Day 1
-  From Week 48 to Week 96 after 48 weeks of 
treatment with DOR/ISL in participants who 
switch to DOR/ISL on Day 1
-  From Week 48 to Week 96 after 48 weeks of 
treatment with DOR/ISL in participants who 
continue baseline ART regimen until Week 48-Adverse events 
-Adverse events leading to 
discontinuation of study intervention
Overall Desig n:
Study Phase Phase 3
Primary Purpose Treatment
Indication HIV infection
Population Participants ≥18years of age with HIV -1who have been 
virologically suppressed for ≥3 months on a stable oral 
2-drug or 3- drug combination (± PK booster) ART .
Study Type Interventional
Intervention Model Parallel
This is a multi- sitestudy.
Type of Control Active control
Study Blinding Unblinded Open -label
Masking No Masking
Estimated Duration of 
StudyThe Sponsor estimates that the study will require 
approximately 2.5 years from the time the participant (or 
their legally acceptable representative) provides documented 
informed consent until the last participant’s last study -
related contact.
08WCSH
PRODUCT: MK-8591A  20
PROTOCOL/AMENDMENT NO.: 017-09
MK-8591A -017-09 FINAL PROTOCOL 26-MAR -2024
Number of Participant s:
Approximately 578 participants will be randomized.
Interventi on Groups and Du ration :
Intervention 
Group s
Intervention 
Group 
Name [CONTACT_677723] 1DOR/
ISL100mg/
0.75 mgQD Oral Day 1 to 
Week 96b Experimental
Group 2Baseline 
ART
RegimenaPer local requirementsDay 1 to 
Week 48Experimental
DOR/
ISL100mg/
0.75 mg QD OralWeek 48 to 
Week 96b Experimental
ART=antiretroviral therapy; CCR5=chemokine receptor type 5; DOR=doravirine; InSTI=integrase 
strand transfer inhibitor; ISL=islatravir; NNRTI=non -nucleoside reverse transcriptase inhibitor; 
NRTI=nucleoside analog reverse transcriptase inhibitor; PI=protease inhibitor; PK=pharmacokinetic; 
QD=once daily.
aAllowed drug classes include NRTIs, NNRTIs, PIs, InSTIs, f usion inhibitors, CCR5 antagonists, 
postattachment inhibitor, and PK booste rs.
bFor participants who are pregnant at the last regularly scheduled study visit (TW 96), study intervention 
will be dispensed at Week 96. In addition, their visit schedule will be extended through the duration of 
the pregnancy and study intervention will be dispensed at Weeks 108, 120, and 132, as applicable.
Total 
Number2
Duration of 
ParticipationEach participant will participate in the study for approximately 108weeks from 
the time the participant provides documented informed c onsent through the 
final contact. After a screening phase of up to 45days, each participant will 
receiv eassigned interv ention for approximately 48 weeks. After 48 weeks of 
assigned therapy, all participants will receive open-label DOR/ISL through 
Week 96. Participants who discontinue study intervention or who become
pregnant will be followed as described in the protocol .
08WCSH
PRODUCT: MK-8591A  21
PROTOCOL/AMENDMENT NO.: 017-09
MK-8591A -017-09 FINAL PROTOCOL 26-MAR -2024
Study Governance Committees:
Steering Committee No
Executive Oversight Committee Yes
Data Monitoring Committee Yes
Clinical Adjudication Committee No
Scientific Advisory Committee Yes
Study governance considerations are outlined in Appendix 1.
Study Accepts Healthy Volunteers :No
A list of abbreviations used in this document can be found in Appendix 9.
1.2 Schema
The study design is depi[INVESTIGATOR_6517] 1.
Figure 1Study Schema and Treatment Plan
ART =antiretroviral therapy ;DOR=doravirine; ISL=islatravir; N=total number of participants in the study ;
n=number of parti cipants per group .
aParticipants are expected to enroll as soon as possible after eligibility is confirmed . In cases of unexpected 
delays in receiving repeat screening laboratory results, screening period of up to [ADDRESS_916802]: MK-8591A  22
PROTOCOL/AMENDMENT NO.: 017-09
MK-8591A -017-09 FINAL PROTOCOL 26-MAR -2024
1.3 Schedule of Activities (SoA)
1.3.1 Schedule of Activities
Study Period
ScreeningOpen -Label Intervention: 
DOR/ISL or 
Baseline ART RegimenOpen -Label Intervention: 
DOR/ISLNotes
Visit Number 1 2 3 4 5 6 7 8 9 10 11 12
Scheduled 
Day/Week 
Screening
Day 1 
(Fasting)
Week 4
Week 12
Week 24 
(Fasting)
Week 36
Week 48 
(Fasting)
Week 52b
Week 60
Week 72
Week 84
Week 96 
(Fasting)Each visit should be calculated from date of
Day 1. A visiting nurse may be utilized for 
visits after randomization per Section [IP_ADDRESS].
Visit Window≤45 
daysa NA ± 7daysTo ensure timely study intervention resupply .
Administrative Procedures
Informed Consent X
Informed Consent 
for Future 
Biomedical 
ResearchX
Informed Consent 
for Study 
Intervention During 
Pregnancy<-------------------------------- X-------------------------------- >Obtain upon confirmation of pr egnancy if 
study intervention will be continued .
Collect and enter 
data from prenatal 
care provider<-------------------------------- X-------------------------------- >For female participants who become pregnant 
and consent to continue study intervention, 
obtain relevant prenatal clinical & laboratory 
data to monitor the safety of the mother & 
fetus per Section 8.11. 6.
Inclusion/Exclusion 
CriteriaX XReview prior to randomization on Day [ADDRESS_916803]: MK-8591A  23
PROTOCOL/AMENDMENT NO.: 017-09
MK-8591A -017-09 FINAL PROTOCOL 26-MAR -2024
Study Period
ScreeningOpen -Label Intervention: 
DOR/ISL or 
Baseline ART RegimenOpen -Label Intervention: 
DOR/ISLNotes
Visit Number 1 2 3 4 5 6 7 8 9 10 11 12
Scheduled 
Day/Week 
Screening
Day 1 
(Fasting)
Week 4
Week 12
Week 24 
(Fasting)
Week 36
Week 48 
(Fasting)
Week 52b
Week 60
Week 72
Week 84
Week 96 
(Fasting)Each visit should be calculated from date of
Day 1. A visiting nurse may be utilized for 
visits after randomization per Section [IP_ADDRESS].
Visit Window≤45 
daysa NA ± 7daysTo ensure timely study intervention resupply .
Medical History X
Prior and 
Concomitant 
Medications 
ReviewX X X X X X X X X X X X
Register Study Visit 
in IRTX X X X X X X X X X X X
Intervention 
Randomization XAll procedures should be completed prior to 
dose on Day 1.
Dispense DOR/ISL 
Using IRTX X X X X X X XParticipants in Group 2 (who are not pregnant) 
will continue their baseline ART from Day 1 
up to Week 48 &then will be dispensed 
DOR/ISL via IRT beginning Week 48 through 
Week 84. Dispense DOR/ISL at Week 96 to 
any pregnant participant whose pregnancy 
and/or postpartum visit(s) extend beyond 
Week 96. See Section 1.3.[ADDRESS_916804]: MK-8591A  24
PROTOCOL/AMENDMENT NO.: 017-09
MK-8591A -017-09 FINAL PROTOCOL 26-MAR -2024
Study Period
ScreeningOpen -Label Intervention: 
DOR/ISL or 
Baseline ART RegimenOpen -Label Intervention: 
DOR/ISLNotes
Visit Number 1 2 3 4 5 6 7 8 9 10 11 12
Scheduled 
Day/Week 
Screening
Day 1 
(Fasting)
Week 4
Week 12
Week 24 
(Fasting)
Week 36
Week 48 
(Fasting)
Week 52b
Week 60
Week 72
Week 84
Week 96 
(Fasting)Each visit should be calculated from date of
Day 1. A visiting nurse may be utilized for 
visits after randomization per Section [IP_ADDRESS].
Visit Window≤45 
daysa NA ± 7daysTo ensure timely study intervention resupply .
Administration of 
EQ-5D-5L, HIV -
SI/SDM, and 
HIVTSQ Patient 
QuestionnairesX X X X XAdministered prior to being seen by 
[CONTACT_180596]. 
Efficacy Procedures
Plasma HIV -1 RNA 
Quantification 
(Real Time PCR)X X X X X X X X X X X X
CD4+ T -cell 
Count /TBNK PanelX X X X X X XCollection forboth Group 1 and Group 2 
participants .Decreases in CD4+ T -cell count 
that meet ECI criteria should be managed per 
Section 1.3.[ADDRESS_916805]: MK-8591A  25
PROTOCOL/AMENDMENT NO.: 017-09
MK-8591A -017-09 FINAL PROTOCOL 26-MAR -2024
Study Period
ScreeningOpen -Label Intervention: 
DOR/ISL or 
Baseline ART RegimenOpen -Label Intervention: 
DOR/ISLNotes
Visit Number 1 2 3 4 5 6 7 8 9 10 11 12
Scheduled 
Day/Week 
Screening
Day 1 
(Fasting)
Week 4
Week 12
Week 24 
(Fasting)
Week 36
Week 48 
(Fasting)
Week 52b
Week 60
Week 72
Week 84
Week 96 
(Fasting)Each visit should be calculated from date of
Day 1. A visiting nurse may be utilized for 
visits after randomization per Section [IP_ADDRESS].
Visit Window≤45 
daysa NA ± 7daysTo ensure timely study intervention resupply .
Directed Physical 
ExaminationX X X X X X X X X X X
Vital Signs X X X X X X X X X X X X Includes pulse, bp, temp, and rr.
12-Lead ECG XMay be performed up to 7 days prior to Day 1 
after allother eligibility criteria are confirmed. 
Contraceptive Use 
Confirmation 
(WOCBP Only)X X X X X X X X X X X
Serum Pregnancy 
Test
(β-hCG; WOCBP 
Only)X
Urine Pregnancy 
Test 
(WOCBP Only)X X X X X X X X X X XConfirm with serum test if urine test is 
positive . If confirmatory serum test is positive, 
participants will be managed per Section 
8.11. 6 and safety of her infant collected per 
Section 8.11. 6.4.1.
HIV-1 & -[ADDRESS_916806]: MK-8591A  26
PROTOCOL/AMENDMENT NO.: 017-09
MK-8591A -017-09 FINAL PROTOCOL 26-MAR -2024
Study Period
ScreeningOpen -Label Intervention: 
DOR/ISL or 
Baseline ART RegimenOpen -Label Intervention: 
DOR/ISLNotes
Visit Number 1 2 3 4 5 6 7 8 9 10 11 12
Scheduled 
Day/Week 
Screening
Day 1 
(Fasting)
Week 4
Week 12
Week 24 
(Fasting)
Week 36
Week 48 
(Fasting)
Week 52b
Week 60
Week 72
Week 84
Week 96 
(Fasting)Each visit should be calculated from date of
Day 1. A visiting nurse may be utilized for 
visits after randomization per Section [IP_ADDRESS].
Visit Window≤45 
daysa NA ± 7daysTo ensure timely study intervention resupply .
HBsAg and HBV 
DNA (Group 1)X X X X X X X X X X XAll participants at screening, only anti -HBc 
positive participants thereafter. HBsAg and HBV 
DNA (Group 2)X X X X X X X X
Chemistry X X X X X X X X X X X XFasting is required at Day 1 and Weeks 24, 48, 
and 96.
HematologyX X X X X X X X X X X XDecreases in total lymphocyte count sthat meet 
ECI criteria should be managed per Section 
1.3.4 and Section 8.11.5.
PT/INR XTest to be performed only in participants 
infected with HCV.
Urinalysis X X X X X
Review of Adverse 
EventsX X X X X X XXX X X X
08WCSH
PRODUCT: MK-8591A  27
PROTOCOL/AMENDMENT NO.: 017-09
MK-8591A -017-09 FINAL PROTOCOL 26-MAR -2024
Study Period
ScreeningOpen -Label Intervention: 
DOR/ISL or 
Baseline ART RegimenOpen -Label Intervention: 
DOR/ISLNotes
Visit Number 1 2 3 4 5 6 7 8 9 10 11 12
Scheduled 
Day/Week 
Screening
Day 1 
(Fasting)
Week 4
Week 12
Week 24 
(Fasting)
Week 36
Week 48 
(Fasting)
Week 52b
Week 60
Week 72
Week 84
Week 96 
(Fasting)Each visit should be calculated from date of
Day 1. A visiting nurse may be utilized for 
visits after randomization per Section [IP_ADDRESS].
Visit Window≤45 
daysa NA ± 7daysTo ensure timely study intervention resupply .
Pharmacokinetics
Blood (Plasma) for 
ISL PK X X X X XAt Week 4, a predose and postdose sample will 
be taken. PK samples will be collected only in 
Group 1. 
Blood (Plasma) for 
Investigational PKX X X X X XAnalysis will be triggered by [CONTACT_180599]. Investigational PK samples will be 
collected for both Group 1 and Group 2 
beyond Week 48.
Blood (Plasma) for 
DOR and ISL PK in 
Pregnant 
Participants<-------------------------------- X-------------------------------- >Collected during the 1st, 2nd,and 3rdtrimesters
and postpartum per Section 8.11. 6.1.
Biomarkers
Blood for Genetic 
Analysisc X
Whole Blood for 
Future Biomedical 
ResearchX X X X XOptional participation; requires FBR consent.
DEXA Scan
(Only Where 
Permitted by [CONTACT_677689])X X XPerform after alleligibility criteria are 
confirmed and within 14 days after Day 1. At 
Weeks 48 and 96 scans, may be performed ± 
14 days of the scheduled visit. May require 
additional planning/scheduling. DEXA should 
not be performed on pregnant participants.
Waist and hip 
measurementsX X X
08WCSH
PRODUCT: MK-8591A  28
PROTOCOL/AMENDMENT NO.: 017-09
MK-8591A -017-09 FINAL PROTOCOL 26-MAR -2024
Study Period
ScreeningOpen -Label Intervention: 
DOR/ISL or 
Baseline ART RegimenOpen -Label Intervention: 
DOR/ISLNotes
Visit Number 1 2 3 4 5 6 7 8 9 10 11 12
Scheduled 
Day/Week 
Screening
Day 1 
(Fasting)
Week 4
Week 12
Week 24 
(Fasting)
Week 36
Week 48 
(Fasting)
Week 52b
Week 60
Week 72
Week 84
Week 96 
(Fasting)Each visit should be calculated from date of
Day 1. A visiting nurse may be utilized for 
visits after randomization per Section [IP_ADDRESS].
Visit Window≤45 
daysa NA ± 7daysTo ensure timely study intervention resupply .
Blood and Urine for 
Renal MarkersX X X X
Blood for 
Inflammatory 
MarkersX X X X
anti-HBc=hepatitis B core antibody; ART=antiretroviral therapy; β -hcg=beta human chorionic gonadotropin; bp=blood pressure; DEXA=Dual X -ray Absorptiometry; DNA=deoxyribonucleic acid; 
DOR=doravirine; ECG=electrocardiogram; ECI=Events of Clinical Interest; EQ- 5D-5L=EuroQol 5-dimensional descriptive system, 5level version; FBR=future biomedical research; HBsAg=hepatitis 
B surface antigen; HBV=hepatitis B virus; HCV=hepatitis C virus; HIV=human immunodeficiency virus; HIV -SI/SDM=Human Immunodeficiency Virus Symptom Index/Symptom Distress Module; 
HIVTSQ=Human I mmunodeficiency Virus Treatment Satisfaction Questionnaire; INR=international normalized ratio; IRT=Interactive Response Tech nology; ISL=islatravir; NA=not applicable; 
PCR=polymerase chain reaction; PK=pharmacokinetic; PT=prothrombin time; RNA=ribonucleic acid; rr=respi[INVESTIGATOR_697]; TBNK=T -and B -lymphocyte and natural killer cell profile ; temp=body 
temperature; WOCBP=a woman/women of childbearing potential.
a  Participants are expected to enroll as soon as possible after eligibility is confirmed. In cases o f unexpected delays in receiving repeat screening laboratory results, screening period up to 45 days is 
allowed.
b The Week 52 procedures apply only to participants in Group 2 .
cThis sample should be drawn for planned analysis of the association between genetic variants in DNA and drug response. This s ample will not be collected at that site if there is either a local law or 
regulation prohibiting collection, or if the IRB/IEC doe s not approve the collection of the sample for these purposes. If the sample is collected, leftover extracted DNA will be stored for future 
biomedical research if the participant (or their legally acceptable representative) provides documented informed con sent for future biomedical research consent. If the planned genetic analyses are not 
approved, but future biomedical research is approved and consent is given, this sample will be collected for the purpose of f uture biomedical research.
08WCSH
PRODUCT: MK-8591A  29
PROTOCOL/AMENDMENT NO.: 017-09
MK-8591A -017-09 FINAL PROTOCOL 26-MAR -2024
1.3.2 Schedule of Acti vities – Viremia Confirmation and End of Treatment (For All Participants Except Those With 
Specified Decrease sin CD4+ T -celland/or Total Lymphocyte Counts)
Study Period Viremia Confirmation End of Treatment Notes
Visit Number Unscheduled Unscheduled
Scheduled Day/Week Viremia ConfirmationEarly Discontinuation 
of TreatmentEnd of Treatment 
Follow -up The End of Treatment Follow- up visit 
should also be performed for participants 
who do not continue study intervention after
Week 96.Visit WindowWithin 2 to 4 Weeks of 
HIV-1 Viremia 
(≥50 copi[INVESTIGATOR_014]/mL)NA42 (+ 7) days after 
the end of treatment
Administrative Procedures
Prior and Concomitant Medications Review X X X
Register Study Visit in IRT X X
Study Intervention Compliance Review X XReconcile doses and study intervention 
compliance.
Administration of EQ-5D -5L, HIV -SI/SDM, 
and HIVTSQ Patient QuestionnairesXAdministered prior to being seen by 
[CONTACT_180596].
Efficacy Procedures
Plasma HIV -1 RNA Quantification
(Real Time PCR)X X X
CD4+ T -cell Count /TBNK Panel XParticipants with decreases in CD4+ T-cell 
count >10% from average baseline valueaor 
who meet relevant ECI criteria at the Early 
Discontinuation of Treatment visit should 
be managed per Section 1.3.[ADDRESS_916807]: MK-8591A  30
PROTOCOL/AMENDMENT NO.: 017-09
MK-8591A -017-09 FINAL PROTOCOL 26-MAR -2024
Study Period Viremia Confirmation End of Treatment Notes
Visit Number Unscheduled Unscheduled
Scheduled Day/Week Viremia ConfirmationEarly Discontinuation 
of TreatmentEnd of Treatment 
Follow -up The End of Treatment Follow- up visit 
should also be performed for participants 
who do not continue study intervention after
Week 96.Visit WindowWithin 2 to 4 Weeks of 
HIV-1 Viremia 
(≥50 copi[INVESTIGATOR_014]/mL)NA42 (+ 7) days after 
the end of treatment
Safety Procedures
Full Physical Examination X X
Vital Signs X XIncludes weight, pulse, bp, temp, and rr.
Contraceptive Use Confirmation 
(WOCBP Only)X X X
Serum Pregnancy Test (WOCBP Only) X XIf serum test is positive, participants will be 
managed per Section 8.11. 6and safety of 
her infant collected per Section 8.11. 6.4.1.
Chemistry X
HematologyXParticipants with d ecreases in total
lymphocyte counts >10% from average 
baseline valueaor who meet relevant ECI 
criteria at the Early Discontinuation of 
Treatment Visit should be managed per 
Section 1.3.4 and Section 8.11.5.
Urinalysis X
Review of Adverse Events X X X
Pharmacokinetics
Blood (Plasma) for Investigational PK X X X Analysis triggered by [CONTACT_180597].
Biomarkers
Whole Blood for Future Biomedical 
ResearchX XIf FBR sample was collected at Viremia 
Confirmation visit, it is not necessary to 
collect another sample at Early 
Discontinuation of Treatment visit.
bp=blood pressure; ECI=Events of Clinical Interest; EQ- 5D-5L=EuroQol 5 -dimensional descriptive system, 5 level version; FBR=future biomedical research; HIV=human immunodeficiency virus; 
HIV-SI/SDM=Human Immunodeficiency Virus Symptom Index/Symptom Distress Module; HIVTSQ=Human Immunodeficiency Virus Treatment Satisfaction Questionnaire; IRT=Interactive 
Response Technology; NA=not applicable; PCR=polymerase chain reaction; PK=pharmacokinetic; RNA=ribonucleic acid; rr=respi[INVESTIGATOR_31145]; TBNK=T -and B -lymphocyte and natural killer cell 
profile ;temp=body temperature; WOCBP=a woman/women of childbearing potential.
a.The average baseline value is defined as the average value between screening (within [ADDRESS_916808] dose of study intervention) and Day 1.
08WCSH
PRODUCT: MK-8591A  31
PROTOCOL/AMENDMENT NO.: 017-09
MK-8591A -017-09 FINAL PROTOCOL 26-MAR -2024
1.3.3 Schedule of Activities for Participants W hose Pregnancy or Postpartum Visit(s) Extends Beyond Week [ADDRESS_916809] regularly 
scheduled study visit (TW 96) and consent sto continue 
study intervention , the visit schedule will be extended to 
allow assessments through each trimester and postpartum . 
Extension visits will only be performed through pregnancy 
& a single postpartum timepoint, as applicable for each 
participant .
Visit Window ±[ADDRESS_916810] and enter data from prenatal care provider <----------------------------- X-------------------------- >Obtain relevant prenatal clinical & laboratory data to 
monitor the safety of the mother & fetus per Section 8.11. 6.
Register Study Visit in IRT X X X X
Dispense DOR/ISL Using IRT X X X
Study Intervention Compliance Review X X X X Reconcile doses and study intervention compliance .
Prior and Concomitant Medications Review X X X X
Evaluation to Receive Continued Study InterventionX X X XAt the end of pregnancy, continued access to DOR/ISL will 
be offered per Section 6.7.
Efficacy Procedures
Plasma HIV -1 RNA Quantification 
(Real Time PCR)X X X X
CD4+ T -cell Count /TBNK PanelX X X XDecreases in CD4+ T-cell count s that meet ECI criteria 
should be managed per Section 1.3.[ADDRESS_916811]: MK-8591A  32
PROTOCOL/AMENDMENT NO.: 017-[ADDRESS_916812] regularly 
scheduled study visit (TW 96) and consent sto continue 
study intervention , the visit schedule will be extended to 
allow assessments through each trimester and postpartum . 
Extension visits will only be performed through pregnancy 
& a single postpartum timepoint, as applicable for each 
participant .
Visit Window ±7 days
Pharmacokinetics
Blood (Plasma) for DOR and ISL PK X X X XCollected during the 1st, 2nd,and 3rdtrimesters and 
postpartum per Section 8.11. 6.1.
Biomarkers
Whole Blood for Future Biomedical Research X X X X Optional participation; requires FBR consent .
DNA=deoxyribonucleic acid; DOR=doravirine; ECI=Events of Clinical Interest; HBsAg=hepatitis B surface antigen; HBV=hepatitis B virus; HIV=human immunodeficiency virus; IRT=Interactive 
Response Technology; ISL=islatravir; PCR=polymerase chain reaction; PK=pharmacokinetic; RNA=ribonucleic acid ; TBNK= T-and B -lymphocyte and natural killer cell profile .
08WCSH
PRODUCT: MK-8591A  33
PROTOCOL/AMENDMENT NO.: 017-09
MK-8591A -017-09 FINAL PROTOCOL 26-MAR -2024
1.3.4 Schedule of Activities for Participants With Specified Decreases in CD4+ T -cell Counts and/or Total Lymphocyte 
Counts
Study PeriodCD4+ T -cell Count and/or 
Total Lymphocyte Count 
ConfirmationEnd of TreatmentCD4+ T -cell Count 
and/or Total
Lymphocyte Count 
Monitoring
DOR/ISL OnlyNotes
Visit Number Unscheduled Unscheduled Unscheduled
Scheduled Day/WeekCD4+ T -cell and/or Total 
Lymphocyte ConfirmationEarly 
Discontinuation of 
TreatmentEnd of Treatment 
Follow -upCD4+ T -cell and/or Total 
Lymphocyte MonitoringSee Sections 8.1.9 and 8.11.5 
for details regarding 
discontinuation and 
monitoring.
Visit WindowWithin 3 to 4 weeks of initial 
decrease 
Note : if total lymphocyte 
count remains ≥1 ×109
cells/L, confirmation of 
decreased lymphocytes is due 
in 10 to 14 weeks (ie, at the 
next routine study visit)NA42 (+ 7) days after 
discontinuing study 
intervention
Administrative Procedures
Prior and Concomitant 
Medications ReviewX X X X
Register Study Visit in IRT X X X
Study Intervention 
Compliance Review XReconcile doses and study 
intervention compliance.
Administration of EQ-5D -5L, 
HIV-SI/SDM, and HIVTSQ 
Patient QuestionnairesXAdministered prior to being 
seen by [CONTACT_180600].
Efficacy Procedures
Plasma HIV -1 RNA 
Quantification
(Real Time PCR)X X
CD4+ T -cell Count /TBNK 
PanelX X X X
CCI
08WCSH
PRODUCT: MK-8591A  34
PROTOCOL/AMENDMENT NO.: 017-09
MK-8591A -017-09 FINAL PROTOCOL 26-MAR -2024
Study PeriodCD4+ T -cell Count and/or 
Total Lymphocyte Count 
ConfirmationEnd of TreatmentCD4+ T -cell Count 
and/or Total
Lymphocyte Count 
Monitoring
DOR/ISL OnlyNotes
Visit Number Unscheduled Unscheduled Unscheduled
Scheduled Day/WeekCD4+ T -cell and/or Total 
Lymphocyte ConfirmationEarly 
Discontinuation of 
TreatmentEnd of Treatment 
Follow -upCD4+ T -cell and/or Total 
Lymphocyte MonitoringSee Sections 8.1.9 and 8.11.5 
for details regarding 
discontinuation and 
monitoring.
Visit WindowWithin 3 to 4 weeks of initial 
decrease 
Note : if total lymphocyte 
count remains ≥1 ×109
cells/L, confirmation of 
decreased lymphocytes is due 
in 10 to 14 weeks (ie, at the 
next routine study visit)NA42 (+ 7) days after 
discontinuing study 
intervention
Plasma for HIV Viral Drug 
Resistance TestingX XIf HIV drug resistance sample 
is collected at Viremia 
Confirmation visit, it is not 
necessary to collect another 
sample at Early 
Discontinuation of Treatment 
visit. Analysis of samples 
collected at End of Treatment 
visits triggered by [CONTACT_180599].
Safety Procedures
Full Physical Examination X X
Vital Signs X XIncludes weight, pulse, bp, 
temp, and rr.
Contraceptive Use 
Confirmation (WOCBP Only)X X
CCI
08WCSH
PRODUCT: MK-8591A  35
PROTOCOL/AMENDMENT NO.: 017-09
MK-8591A -017-09 FINAL PROTOCOL 26-MAR -2024
Study PeriodCD4+ T -cell Count and/or 
Total Lymphocyte Count 
ConfirmationEnd of TreatmentCD4+ T -cell Count 
and/or Total
Lymphocyte Count 
Monitoring
DOR/ISL OnlyNotes
Visit Number Unscheduled Unscheduled Unscheduled
Scheduled Day/WeekCD4+ T -cell and/or Total 
Lymphocyte ConfirmationEarly 
Discontinuation of 
TreatmentEnd of Treatment 
Follow -upCD4+ T -cell and/or Total 
Lymphocyte MonitoringSee Sections 8.1.9 and 8.11.5 
for details regarding 
discontinuation and 
monitoring.
Visit WindowWithin 3 to 4 weeks of initial 
decrease 
Note : if total lymphocyte 
count remains ≥1 ×109
cells/L, confirmation of 
decreased lymphocytes is due 
in 10 to 14 weeks (ie, at the 
next routine study visit)NA42 (+ 7) days after 
discontinuing study 
intervention
Serum Pregnancy Test 
(WOCBP Only)X XIf serum test is positive, 
participants will be managed 
per Section 8.11.6 and safety 
of her infant collected per 
Section [IP_ADDRESS].1.
Chemistry X
Hematology X X X X
Urinalysis X
Review of Adverse Events X X X X
Pharmacokinetics
Blood (Plasma) for 
Investigational PKX XPK analysis triggered by 
[CONTACT_180597].
Biomarkers
Whole Blood for Future 
Biomedical ResearchX
bp=blood pressure; EQ -5D-5L=EuroQol five -dimensional descriptive system, five level version; FBR=future biomedical research; HIV=human immunodeficiency virus; HIV -SI/SDM=Human 
Immunodeficiency Virus Symptom Index/Symptom Distress Module; HIVTSQ=Human Immun odeficiency Virus Treatment Satisfaction Questionnaire; IRT=Interactive Response Technology; 
NA=not applicable; PCR=polymerase chain reaction; PK=pharmacokinetic; RNA=ribonucleic acid; rr=respi[INVESTIGATOR_697]; TBNK=T -and B -lymphocyte and natural killer cell p rofile ; temp=body 
temperature; WOCBP=a woman/women of childbearing potential.
CCI
08WCSH
PRODUCT: MK-8591A  36
PROTOCOL/AMENDMENT NO.:   017 -09
MK-8591A -017-09 FINAL PROTOCOL 26-MAR -2024
2 INTRODUCTION
DOR/ISL (also known as MK-8591A or MK-8591/DOR) is a novel 2- drug FDC of DOR (a 
recently approved NNRTI ) and ISL (a first -in-class investigational NRTTI ).DOR /ISL is 
being developed for QDtreatment of HIV-1infection in adults and adolescents .
2.[ADDRESS_916813] to live near -normal 
lifespans [Trickey, A., et al 2017] . With anticipation of long -term treatment, the long -term 
tolerability and safety of antiretrovirals have become increasingly important considerations .
The current standard- of-care for the treatment of HIV -[ADDRESS_916814] agent ( eg, InSTI , NNRTI, or PI) [AIDS info 2017] [European AIDS Clinical Society 
2016] [World Health Organization 2016] . Although such regimens have become increasingly 
well tolerated and highly efficacious, the current paradigm of lifelong daily treatment is 
associated with a need for simpler andsafer regimens, with reduced long -term drug 
exposure. Furthermore, as the population living with HIV ages, there is increasing concern
for the risks of long -term toxicity andDDIs, with respect to co morbid conditions (ie,
neuropsychiatric, cardiovascular).
There is accumulating evidence that simplified 2 -drug regimens can achieve efficacy 
comparable to that of 3-drug regimens, better tolerability, andimprove quality of life, which 
can help to sustain virologic suppression [Llibre, J. M., et al 2018] [Cahn, P., et al 2019] 
[Panel on Antiretroviral Guidelines for Adults and Adolescents 2018] . The viability of 
2-drug regimens depends on both components having distinct mechanisms of action with at 
least 1 of the components having a relatively high barrier to resistance . 
DOR/ISL has the potential to be an agent for the treatment of HIV -1 infection in the switch 
setting due to its potent antiretroviral activity (including activity against common NRTI -and 
NNRTI -resistant variants ) by [CONTACT_180601] , 
lack of food requirements, and 
favorable tolerability and DDI profile sobserved to -date.
2.2 Background
Refer to the IB s/approved labeling for detailed background information on DOR and ISL.
2.2.[ADDRESS_916815] member of a new class of antiretroviral agents, known as NRTTIs, that block 
HIV-1 reverse transcriptase by [CONTACT_180602]. It is an inactive nucleoside 
analog that is converted to the pharmacologically active triphosphate (ISL -TP)form via 
endogenous intracellular kinases. It acts through multiple mechanisms, including immediate 
chain termination by [CONTACT_180603] [Michailidis E 2014] .
08WCSH
PRODUCT: MK-8591A  37
PROTOCOL/AMENDMENT NO.:   017 -09
MK-8591A -017-09 FINAL PROTOCOL 26-MAR -2024
ISLis differentiated from other HIV -1 antiretrovirals by[CONTACT_180604] ,long half -life, and 
favorable drug resistance profile. A t the proposed dose of 0.75 mg QD, ISLachieves higher 
steady- state IQs(the ratio of drug exposure to viral susceptibility [C trough/IC 50]) against 
wild-type HIV -[ADDRESS_916816] both wild -type HI V-1 
virus and frequently transmitted NNRTI -resistant variants (eg, K103N, Y181C, G190A ,and 
E138K) .The safety and efficacy profiles of DOR have been well characterized in Phase 3 
clinical studies conducted in treatment -naïve adult participants [Orkin, C., et al 2018] 
[Molina, J. M., et al 2018] and in virologically suppressed adult participants switching from a 
stable a ntiretroviral regimen (MK- 1439A Protocol 024) .
2.2.3 Doravirine /Islatravir
DOR/ISL is an FDC containing DOR (100 mg) and ISL (0.75 mg) ,administered as a single 
tablet QD. DOR and ISL represent [ADDRESS_916817] classes of antiretrovirals that inhibit reverse 
transcription by [CONTACT_129427]. Based on the profiles of each of these drugs and data 
available to- date, the combination DOR/ISL is expected to be well tolerated and highly 
efficacious, with a high barrier to resistance . The combination has demonstr ated additive 
antiretro viral activity in vitro and has suppressed emergence of resistance at clinically
relevant concentrations.
The combination of DOR and ISL (administered as single -entities, DOR + ISL) is being 
evaluated in an ongoing randomized Phase 2 study (MK -8591 P011) in approximately 90 
treatment -naïve adult participants with HIV -1. Participants were initially assigned to receive 
either DOR + ISL and 3TC or an FDC of DOR, 3TC, and TDF (DOR/3TC/TDF). 
Participants receiving DOR + ISL + 3TC who achie ved HIV -1 RNA <50 copi[INVESTIGATOR_014]/mL at Week 
20 (or later) discontinued 3TC at their next study visit (most were able to discontinue 3TC at 
Week 24) while continuing DOR + ISL. At Week s48and 96 , the percentage of participants 
with HIV- 1 RNA <50 copi[INVESTIGATOR_014]/mL among th ose who received the 2 -drug regimen of DOR + 
ISL was comparable to those who received the 3 -drug regimen of DOR/3TC/TDF. The 
majority of participants maintained virologic suppression through Week 144. None of the 
participants with protocol -defined virologi c failure rebounded above the clinically relevant 
HIV-1 RNA >200 copi[INVESTIGATOR_014]/mL cut off. As such, no participant met the criteria for resistance 
testing. DOR + ISL, administered with 3TC or alone as a 2 -drug regimen, had a favorable 
tolerability profile through Week 96, comparable to that of DOR/3TC/TDF .Mean changes 
from baseline in CD4+ T -cell count were comparable for DOR/3TC/TDF and each dose of 
ISL as a 3- drug regimen (at Week 24) or a 2 -drug regimen (at Weeks 48, 96, 144).
08WCSH
PRODUCT: MK-8591A  38
PROTOCOL/AMENDMENT NO.:   017 -09
MK-8591A -017-09 FINAL PROTOCOL 26-MAR -2024
The clinical development program of DOR/ISL includes ongoing studies in treatment -naïve 
adults (P020), virologically suppressed adults (P017 and P018 ), heavily treatment -
experienced participants (P019), and participants <18 years of age and weighing ≥35 kg 
(P028) .
2.2.4 Information on Other Study -related Therapy
For p articipants in Group 2, referto local labeling for detailed information ontheir continued
baseline ART .
2.3 Benefit/Risk Asse ssment
Although it cannot be guaranteed that participants in clinical studies will directly benefit 
from treatment during participation, as clinical studies are designed to provide information 
about the safety and effectiveness of an investigational medicine, the totality of available 
nonclinical and clinical data supports continued evaluation of DOR/ISL in Phase 3 clinical 
studies.
The comprehensive nonclinical safety evaluations of DOR (an approved NNRTI) and ISL 
(an investigational NRTTI) as mono -entities have not revealed toxicities of concern for daily 
dosing. Nonclinical developmental and reproductive toxicity studies did not identify any 
clinically relevant concerns that would preclude continued dosing of DOR/ISL in participants 
who become pregnant during the study. Both mono- entities are differentiated by a high 
barrier to resistance in vitro with DOR exhibiting potent activity against the most prevalent 
NNRTI -resistant mutations (eg, K103N, Y181C, G190A, and E138K) and ISL against 
common NRTI -resistant muta tions (eg, M184V and TAMs). Both may be administered 
without regard to food, have a low potential for DDIs, and have favorable PK and tolerability 
profiles.
High potency against wild- type and resistant variants of HIV -1 virus and a long half -life 
make ISL a suitable candidate for development for the treatment of HIV -1 infection . Across 
the clinical development program, ISL administered alone or with DOR, was generally well 
tolerated. In the dose -ranging study ( MK-8591 P011), ISL+DOR+3TC (as a 3 -drug regimen) 
achieved virological suppression in most (>90%) treatment- naïve participants by [CONTACT_10585] 24. 
ISL+DOR (as a 2 -drug regimen) maintained virologic suppression of HIV -1 RNA 24 and 48 
weeks after switching from the 3- drug regimen and through Week 144. In 2ongoing Phase 3 
studies evaluating DOR/ISL for daily treatment of HIV -1 in virologically suppressed 
participants ( MK-8591A P0 17 and MK -8591A P018) ,approximately 95% of 658 
participants enrolled in the DOR/ISL arm completed 48 week s oftreatment in both studies.
In P017 and P018, t he percentage of participants with HIV -1 RNA ≥50 copi[INVESTIGATOR_014]/mL was <1% 
for the DOR/ISL group and a high percentage of participants ( >93%to 95% ) in the DOR/ISL 
group maintained virologic suppression (HIV -1 RNA <50 copi[INVESTIGATOR_014]/mL) compara ble to baseline 
ART (P017) and BIC/FTC/TAF (P018) at Week 48. To date, no viral resistance to either 
component of DOR/ISL has been shown in the Phase 2 (P011) and Phase 3 studies (P017 and 
P018). At the doses administered for daily treatment, DOR/ISL has b een well tolerated and 
associated with low rates of drug -related AEs.
08WCSH
PRODUCT: MK-8591A  39
PROTOCOL/AMENDMENT NO.:   [ADDRESS_916818] trends of total lymphocytes counts and CD4+ T -cell counts were observed in 
studies with ISL alone or in combination with other antiviral agents. In a Phase 2 study (MK -
8591 P013) for once weekly HIV-1 treatment, decreases in total lymphocyte and CD4+ T -
cell counts from baseline were observed in the ISL 20 mg + MK -8507 treatment arms at 
Week 12 and Week 24. Decreases from baseline in total lymphocyte count were observed in 
all dos ing arms of ISL + MK -8507 starting at Week 8 with further decreases continuing 
through Week 24. Twenty of 58 participants on ISL + MK -8507 had a decrease in total
lymphocyte count of >30% (of whom 9 had a >50% reduction) by [CONTACT_10585] 24. These 
reductions were m ore pronounced in the 2 higher MK- 8507 dose arms (200 and 400 mg), 
potentially indicating a dose -response relationship. Dosing of ISL+MK -8507 in P013 has 
been discontinued.
In the Phase 2 randomized, double -blind, placebo- controlled study evaluating 60 mg and 120 
mg of ISL monthly for PrEP in participants at low -risk of HIV -1 infection (MK -8591 P016), 
there was a 21% mean decrease in total lymphocytes observed in the 60 mg arm (the dose 
being evaluated in Phase 3 PrEP studies) and a 36% decrease in total ly mphocytes observed 
in the 120 mg arm. In this population of HIV -1 uninfected participants, the mean decreases 
were in the normal range and there was no increase in clinical AEs related to infection. 
Dosing of oral ISL 60 mg QM has been discontinued in PrEP clinical studies.
In an interim analysis for each of the Phase 3 studies studying DOR/ISL 100 mg/0.75 mg for 
HIV-1 treatment, (P017 and P018), there were mean decreases from baseline in total
lymphocyte counts at Week 48 of 10.6% and 8.5% in the DOR/ISL g roups (in P017 and 
P018 , respectively) compared with mean increases from baseline of 2.27% and 3.46% in the 
comparator arms in P017 and P018, respectively). In the same studies, DOR/ISL -treated 
participants had mean changes from baseline in CD4+ T -cell count of - 0.7% (P017) and 
+0.9% (P018) compared with mean increase sof 8.7% in the baseline ART group (P017) and 
12.8% in the BIC/FTC/TAF group (P018) . The decreases in CD4+ T- cell counts and total
lymphocyte counts have not been associated with an increased incidence of infection or other 
AEs. The clinical impact of these laboratory changes over the long term is unknown, and the 
Sponsor is assessing the reversibility of the reductions in CD4+ T -cell and total lymphocyte 
counts . To mitigate the risk, increased monitoring of CD4+ T -cell and total lymphocyte 
counts and strict stoppi[INVESTIGATOR_180558]/ISL studies. At this time, the data 
review support scontinuation of the Phase 3 clinical studies for the DOR/ISL 100 mg/0.75 
mg HIV-1once -daily treatment program.
Additional details regarding specific benefits and risks for participants in this clinical study 
may be found in the accompanying IBs and informed consent documents.
3 HYPOTHESE S, OBJECTIVES ,AND ENDPOINTS
Hypotheses are aligned with objectives in the Objectives and Endpoints table.
The following objectives will be evaluated in participants ≥[ADDRESS_916819] been virologically suppressed for ≥3 months on a stable oral 2 -drug or 3 -drug 
combination (± PK booster) ART.
08WCSH
PRODUCT: MK-8591A  40
PROTOCOL/AMENDMENT NO.:   017 -09
MK-8591A -017-09 FINAL PROTOCOL 26-MAR -2024
Objectives Endpoints
Primary
To evaluate the antiretroviral activity 
following switch to DOR/ISL compared 
to continued baseline ART as assessed 
by [CONTACT_677690]-1 RNA ≥50 copi[INVESTIGATOR_014]/mL at Week 48.
Hypothesis (H1) : DOR/ISL is non- inferior 
to continued baseline ART as measured by 
[CONTACT_677691] -1 
RNA ≥50 copi[INVESTIGATOR_014]/mL at Week 48. A margin 
of 4 percentage points is used to define non -
inferiority.HIV-1 RNA
To evaluate the safety and tolerability of
switch to DOR/ISL compared to 
continued baseline ART as assessed by 
[CONTACT_180590] 48 .Adverse events
Adverse events leading to 
discontinuation of study intervention
Secondary
To evaluate the antiretroviral activity 
following switch to DOR/ISL compared 
to continued baseline ART as assessed 
by [CONTACT_677690]-1 RNA <40 copi[INVESTIGATOR_014]/mL and 
<50copi[INVESTIGATOR_014]/mL at Week 48.HIV-1 RNA
To evaluate the antiretroviral activity of 
DOR/ISL from Week 48 to Week 96 
after 48 weeks of treatment with 
DOR/ISL in participants who continue 
baseline ART regimen until Week 48 as 
assessed by [CONTACT_677692] 96:
-HIV-1 RNA ≥ 50 copi[INVESTIGATOR_014]/mL
-HIV-1 RNA <50 copi[INVESTIGATOR_014]/mL
-HIV-1 RNA <40 copi[INVESTIGATOR_014]/mLHIV-[ADDRESS_916820]: MK-8591A  41
PROTOCOL/AMENDMENT NO.:   017 -09
MK-8591A -017-09 FINAL PROTOCOL 26-MAR -2024
Objectives Endpoints
To evaluate the sustained antiretroviral 
activity of DOR/ISL from Day 1 to 
Week 96 in participants who switch to 
DOR/ISL on Day 1 as assessed by [CONTACT_677693] 96:
-HIV-1 RNA ≥ 50 copi[INVESTIGATOR_014]/mL
-HIV-1 RNA <50 c opi[INVESTIGATOR_014]/mL
-HIV-1 RNA <40 copi[INVESTIGATOR_014]/mLHIV-1 RNA
To evaluate the immunologic effect of
switch to DOR/ISL compared to 
continued baseline ART as measured by 
[CONTACT_180592]4+ T- cell 
count at Week 48.CD4+ T- cell count
To evaluate the immunologic effect of 
DOR/ISL at Week 96 as assessed by [CONTACT_677694]4+ T- cell count:
-From baseline (Day 1) to Week 96 
after 96 weeks of treatment with 
DOR/ISL in participants who switch 
to DOR/ISL on Day 1
-From Week 48 to Week 96 after 48 
weeks of treatment with DOR/ISL in 
participants who switch to DOR/ISL
on Day 1
-From Week 48 to Week 96 after 48 
weeks of treatment with DOR/ISL in 
participants who continue baseline 
ART regimen until Week 48CD4+ T- cell count
To evaluate the development of viral 
drug resistance to any study intervention
in participants who switch to DOR/ISL
and participants who continue baseline 
ART regimen .Viral resistance -associated substitutions
08WCSH
PRODUCT: MK-8591A  42
PROTOCOL/AMENDMENT NO.:   017 -09
MK-8591A -017-09 FINAL PROTOCOL 26-MAR -2024
Objectives Endpoints
To evaluate the effect on fasting lipid 
profiles following switch to DOR/ISL
compared to continued baseline ART by 
[CONTACT_677685] (PI -containing 
regimens [including PI -+ InSTI -
conta ining regimens] , InSTI -based 
regimens [non -PI-containing regimens] ,
and all other non -PI-and non -InSTI -
containing regimens ),as measured by 
[CONTACT_677686] 24 and 48.
If non -inferiority of HIV -1 RNA 
≥50copi[INVESTIGATOR_014]/mL at Week 48 (H1)is met, 
the following hypothesis will be tested 
for each strat umsequentially in the order 
ofPI-containing regimens, InSTI -
containing regimens, and all other 
regimens : 
Hypothesis (H2): DOR/ISL is superior to 
continued baseline ART in each baseline 
ART stratum(PI-containing regimens 
[including PI -+ InSTI -containing 
regimens], InSTI -based regimens 
[non-PI-containing regimens], and all other 
non-PI-and non -InSTI -containing regimens) 
as measured by [CONTACT_677695] l ipi[INVESTIGATOR_648138] 48.Fasting low -density lipoprotein 
cholesterol and non -high-density 
lipoprotein cholesterol
To evaluate the effect of switch to 
DOR/ISL compared to continued 
baseline A RT of an InSTI -based 
regimen (non- PI-containing regimen) on 
weight, as measured by [CONTACT_677696] 48.Weight
08WCSH
PRODUCT: MK-8591A  43
PROTOCOL/AMENDMENT NO.:   017 -09
MK-8591A -017-09 FINAL PROTOCOL 26-MAR -2024
Objectives Endpoints
To evaluate the safety and tolerability of 
DOR/ISL as assessed by [CONTACT_677697] 96:
-From baseline (Day 1) after 96
weeks of treatment with DOR/ISL in
participants who switch to DOR/ISL
on Day 1
-From Week 48 to Week 96 after 48 
weeks of treatment with DOR/ISL in 
participants who switch to DOR/ISL
on Day 1
- F rom Week 48 to Week 96 after 48 
weeks of treatment with DOR/ISL in
participants who continue baseline 
ART regimen until Week 48Adverse events 
Adverse events leading to 
discontinuation of study intervention
Tertiary/Exploratory
To evaluate the effects on fasting lipid 
and metabolic profiles, renal function, 
inflammation, and body composition 
switch to DOR/ISL compared to 
continued baseline ART as measured by 
[CONTACT_677698] 48.Laboratory and radiological markers 
08WCSH
PRODUCT: MK-8591A  44
PROTOCOL/AMENDMENT NO.:   017 -09
MK-8591A -017-09 FINAL PROTOCOL 26-MAR -2024
Objectives Endpoints
To evaluate the effects on fasting lipid 
and metabolic profiles, renal function, 
inflammation ,and body composition of 
DOR/ISL at Week 96 as assessed by:
-Change from baseline (Day 1) to 
Week 96 in weight, laboratory, and 
radiological laboratory markers after 
96 weeks of treatment with DOR/ISL
inparticipants who switch to 
DOR/ISL on Day 1
-Change from Week 48 to Week 96 in 
weight, laboratory, and radiological 
laboratory markers after 48 weeks of 
treatment with DOR/ISL in 
participants w ho switch to DOR/ISL
on Day 1
-Change from Week 48 to Week 96 in 
weight, laboratory, and radiological 
laboratory markers after 48 weeks of 
treatment with DOR/ISL in 
participants who continue baseline 
ART regimens until Week 48Weight, laboratory, and radiol ogical 
markers
To evaluate the pharmacokinetics of 
ISL, when administered as a component 
of DOR/ISL.Pharmacokinetic values, such as AUC, 
Cmax,and C 24
To describe PROs related to HRQoL, 
self-reported HIV symptoms, and 
treatment satisfaction ofswitch to 
DOR/ISL compared to continued 
baseline ART at Week 48 . HRQoL, HIV symptom burden, and 
treatment satisfaction
To explore the antiretroviral activity 
following switch to DOR/ISL compared 
to continued baseline ART as assessed 
by [CONTACT_677699] 48 .Time to loss of virologic response
08WCSH
PRODUCT: MK-8591A  45
PROTOCOL/AMENDMENT NO.:   017 -09
MK-8591A -017-09 FINAL PROTOCOL 26-MAR -2024
Objectives Endpoints
To explore the relationship between 
genetic variation and response to the 
treatment(s) administere d, and 
mechanisms of disease. Variation across 
the human genome may be analyzed for 
association with clinical data collected in 
this study.Germline genetic variation
Success of this study is predicated only on establishing non- inferiority of DOR/ISL to 
continued baseline ART with respect to the percentage of participants with HIV -1 RNA 
≥50copi[INVESTIGATOR_014]/mL at Week 48 (ie, establishing statistical significance of H1).
4 S TUDY DESIGN
4.1 Overall Design
This is a P hase 3, randomized, active -controlled, multi- site, open -label clinical study to 
evaluate a switch from a nystable oral 2- drug or 3-drug combination (± PKbooster) ART 
regimen to DOR/ISL QD in participants with HIV -[ADDRESS_916821] been virologically suppressed 
for ≥3 months with no history of treatment failure .
A total of approximately 578 participants will be randomized (stratified by [CONTACT_677700]: PI -containing [including PI -+ InSTI -containing] regimens, InSTI -based [ non-PI-
containing] regimens , or all other [non-PI-and non -InSTI -containing] regimens) in a 1:1 
ratio into 1 of 2 treatment groups (Figure 1):
Group 1 (n= approximately 289): Switch from baseline ART to DOR/ISL QDon Day 1
Group 2 (n= approximately 289): Continue baseline ART until Week 48
After 48 weeks of assigned therapy, all participants will receive DOR/ISL QD through 
Week 96.Any participants with confirmed viremia, as described in Section [IP_ADDRESS]. 2, will be 
assessed for development of viral drug resistance and potential discontinuation from study 
intervention.
Participant safety will be monitored by a n independent eDMC through periodic review of 
safety and efficacy data (received from an independent statistician) throughout the study 
(Appendix 1).When 40% of target enrollment have completed Week 24, including visit 
assessments, a n interim analysis (which will hereafter be referred to as the “Week 24 interim 
analysis”) to assess futility based on Week 24 data is planned (Section 9.7).
Specific procedures to be performed during the study, as well as their prescribed ti mes and 
associated visit windows, are outlined in the SoA in Section 1.3. Details of each procedure 
are provided in Section 8.
08WCSH
PRODUCT: MK-8591A  46
PROTOCOL/AMENDMENT NO.:   017 -09
MK-8591A -017-09 FINAL PROTOCOL 26-MAR -2024
4.2 Scientific Rationale for Study Design
The randomized active -controlled non- inferiority study design is consistent with FDA 
regula tory guidance [Food and Drug Administration (CDER) 2015] and is considered 
appropriate for a treatment -experienced study population that is switching from another 
stable ART regimen with HIV RNA <50 copi[INVESTIGATOR_014]/mL . Small differences in virologic efficacy, 
emergence of resistance, and loss of tolerability or safety may be detected prior to 48 weeks
of treatment ,particularly for therapi[INVESTIGATOR_180559]. Thus, aligned 
with regulatory guidance [Food and Drug Administration (CDER) 2015] , the primary 
efficacy analysis will occur after 48 weeks of treatment with DOR/ISL or continued basel ine 
ART regimens .
It is anticipated that the baseline ART regimens will be heterogenic and, in some cases, may 
be associated with considerable pi[INVESTIGATOR_13551]. Thus, switching participants who are on 
continued baseline ART regimen to DOR/ISL at Week 48may sim plify regimens for 
participants continuing their baseline ART regimen ,thereby [CONTACT_677701],
including improving study retention.
4.2.1 Rationale for Endpoints
[IP_ADDRESS] Efficacy Endpoints
[IP_ADDRESS].1 HIV -1 RNA Measurements 
The primary efficacy endpoint in this s tudy is plasma HIV -1 RNA ≥50 copi[INVESTIGATOR_014]/mL. Eligible 
participants in the switch population being studied are virologically suppressed, with HIV- 1 
RNA <50 copi[INVESTIGATOR_014]/mL at baseline. The assessment of interest is the percentage of participants 
who are unable to maintain virologic suppression after switching to a new antiretroviral 
regimen.
Clinical studies of antiretroviral agents in multiple drug classes have demonstrated that 
virologic suppression of HIV -1 RNA to <50 copi[INVESTIGATOR_014]/mL reflects a clinically relevant standar d 
used across development programs for antiretroviral therapi[INVESTIGATOR_677667] 
[Vandenhende, M. A., et al 2015] . Suppressing HIV- 1 RNA to <50 copi[INVESTIGATOR_014]/mL preserves the 
immune system and minimizes the risk of opportunistic infections and disease progression.
The secondary efficacy endpoint of plasma HIV -1 RNA <40 copi[INVESTIGATOR_014]/mL corresponds to the 
lower limit of quantificat ion of the assay being used in this study.
[IP_ADDRESS].2 Definition of Clinically Significant Confirmed Viremia 
For the purpose of managing participants in this study , clinically significant confirmed 
viremia is defined as: 
Virologic Rebound : Two consecutive (2 to 4weeksapart) occurrences of HIV-1 RNA 
≥200 copi[INVESTIGATOR_014]/mL at any time during the study.
08WCSH
PRODUCT: MK-8591A  47
PROTOCOL/AMENDMENT NO.:   [ADDRESS_916822] for definition of patients with low -level viremia (viral 
load ≥50 and <200 copi[INVESTIGATOR_014]/mL), and the predictive implication of such low -level viremia is 
uncertain [Vandenhe nde, M. A., et al 2015] [Charpentier, C., et al 2014] . The US Department 
of Health and Human Services guidelines currently define virologic failure as confirmed HIV 
RNA ≥200 copi[INVESTIGATOR_014]/mL and do not recommend that low -level viremia (detectable HIV RNA 
<200 copi[INVESTIGATOR_014]/mL) automatically result in treatment modification or more frequent virologic 
monitoring [Panel on Antiretroviral Guidelines for Adults and Adolescents 2018] . 
Participants with HIV -1 RNA between 50 and 200 c opi[INVESTIGATOR_014]/mL have a lower risk of 
developi[INVESTIGATOR_180561] -1 RNA >200 copi[INVESTIGATOR_014]/mL and should 
continue on their current regimen, with HIV -1 RNA levels monitored as outlined in 
Section 8.2.2 .
An HIV- 1 RNA level of ≥50 copi[INVESTIGATOR_014]/mL must be confirmed and requires further management 
as described in Section 8.2.2.
[IP_ADDRESS] Safety Endpoints
Safety evaluations will include physical examinations (including vital signs) and laboratory 
tests ( eg, hematology, chemistry ,and urinalysis) performed per S oA (Section 1.3). AEs will 
be evaluated at each visit and assessed according to the guidelines in Section 8.4 and 
Appendix 3. Participants may be asked to return for unscheduled visits to perform additional 
safety monitoring.
[IP_ADDRESS] Weight, Laboratory, and Radiol ogical Markers
The study will compare changes in weight, laboratory, and radiological markers from 
baseline to Week [ADDRESS_916823] of DOR/ISL on the 
following:
Weight
Compared with other antiretroviral classe s, use of integrase inhibitors in patients with HIV -1 
has been associated with greater increases in body weight [Hill, A., et al 2019] . Thus, the 
mean change in weight will be measured to compare the effect of a switch to DOR/ISL with
continued InSTI -based regimen (Section 8.8.5) .
Inflammation
Causes of persistent inflammation and thrombotic activity in patients with HIV -1 remain 
topi[INVESTIGATOR_180562] [Baker, J. V., et al 2011] [Knudsen, T. B., et al 2016] 
[Wang, H., et al 2016] ; thus, key indicators of i nflammation will be m easured(Section 
8.8.2) .
Renal Function
Decreases in renal function have been noted with the use of certain NRTIs [U.S. Prescribing 
Information 2019] ; thus, key indicators of renal function will be measur ed(Section 8.8.3) .
08WCSH
PRODUCT: MK-8591A  48
PROTOCOL/AMENDMENT NO.:   [ADDRESS_916824] been associated with lipid abnormalities [U.S. Prescribing 
Information 2017] ; thus, key indicators of fasting lipid profiles will be m easured(Section 
8.8.4) .
Insulin resistance has been reported with certain antiretroviral therapi[INVESTIGATOR_014] [Carr, A., et al 1998] . 
Itisassociated with metabolic complications including diabetes, cardiovascular disease, fatty 
liver and weight gain [Vazquez -Carrera, M. 2016] . Fasting insulin and glucose will be 
measured to calculate HOMA -IR(Section 8.8.4) .
Body Composition
Decreases in BMD and lipodystrophy (peripheral and central fat redistribution) have b een 
reported in patients with HIV -1 receiving ART [AIDS info 2017] , particularly with the use of 
certain NRTIs. Key indicators of body composition (including DEXA assessments )will be 
measur ed(Section 8.8. 6).
[IP_ADDRESS] Pharmacokinetic Endpoints
PKsamples collected from all participants as described in the SoA and Section 8.6 will be 
used to evaluate PK concentrations of ISL, and as appropriate , PK-efficacy , PK-
pharmacodynamic, and PK -AE relationships o f ISL. PK values such as AUC, C max, and 
C24will be explored.
[IP_ADDRESS] Patient -reported Outcomes
PROs can provide unique information on the impact of HIV infection and its treatment from 
the patients’ perspective as some domains are difficult to observe or are subj ective and best 
collected through patient report. HIV infection and its treatment can impair HRQoL. 
Symptom burden associated with HIV treatment has decreased with improvements in ART 
regimens but persists despi[INVESTIGATOR_677668]. In conjunction 
with efficacy and safety, PRO data may help clinicians and patients in making informed 
decisions on appropriate ART regimens. HTA authorities in many countries recommend 
patient perspectives data and HRQoL measurement as part of their drug benefit evaluations. 
HRQoL data is used to estimate health utility scores, which inform cost -effectiveness model 
analysis.
This study will include 3 self -administered PRO questionnaires. The EQ -5D-5L, a generic 
HRQoL questionnaire, will provide a simple descriptive profile and index value for health 
status used to compute health utilities for health economic analyses. The HIV -SI (also known 
as HIV SDM) is a 20 -item HIV disease -specific questionnaire designed to assess the 
prevalence and burden of adverse e ffects associated with ART regimens. The HIVTSQ is a 
10-item instrument used to measure satisfaction with medications for people with HIV 
infection. The status version (HIVTSQs) will be used to evaluate treatment satisfaction over 
time.
08WCSH
PRODUCT: MK-8591A  49
PROTOCOL/AMENDMENT NO.:   017 -09
MK-8591A -017-09 FINAL PROTOCOL 26-MAR -2024
[IP_ADDRESS] Planned Exploratory Biomarker Research
[IP_ADDRESS].[ADDRESS_916825] a participant’s response to therapy, susceptibility to, severity, 
and progression of disease. Variable response to therapy may be due to genetic determinants 
that impact drug absorption, distribution, metabolism, and excretion; mechanism of action of 
the drug; disease etiology; and/or molecular subtype of the disease being treated. Therefore, 
where local regulations and IRB/IEC allow, a sample will be collected for DNA analysis 
from consenting participants.
DNA samples may be used for research related to the study intervention( s), the disease under 
study, or related diseases. They may also be used to develop tests/assays including diagnostic 
tests related to the dise ase under study, related diseases, and study intervention(s). Genetic 
research may consist of the analysis of 1 or more candidate genes , the analysis of genetic 
markers throughout the genome , or analysis of the entire genome. Analysis may be 
conducted if i t is hypothesized that this may help further understand the clinical data.
The samples may be analyzed as part of a multi -study assessment of genetic factors involved 
in the response to understand study disease or related conditions.
[IP_ADDRESS] Future Biomedical Rese arch
The Sponsor will conduct future biomedical r esearch on specimens for which consent was 
provided during this study. This research may include genetic analyses (DNA), gene 
expression profiling (RNA), proteomics, metabolomics (serum, plasma), and/or the 
measurement of other analytes, depending on whi ch specimens are consented for future 
biomedical r esearch.
Such research is for biomarker testing to address emergent questions not described elsewhere 
in the protocol (as part of the main study) and will only be conducted on specimens from 
appropriately consented participants. The objective of coll ecting/retaining specimens for 
future biomedical r esearch is to explore and identify biomarkers that inform the scientific 
understanding of diseases and/or their the rapeutic treatments. The overarching goal is to use 
such information to develop safer, more effective drugs/vaccines, and/or to ensure that 
participants receive the correct dose of the correct drug/vaccine at the cor rect time. The 
details of future biomedi cal research are presented in Appendix 6.
4.2.2 Rationale for the Use of Comparator/Placebo
This study will evaluate switching from various baseline regimens to reflect the diverse 
regimens that are currently used and from which patients might be switched. Parti cipants’ 
baseline antiretroviral combinations have likely been chosen on a case -by-case basis, for side 
effect profile, schedule, pi[INVESTIGATOR_13551], or any number of other reasons. Allowed ART regimens 
will include oral 2 -drug or 3- drug combination (± PKbooster ) (provided a participant meets 
all other inclusion requirements and does not meet any exclusionary criteri on). This allows 
better representation of the real -world use of antiretroviral agents and current HIV -[ADDRESS_916826]: MK-8591A  50
PROTOCOL/AMENDMENT NO.:   017 -09
MK-8591A -017-09 FINAL PROTOCOL 26-MAR -2024
treatment guidelines. This study will be open- label because blinding of all potential baseline 
regimens is considered infeasible, not only because of the anticipated diversity of the 
baseline regimens, but also because it could result in a large pi[INVESTIGATOR_677669] -tablet regimens QDat baseline. Further, the primary efficacy endpoint 
is based on HIV-1 RNA results, an obje ctive laboratory value, which is less susceptible to 
unblinding bias.
4.2.3 Rationale for the Selected Participant Population
The rationale for the participant population selected for this study is as follows:
Participants Switching ART Regimens: Although many A RT regimens are associated 
with a high likelihood of achieving and maintai ning undetectable HIV -1 RNA levels, 
globally, while 70% of all persons living with HIV know their HIV status, only 44% are 
virologically suppressed [Joint United Nations Programme on HIV/AIDS 2017] . Drug -
associated adverse effects and toxicities, food requirements, high pi[INVESTIGATOR_180564], and/or 
dosing frequency and DDIs with concomitant medications are among the reasons that 
may contribute to l ack of adherence to prescribed ART regimens. These are the same 
motivators for patients and prescribers to consider switching components of an 
antiretroviral regimen even in the setting of viral suppression, before failure can occur.
Furthermore, given the aging of the population with HIV, it is anticipated that switches 
will become even more common in the setting of ongoing concerns for the risks of long-
term toxicity, DDIs, and comorbid conditions (ie, neuropsychiatric, cardiovascular).
Participants With Virological Suppression for ≥3 Months : With increasing prevalence 
of early treatment initiation, increasing life expectancy for those who are infected with 
HIV-1, and decreasing incidence rates of new HIV -1 infections in many parts of the
world, an important population in need of improved treatment regimens are those who are 
already virologically suppressed. Data from the ongoing Phase 2study ( MK-8591 P011)
demonstrate that after receiving at least 3 months of the 3- drug regimen of DOR +ISL+
3TC, almost all participants with HIV -1 RNA < 50copi[INVESTIGATOR_014] /mL maintained virologic 
suppression on a 2-drug regimen of DOR + ISL through an additional [ADDRESS_916827] demonstrated stable suppression with an HIV -1 RNA <50 copi[INVESTIGATOR_014]/mL for ≥[ADDRESS_916828] udy will be representative of the drug’s use in a broader patient population. As 
1example, non- Caucasian females and males were found to have higher plasma 
concentrations of EF V(an NNRTI) than their Caucasian counterparts, indicating an 
increased risk of EFV-induced toxicity in non -Caucasian patients [Burger, D., et al 2005] . As 
another example, among the population with HIV in the US, those of African heritage have 
08WCSH
PRODUCT: MK-8591A  51
PROTOCOL/AMENDMENT NO.:   017 -09
MK-8591A -017-09 FINAL PROTOCOL 26-MAR -2024
been found to be less li kely to maintain virologic suppression compared to other groups ,and 
the factors contributing to this remain to be elucidated [Weintrob, A. C., et al 2009] 
[Ribaudo, H. J., et al 2013] . Thus, subgroup ana lyses on race and ethnicity will be performed 
to better understand how these parameters may influence clinical outcome and toxicity.
4.2.5 Rationale for Collecting Gender Identity Data
Transgender people, defined as those whose gender identities and/or expressions differ from 
the sex assigned to them at birth, have a high prevalence and incidence of HIV infection 
globally [Poteat, T., et al 2016]. Specifically, transgender women have an increased risk of 
HIV infection attributed to challenges associated with copi[INVESTIGATOR_677670] ,such 
as discrimination, stigmatization ,and marginalization [Centers for Disease Control and 
Prevention 2019] [Department of HIV/AIDS 2015] . When considering HIV treatment ,the 
WHO considers transgender people to be a separate key population because of their specific 
health needs and high vulnerability [Department of HIV/AIDS 2015] . Data will be collected 
in this study to assess clinical outcomes in the transgender population .
4.2.6 Rationale for Infant Safety Data Collection
Follow -up through 1 year of age for infants born to participants who become pregnant while 
receiving study intervention provides the ability to monitor growth and development as well 
as potential adverse effects that may be associated with prenatal drug exposure. Growth 
parameters (ie, length, weight, and head circumference) withi n normal range at 
approximately 1 year of age are key noninvasive indicators that a serious congenital 
malformation caused by [CONTACT_140214].
4.2.7 Rationale for Continuing Study Intervention During Pregnancy
The US Department of Health and Human Services guidelines currently advise that women 
who become pregnant while receiving ART for HIV infection should continue their regimen 
provided it is safe, well tolerated, and effective at virologic suppression since altering the 
regimen could cause an increase in viral load [Panel on Treatment of Pregnant Women with 
HIV Infection and Prev 2018] . Nonclinical development al and reproductive toxicology 
studies did not identify any teratogenicity or other clinically relevant concerns that would 
preclude continued dosing of DOR/ISL in participants who become pregnant and consent to 
continue study intervention (where allowed b y local regulations, health authorities, and ethics 
committees and as appropriate based on available data/local standard -of-care guidelines) 
(Sections [IP_ADDRESS] and 8.11.6 ).For those participants continuing on their baseline ART 
regimens who become pregnant and consent to continue study intervention, investigators will 
need to follow local circulars/guidelines for the baseline ART regimen.
There are no clinical data currently available to support breastfeeding by [CONTACT_180617]/ISL.
08WCSH
PRODUCT: MK-8591A  52
PROTOCOL/AMENDMENT NO.:   017 -09
MK-8591A -017-09 FINAL PROTOCOL 26-MAR -2024
4.3 Justi fication for Dose
Inhibitory quotient (C trough /IC50) is the ratio of drug exposure to viral susceptibility. In a 
Phase 1b proof of concept study (MK -8591 P003), single doses as low as 0.[ADDRESS_916829] anti retro viral activity at 7 days postdose; this low single dose provided an IQ threshold 
of 5for wild -type HIV -[ADDRESS_916830] the ISL -TP concentrations achieved after 
a single dose of 0.75 mg ISLprovide IQs of 21 and 4 for wild -type and M184V virus, 
respectively. After 7 daily doses of 0.75 mg ISL, IQs increase to 113 for wild- type virus and 
23 for M184V/I virus. Anti retro viral activity against the exceedingly rare 69ins + M184I/V 
mutant virus (the NRTI mutant with the highest potency reduction for ISL) is expected to be 
achieved after 7 daily doses, with an IQ of 5. Steady -state concentrations at later timepoints
will produce even higher IQs, as there is additional accumulation of ISL-TP. These 
simulations support the selection of 0.75 mg ISLin combination with 100 mg DOR to 
maintain virologic suppression in participants who switch from a stable ART regimen at 
baseline.
In the Phase 2 clinical study (MK-8591 P011) , 3daily doses of ISL(0.25, 0.75, and 2. 25mg)
were evaluated in combination with DOR (100 mg)+3TC for 24weeks and subsequently 
with DOR alone through Week 48. All 3 doses of ISLwith DOR ±3TC demonstrated potent 
antiretroviral activity comparable with the comparator, DOR/3TC/TDF ,as demonstrated by 
[CONTACT_677702] :the proportion of participants with HIV -1 RNA
<50copi[INVESTIGATOR_014]/mL at both Weeks 24 and 48 . Overall, no ISLdose-response for efficacy was 
observed. Graphical analysis of steady- state ISL-TP trough concentrations and response at 
Week 48from P011 showed no trends in exposure -response. The totality of these efficacy 
data supports the conclusion that the dose range studied (0.25 to2.25 mg daily) is on the 
plateau of the dose -response curve. P011 also demonstrated that all doses of ISLstudied, 
when administered with DOR +3TC or DOR alone , hada favorable safety and tolerability 
profile through Week 48compar able with that of DOR/3TC/TDF .
DOR will be administered at the approved dose of 100 mg. This dose has been studied in 
Phase 1 to 3 clinical studies in treatment -naïve and virologically suppressed participants with 
HIV-1 and was selected based upon favorable efficacy, safety, tolerability, and metabolic 
profiles as confirmed in Phase 3 clinical studies [Orkin, C., et al 2018] [Molina, J. M., et al 
2018] (MK- 1439A Protocol 024) .Of note , among 32 participants in MK-1439A Protocols 
024 and 030 infected with HIV- 1 harbor ing theNNRTI resistance mutations K103N, Y181C, 
and/or G190A at study entry , allachieved virologic suppression following 48 weeks of 
treatment with DOR/3TC/TDF ( 24 of 32 participants had been virologically suppressed onPI 
[INVESTIGATOR_180566] 8 had been treatment -naïve ).
In summary, a 0.75- mg dose of ISLin combination with [ADDRESS_916831]: MK-8591A  53
PROTOCOL/AMENDMENT NO.:   [ADDRESS_916832] participant (or their legally acceptable representative) 
provides documented informed consent. The overall study ends when the last participant 
completes the last study -related contact, withdraws consent, or is lost to follow- up (ie, the 
participant is unable to be co ntacted by [CONTACT_093]) .
4.4.1 Clinical Criteria f orEarly Study Termination
The clinical study may be terminated early if the extent (incidence and/or severity) of 
emerging effects/clinical endpoints is such that the risk/benefit ratio to the study populat ion 
as a whole is unacceptable. In addition, further recruitment in the study or at (a)particular 
study site(s) may be stopped due to insufficient compliance with the protocol, Good Clinical 
Practice ( GCP ), and/or other applicable regulatory requirements, procedure -related problems 
or the number of discontinuations for administrative reasons is too high .
Early study termination will also be considered if futility criteria are met at the Week 24 
interim analysis (Section 9.7).
5 STUDY POPULATION
Participants ≥18years of age with HIV -[ADDRESS_916833] been virologically suppressed for 
≥3months on anystable oral 2 -drug or 3- drug combination (± PKbooster) ART will be 
enrolled in this study.
Prospective approval of protocol deviations to recruitment and enrollment cr iteria, also 
known as protocol waivers or exemptions, is not permitted.
5.1 Inclusion Criteria
A participant will be e ligible for inclusion in the study if the participant:
Type of Participant and Disease Characteristics
1.Is HIV- 1 positive with plasma HIV -1 RNA <50 copi[INVESTIGATOR_014]/mL at screening.
Note: A single repeat of the plasma HIV -[ADDRESS_916834] will be allowed, provided 
results are available within the 45 -day screening window.
2.Hasbeen receiving continuous, stable oral 2 -drug or 3- drug combination (± PKbooster) 
with documented viral suppression ( HIV-1 RNA <50 copi[INVESTIGATOR_014]/mL) for ≥[ADDRESS_916835] or current regimen.
Note: A nonclinically significant HIV-1 RNA result above the limit of quantification ( ie, 
transient detectable viremia) during the [ADDRESS_916836]: MK-8591A  54
PROTOCOL/AMENDMENT NO.:   017 -09
MK-8591A -017-09 FINAL PROTOCOL 26-MAR -2024
Note: Previous regimen switches for tolerability, side eff ects, dosing convenience, or cost 
are permitted if they occurred >[ADDRESS_916837] 18years of age at the time of signing the informed consent.
Contraception/Pregnancy
4.A female participant is eligible to participate if she is not pregnant or breastfeeding, and 
at least one of the following conditions applies:
Is not a woman of childbearing poten tial (WOCBP)
OR
Is a WOCBP and using an acceptable contraceptive method, or be abstinent from 
heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long 
term and persistent basis), as described in Appendix [ADDRESS_916838] 6 weeks, corresponding to the time needed to eliminate any study 
intervention(s) (eg, 5 terminal half -lives) after the last dose of study intervention. The 
investigator should evaluate the potential for contraceptive method failur e (ie, 
noncompliance, recently initiated) in relationship to the first dose of study 
intervention.
A WOCBP must have a negative highly sensitive pregnancy test ([urine or serum] as 
required by [CONTACT_427]) within [ADDRESS_916839] dose of study intervention.
If a urine test cannot be confirmed as negative (eg, an ambiguous result), a serum 
pregnancy test is required. In such cases, the participant must be excluded from 
participation if the serum pregnancy result is positive.
Additional requirements for pregnancy testing during and after study intervention are 
located in Appendix 2 .
The investigator is responsible for review of medical history, menstr ual history, and 
recent sexual activity to decrease the risk for inclusion of a woman with an early 
undetected pregnancy.
Informed Consent
5.The participant (or their legally acceptable representative) has provide ddocumented
informed consent for the study. The participant may a lso provide consent for f uture 
biomedical r esearch. However, the participant may participate in the main study without 
participating in future biomedical r esearch.
08WCSH
PRODUCT: MK-8591A  55
PROTOCOL/AMENDMENT NO.:   [ADDRESS_916840] be excluded from the study if the participant:
Medical Conditions
1.Has HIV-2infection.
2.Has hypersensitivity or other contraindication to any of the components of the study 
interventions as determined by [CONTACT_093].
3.Has a nactive diagnosis of hepatitis due to any cause, including active HBV coinfection 
(defined as H BsAg-positive or HBV DNA positive ).
Note: Past HBV infection or previous HBV vaccination (defined as H BsAg- negative and 
positive for antibody against H BsAg) is not an exclusion criterion.
Note: Participants who do not demonstrate immunity to HBV are encouraged to be 
vaccinated against HBV.
Note: Chronic HCV infection (detectable HCV RNA) and treatment with direct -acting 
antiviral therapi[INVESTIGATOR_677671],provided the participant has stable liver function 
tests and no significant hepatic synthetic dysfunction. Hepatic synthetic dysfunction is
defined as a serum albumin <2.8 g/dL or an INR >1.7 in the absence of another 
explanation for the abnormal laboratory value.
4.Has a history of malignancy ≤5 years prior to signing informed consent except for 
adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or 
cutaneous Kaposi’s sarcoma.
5.Has a history or current evidence of any condition (including active tuberc ulosis 
infection) , therapy, laboratory abnormality or other circumstance (including drug or 
alcohol use or dependence) that might, in the opi[INVESTIGATOR_871], confound the 
results of the study or interfere with the participant’s participation for t he full duration of 
the study, such that it is not in the best interest of the participant to participate.
Prior/Concomitant Therapy
6.Is taking or is anticipated to require systemic immunosuppressive therapy ,immune 
modulators , or any prohibited therapi[INVESTIGATOR_33944] 6.5 from 45days prior to 
Day 1 through the study treatment period .
Note: Time -limited courses of corticosteroids (eg, for asthma exacerbation) will be 
allowed.
7.Is currently taking long- acting cabotegravir -rilpi[INVESTIGATOR_12979].
08WCSH
PRODUCT: MK-8591A  56
PROTOCOL/AMENDMENT NO.:   017 -09
MK-8591A -017-09 FINAL PROTOCOL 26-MAR -2024
Prior/Concurrent Clinical Study Experience
8.Is currently participating in or has participated in a clinical study with an investigational 
compound or device from 45 days prior to Day 1 through the study treatment period.
Note: Conc urrent participation in observational or non- interventional studies may be 
permitted and should be discussed with the Sponsor prior to enrollment and through 
study duration.
Diagnostic Assessments
9.Has a documented or known virologic resistance to DOR , as d emonstrated by [CONTACT_180618]:
V106A/M, V108I, Y188L, H221Y, P225H, F227C/L, M230I/L, L234I, P236L, or 
Y318F.
Note: Participants who do not have documentation of resistance testing may enroll.
10.Has exclusionary laboratory values (completed by [CONTACT_2237]) within 45 days 
prior to Day 1 as listed in Table 1 .
Note: A single repeat of a laboratory screening test will be allowed for test results that 
are unexpected based on documented prior laboratory results, but the repeat test results 
must be ava ilable within the 45 -day screening window.
Table 1 Laboratory Exclusion Criteria
Laboratory Assessment Exclusionary Values
Alkaline Phosphatase >3 × ULN
AST >5× ULN
ALT >5 × ULN
Hemoglobin <9.0 g/dL (female) or <10.0 g/dL (male)
Calculated Cr cl ≤30 mL/min based on the Cockcroft- Gault 
equation (Appendix 8).
ALT=alanine aminotransferase; AST =aspartate aminotransferase; Crcl=creatinine clearance; ULN=upper 
limit of normal.
08WCSH
PRODUCT: MK-8591A  57
PROTOCOL/AMENDMENT NO.:   017 -09
MK-8591A -017-09 FINAL PROTOCOL 26-MAR -2024
Other Exclusions
11.Is female and expecting to conceive or donate eggs at any time during the study.
Note: Investigators should provide appropriate guidance to female participants 
regarding egg donation after completion of the study intervention. Consistent with the 
recommendations for contraceptive us e, it is recommended that all female participants 
refrain from egg donation for [ADDRESS_916841] dose of study intervention.
Note: Donation of sperm should follow local guidelines for individuals who are HIV-
positive .
5.3 Lifestyle Considerations
There are no lifestyle restrictions.
5.4 Screen Failures
Screen failures are defined as participants who consent to participate in the clinical study, but 
are not subsequently randomized in the study. A minimal set of screen failure information is 
required to e nsure transparent reporting of screen failure participants to meet the 
Consolidated Standards of Reporting Trials (CONSORT) publishing requirements and to 
respond to queries from regulatory authorities. Minimal information includes demography, 
screen failu re details, eligibility criteria, and any AEs or SAEs meeting reporting 
requirements as outlined in the data entry guidelines.
5.5 Participant Replacement Strategy
A participant who discontinues from study intervention OR withdraws consent from the 
study will not be replaced.
6 STUDY INTERVENTION
Study intervention is defined as any investigational intervention(s), marketed product(s), 
placebo, or me dical device(s) intended to be administered to a study participant according to 
the study protocol .
Clinical supplie s (study intervention provided by [CONTACT_1034] )will be packaged to support 
enrollment .Clinical supplies will be affixed with a clinical label in accordance with 
regulatory requirement s.
6.1 Study Intervention(s) Administered
The study interventions to be used in this study are outlined inTable [ADDRESS_916842]: MK-8591A  58
PROTOCOL/AMENDMENT NO.: 017-09
MK-8591A -017-09 FINAL PROTOCOL 26-MAR -2024
Table 2 Study Intervention s
Arm 
NameArm TypeIntervention 
NameTypeDose 
FormulationUnit Dose 
Strength(s)Dosage 
Level(s)Route of 
AdministrationTreatment 
PeriodUseIMP/
NIMPSourcing
Group 1 Experimental DOR/ISL Drug Tablet 100 mg/
0.75 mg100 mg/
0.75 mg QDOral Day 1 to 
Week 96cExperimental IMP Provided 
centrally by 
[CONTACT_351915] 2 Active 
ComparatorBaseline 
ART 
RegimenaDrug Administered 
as per 
approved 
labelAdministered 
as per 
approved 
labelAdministered 
as per 
approved 
labelOral Day 1 to 
Week 48Experimental IMP Local 
country-
level 
sourcingb
Group 2 Experimental DOR/ISL Drug Tablet 100 mg/
0.75 mg100 mg/
0.75 mg QDOral Week 48 to 
Week 96cExperimental IMP Provided 
centrally by 
[CONTACT_677703]=antiretroviral therapy; CCR5=chemokine receptor type 5; DOR=doravirine; InSTI=integrase strand transfer inhibitor; ISL=islatravir; NNRTI=non -nucleoside reverse 
transcriptase inhibitor; NRTI=nucleoside analog reverse transcriptase inhibitor; PI=protease inhibitor; PK=pharmacokinetic; QD=once daily.
aAllowed drug classes include NRTIs, NNRTIs, PIs, InSTIs, fusion inhibitors, CCR5 antagonists, postattachment inhibitor, and PK boosters .
bThe Sponsor will not provide baseline ART regimens. Participants will provide their own ART medications , in accordance with local regulations .
cFor participants who are pregnant at the last regularly scheduled study visit (TW 96), study intervention will be dispensed at Week 96. In addition, their visit s chedule will be 
extended through the duration of the pregnancy and study intervention will be dispensed at Weeks 108, 120, and 132, as applic able.
Definition Investigational Medicinal Product (IMP) and Non -Investigational Medicinal Product (NIMP) is based on guidance issued by [CONTACT_63512]. Regional 
and/or Country differences of the definition of IMP/NIMP may exist. In these circumstances, local legislation is followed.
08WCSH
PRODUCT:   MK-8591A  59
PROTOCOL/AMENDMENT NO.:   017 -09
MK-8591A -017-09 FINAL PROTOCOL 26-MAR -2024
All supplies indicated in Table 2 will be provided per the "Sourcing" column depending upon 
local country operational requirements. If local sourcing, e very attempt should be made to 
source these supplies from a single lot/ba tch number .
Refer to Section 8.1.8 for details regarding administration of the study intervention.
6.2 Preparation/Handling/Storage/Accountability
6.2.[ADDRESS_916843] be stored 
in a secure, environmentally controlled, and monitored (manual or automated) area in 
accordance with the labeled storage conditions with access limited to the investigator and 
authorized site staff.
The investigator, institution, or the head of the medical institution (where applicable) is 
responsible for study intervention accountability, reconciliation, and record maintenance (ie, 
receipt, reconciliation, and final disposition records).
For all study sites, the local country Sponsor personnel or designee will provide appropriate 
documentation that must be completed for drug accountability and return, or local discard 
and destruction if appropriate. Where local discard and destruction is appropriate, the 
investigator is responsible for ensuring that a local discard/destruction procedure is 
documented.
The study site is responsible for recording the lot number, manufacturer, and expi[INVESTIGATOR_677672] (if applicable) as per local guidelines unless otherwise 
instructed by [CONTACT_1034].
The investigator shall take responsibility for and shall take all steps to maintain appropriate 
records and ensure appropriate supply, storage, handling, distrib ution, and usage of study 
interventions in accordance with the protocol and any applicable laws and regulations .
08WCSH
PRODUCT:   MK-8591A  60
PROTOCOL/AMENDMENT NO.:   017 -09
MK-8591A -017-09 FINAL PROTOCOL 26-MAR -2024
6.3 Measures to Minimize Bias: Randomization and Blinding
6.3.1 Intervention Assignment
Intervention randomization will occur centrally using an interac tive response technology 
(IRT) system. There are 2study intervention arms. Participants will be assigned randomly in 
a 1:1ratio to Group 1 orGroup 2 , respectively.
6.3.2 Stratification
Intervention randomization will be stratified according to the following factor:
Baseline ART R egimen
oPI-containing regimens (including PI -+ InSTI -containing regimens)
oInSTI -based regimens ( non-PI-containing regimens)
oAll other non-PI-and non -InSTI -containing regimens
The single s tratification factor help s toensur e that the treatment arms will be well -balanced, 
and the study results will not be confounded by [CONTACT_3038]’ baseline ART regimens.
6.3.3 Blinding
This is an open -label study; therefore, the Sponsor, investigator, and participant will know 
the intervention administered.
6.4 Study Intervention Compliance
Participants should be instructed to bring the study intervention bottles, whether clinical 
supplies provided by [CONTACT_677704], to their visits. At 
each visit, the number of tablets remaining in the study packaging will be counted, reviewed,
and recorded. The results will be used to assess participant compliance . If a di screpancy is 
noted, the investigator/study coordinator must discuss the discrepancy with the participant 
and the explanation must be documented. Participants in both treatment arms should be 
reminded of the importance of taking their study interven tion as instructed for the entire 
duration of the study.
Decisions to temporarily withhold study intervention because of an AE or other reason (s)
will be reviewed on a case -by-case basis by [CONTACT_093]. Interruptions from the protocol -
specified treatment plan that are expected to be [ADDRESS_916844]:   MK-8591A  61
PROTOCOL/AMENDMENT NO.:   017 -09
MK-8591A -017-09 FINAL PROTOCOL 26-MAR -2024
6.5 Concomitant Therapy
Medications specifically prohibited in the exclusion criteria are not allowed during time 
periods specified by [CONTACT_151524] . If there is a clinical 
indication for any medications specifically prohibited, discontinuation from study 
intervention may be required. The investigator should discuss any questions regarding this 
with the Sponsor Clinical Director . The final decision on any supportive therapy rests with 
the investigator and/or the participant ’s primary physician. However, the decision to c ontinue 
the participant on study intervention requires the mutual agreement of the investigator, the 
Sponsor, and the participant.
Prior and concomitant therapi[INVESTIGATOR_180568] 3 are not permitted from 45 days prior to 
Day 1 through the study treatment period. Table 3 is not comprehensive, and the investigator 
should use his/her medical judgment when assessing a participant’s prior and concomitant 
therapy(ies). The Sponsor Clinical Director or designee should be contact[CONTACT_180622] a therapy not on the list below or regarding potential DDI interactions with a 
specific treatment that the participant may plan to receive.
In instances where the local product circular for DOR or baseline ART regimen is more 
restrictive with regard to prohibited (ie, contraindicated or not recommended) therapy(ies), 
the local product circular supersedes this section .
08WCSH
PRODUCT:   MK-8591A  62
PROTOCOL/AMENDMENT NO.:   017 -09
MK-8591A -017-09 FINAL PROTOCOL 26-MAR -2024
Table 3 Prohibited Therapi[INVESTIGATOR_180569]3A
inducersIncluding bu t not limited to:
Carbamazepi[INVESTIGATOR_181758]. John’s Wort
Herbal remedies
Modafinil
Bosentan
Nafcillin
Non- study ART All non -study a ntiretrovirals ( with the exception of 
baseline ART during the screening period and 
intrapartum treatment [eg, IV AZT] in the case of 
pregnancy ) including treatments for a viral infection 
other than HIV -1, such as hepatitis B, with an agent 
that is active against HIV -1(eg,adefovir, TDF, TAF, 
FTC, or 3TC).
Entecavir therapy for HBV infection is permitted.
Immunosuppressive ther api[INVESTIGATOR_180571], immune modulators or other 
systemic immunosuppressive therapy, including 
interferon -based treatment for hepatitis
Time-limited courses of corticosteroids (eg, for 
asthma exacerbation) are permitted.
Investigational agents All non- study investigational agents including devices
Additional prohibited therapi[INVESTIGATOR_677673]
3TC=lamivudine; ART=antiretroviral therapy; CYP3A=cytochrome P450 3A ; FTC=emtricitabine; HBV=hepatitis B 
virus; HIV=human immunodeficiency virus; ISL=islatravir; TAF=tenofovir alafenamide; TDF=tenofovir disoproxil 
fumarate .
6.5.[ADDRESS_916845]:   MK-8591A  63
PROTOCOL/AMENDMENT NO.:   017 -09
MK-8591A -017-09 FINAL PROTOCOL 26-MAR -2024
6.6 Dose Modification (Escalation/Titration/Other)
Dose modification of DOR/ISL is not permitted during the study.
Modifications and/or regimen changes may be permissible in the baseline ART arm
(Group 2),but require S ponsor approval (ie, FTC and 3TC substitutions, protease inhibitor 
dose escalation during pregnancy ). 
6.7 Intervention After the End of the Study
At the end of Week 96, provided development of DOR/ISL continues, all eligible 
participants will be given the option to continue rece ivingstudy intervention without 
interruption (eg, as part of a rollover study) until it becomes locally available .Eligible 
participants arethose who have completed the last scheduled study visit andare considered 
by [CONTACT_677705]/ISL.
Participants who complete the Week [ADDRESS_916846] decreases in CD4+ T -
cell and/or total lymphocyte counts that meet ECI criteria (Section 8.4.7) at Week [ADDRESS_916847] a confirmation visit in this study (per Section 8. 11.5 and Section 1.3.4) .
Upon repeat testing, i f discontinuation criteria (Section 7.1) a re confirmed, participation 
in the rollover study will be stopped.  
 
Upon repeat testing, if disc ontinuation criteria (Section 7.1) are not confirmed, the 
participant will continue to participate in the rollover study only .
Participants who decline participation in the rollover study whose Week 96 visit shows 
decreases in CD4+ T -cell and/or total lymphocyte counts should be managed per 
Section [IP_ADDRESS] .
6.8 Clinical Supplies Disclosure
This study is open- label; therefore, the participant, the study site personnel, the Sponsor, 
and/or designee are not blinded. Study intervention (name, strength, or potency) is included 
in the label text; random code/disclosure envelopes or lists are not provided.
CCI
CCI
08WCSH
PRODUCT:   MK-8591A  64
PROTOCOL/AMENDMENT NO.:   [ADDRESS_916848] be collected through the participant’s last scheduled foll ow-
up, even if the participant has discontinued study intervention. Therefore, all participants 
who discontinue study intervention prior to completion of the protocol -specified treatment 
period will still continue to participate in the study as specified in Section 8.11.3.
Participants may discontinue study intervention at any time for any reason or be d iscontinued 
from the study intervention at the discretion of the investigator should any untoward effect 
occur. In addition, a participant may be discontinued from study intervention by [CONTACT_19419], the study plan is violated, or 
for administrative and/or other safety reasons. Specific details regarding procedures to be 
performed at study intervention discontinuation are provided in Section 8.11.3.
A participant must be discontinued from study intervention but continue to be monitored per 
Section 8.11.3 for any of the following reasons:
The participant requests to discontinue study interven tion.
The participant has a medical condition or personal circumstance (for pregnancy, see 
Section 8.11.6 ) which, in the opi[INVESTIGATOR_11922]/or Sponsor, places the 
participant at unnecessary risk from continued administration of study interven tion.
The participant chooses to breastfeed.
Note: Study intervention can continue until b reastfeeding is initiated.
The participant has confirmed HIV -1 virologic rebound as defin ed in Section [IP_ADDRESS].2.
Occurrence of any Category C conditions included in the CDC 1993 Revised 
Classification System for HIV Infection and Expanded Surveillance Case Definition for 
AIDS Among Adolescents and Adults [Centers for Disea se Control (CDC) 1992] .
The participant has an SAE or Grade [ADDRESS_916849]:   MK-8591A  65
PROTOCOL/AMENDMENT NO.:   [ADDRESS_916850] be discontinued from study inte rvention for any of the following reasons ,
but continue to be monitored per Section 8.11. 5:
1.Discontinuation criteria for CD4+ T -cellcount:
a.For participants with an average baseline* CD4+ T -cell count ≥500 cells/mm3, a 
≥30% reduction from average baseline in CD4+ T -cell count AND a CD4+ T -cell 
count decrease to <500cells/mm3on 2 consecutive measurements taken 3to 4 weeks 
apart
OR
b.For participants with an average baseline* CD4+ T -cell count <500 cells/mm3, a 
≥30% reduction from average baseline in CD4+ T -cell count on 2 consecutive 
measurements taken 3to 4 weeks apart
OR
c.For allparticipants with an average baseline* CD4+ T -cell count ≥200 cells/mm3
(including participants with an average baseline CD4+ T- cell count <200 cells/mm3
who ha ve increases in CD4 T -cell count to  200cells/mm3for 3 consecutive 
months), a CD4+ T- cell count decrease to <200 cells/mm3on 2 consecutive 
measurements taken 3to 4 weeks apart
2.Discontinuation criteria for total lymphocyte count:
a.For participants with an average baseline* total lymphocyte count ≥1×109cells/L :
i. a ≥30% reduction from average baseline *total lymphocyte count AND a decrease 
in total lymphocyte count to <1 ×109cells/L on 2 consecutive measurements 
taken 3 to 4 weeks apart
OR
ii. a ≥30% reduction from average baseline *total lymphocyte count with total
lymphocyte count remaining ≥1 ×109cells/L on 2 consecutive measurements 
taken 10 to 14 weeks apart
b.For participants with an average baseline* total lymphocyte count <1 ×109cells/L, a 
≥30% reduction from average baseline * total lymphocyte count on 2 consecutive 
measurements taken 3to 4 weeks apart
* Average baseline is defined as theaverage value between screening (within [ADDRESS_916851] dose of study intervention) and Day 1.
08WCSH
PRODUCT:   MK-8591A  66
PROTOCOL/AMENDMENT NO.:   [ADDRESS_916852] be withdrawn from the study if the participant withdraws consent from the 
study.
If a participant withdraws from the study, they will no longer receive study intervention or be 
followed at scheduled protocol visits.
Specific details regarding procedures to be performed at the time of withdrawal from the 
study, as well as specific det ails regarding withdrawal from future biomedical r esearch, are 
outlined in Section 8.1.9. The procedures to be performed should a participant repeatedly fail 
to return for scheduled visits and/or if the study site is unable to contact [CONTACT_111953] 7.3.
7.[ADDRESS_916853] t o Follo w-up
If a participant fails to return to the clinic for a required study visit and/or if the site is unable 
to contact [CONTACT_2299], the following procedures are to be performed:
The site must attempt to contact [CONTACT_19423]. If the 
participant is contact[INVESTIGATOR_530], the participant should be counseled on the importance of 
maintaining the protocol -specified visit schedule.
The investigator or designee must make every effort to regain contact [CONTACT_19424] (eg, telephone calls and/or a certified letter to the participant’s last 
known mailing address or locally equivalent methods). These contact [CONTACT_19425]’s medical record.
8 STUDY ASSESSMENTS AND PROCEDURES
Study procedures and their timing are summarized in the SoA.
Adherence to the study design requirements, including those specified in the SoA, is 
essential and required for study conduct.
The investigator is responsible for ensuring that procedures are conducted by 
[CONTACT_19426] (by [CONTACT_8640], training, and experience) staff. Delegation of study 
site personnel responsibilities will be docu mented in the Investigator Trial File Binder (or 
equivalent).
All study- related medica l decisions must be made by [CONTACT_19427] a qualified 
physician.
All screening evaluations must be completed and reviewed to confirm that potential 
participants meet all eligibility criteria. The investigator will maintain a screening log to 
record details of all participants screened and to confirm eligibility or record reasons for 
screening failure, as applicable.
08WCSH
PRODUCT:   MK-8591A  67
PROTOCOL/AMENDMENT NO.:   017 -09
MK-8591A -017-09 FINAL PROTOCOL 26-MAR -2024
Additional evaluations/testing may be deemed necessary by [CONTACT_88686]. In some cases , such evaluation/testing 
may be potentially sensitive in nature (eg, HIV, Hepatitis C), and thus local regulations 
may require that additional informed consent be obtained from the participant. In these 
cases, such evaluations/testing will be performed in accordance with those regulations.
The amount of blood collected from each participant over the fullduration of the study is 
provided in Appendix 2. 
Repeat or unscheduled samples may be taken for safety reasons or for technical issues with 
the samples.
8.1 Administrative and General Procedures
8.1.1 Informed Consent
The investigator or medically qualified designee (consistent with local requirements) must 
obtain documented informed consent from each potential participant or their legally 
acceptable representative prior to participating in this clinical study or future biomedical 
research .If there are changes to the participant’s status during the study (eg, health or age of 
majority requirements), the investigator or medically qualified designee must ensure the 
appropriate documented informed consent is in place .
[IP_ADDRESS] General Informed Consent
Informed consent given by [CONTACT_19429] a consent form. The form must include the trial protocol n umber, trial 
protocol title, dated signature, and /agreement of the participant (or his/her legally acceptable 
representative) and of the person conducting the consent discussion.
A copy of the signed and dated informed consent form should be given to the participant (or 
their legally acceptable representative) before participation in the study.
The initial ICF, any subsequent revised ICF, and any written information provided to the 
participant must receive the IRB/IEC’s approval/favorable opi[INVESTIGATOR_375880] e of use. The 
participant or his/her legally acceptable representative should be informed in a timely manner 
if new information becomes available that may be relevant to the participant’s willingness to 
continue participation in the study. The communication of this information will be provided 
and documented via a revised consent/assent form or addendum to the original consent/assent 
form that captures the participant’s or the participant’s legally acceptable representative’s 
dated signature .
Specifics abou t the study and the study population are to be included in the study informed 
consent form. 
Informed consent will adhere to IRB/IEC requirements, applicable laws and regulations, and 
Sponsor requirements.
08WCSH
PRODUCT:   MK-8591A  68
PROTOCOL/AMENDMENT NO.:   017 -09
MK-8591A -017-09 FINAL PROTOCOL 26-MAR -2024
[IP_ADDRESS] Consent and Collection of Specimens for Future Biomedical Research
The investigator or medically qualified designee will explain the future biomedical research 
consent to the participant, or the participant’s legally acceptable representative, answer all of 
his/her questions, and obtain document ed informed consent before performing any procedure 
related to future biomedical research. A copy of the informed consent will be given to the 
participant before performing any procedure related to future biomedical research.
[IP_ADDRESS] Consent for Postnatal Infant S afety Data Collection Through One Year of 
Age
The investigator or medically qualified designee will explain the consent for infant safety 
data collection to the participant, or the participant’s legally acceptable representative, 
answer all questions, and obtain documented informed consent before collecting any data 
related to infant safety. A copy of the informed consent will be given to the participant.
[IP_ADDRESS] Consent for Continuation of Study Intervention During Pregnancy
Upon learning that a participant is pre gnant, the investigator or medically qualified designee 
and the participant will discuss the potential benefits and risks of continuing (or 
discontinuing) study intervention ( Section 8.11.6 ). A separate consent is required to continue 
study intervention in participants who become pregnant. The investigator or medically 
qualified designee will explain the consent to the participant, or the participant’s legally 
acceptable representative, answer all of her questions, and obtain documented informed 
consent bef ore continuing study intervention. A copy of the informed consent will be given 
to the participant .
[IP_ADDRESS] Consent to Participate in the Optional Plasma/PBMC PK Substudy
(Applicable Only to the [LOCATION_002])
SeeSection [IP_ADDRESS] .1.
8.1.2 Inclusion/Exclusion Criteria
All inclusion and exclusion criteria will be reviewed by [CONTACT_093] ,who is a qualified 
physician, to ensure that the participant qualifies for the study.
8.1.[ADDRESS_916854] information (including direct 
telephone numbers) to be used in the event of an emergency. The investigator or qualified 
designee w ill provide the participant with a participant identification card immediately after 
the participant provides documented informed consent. At the time of intervention
randomization, site personnel will add the treatment /randomization number to the participant 
identification card.
08WCSH
PRODUCT:   MK-8591A  69
PROTOCOL/AMENDMENT NO.:   [ADDRESS_916855] information for the emergency 
unblinding call center so that a healthcare provider can obtain information about study 
intervention in emergency situations where the investigator is not available.
8.1.4 Medical History
A medical history will be obtained by [CONTACT_27404]. The medical 
history should include information pertaining to the diagnosis of HIV -1 and AIDS (if 
applicable) and year diagno sed.If the participant has been previously diagnosed with any 
AIDS-defining conditions or CD4 + T-cell count <200 cells/mm3, the condition as well as a 
corresponding medical history of AIDS must be reported. In addition, participants’ history of 
smoking andalcohol consumption should be obtained and recorded on the appropriate eCRF .
8.1.5 Prior and Concomitant Medications Revi ew
[IP_ADDRESS] Prior Medications
The investigator or qualified designee will review prior medication use and record prior 
medication taken by [CONTACT_677706] [ADDRESS_916856] dose of study intervention .
All prior ARTs taken by [CONTACT_180629] (if available) will be 
recorded before the first dose of study intervention .
[IP_ADDRESS] Concomitant Medications
The investigator or qualified designee will record medication, if any, taken by [CONTACT_19432].
8.1.[ADDRESS_916857] not be re -used for 
different participants.
Any participant who is screened multiple times will retain the original screening number 
assigned at the initial screening visit. Specific details on the screening/rescreening visit 
requirements are provided in Section 8.11.1.
8.1.7 Assignment of Treatment/Randomization Numb er
All eligible participants will be randomly allocated and will receive a 
treatment /randomization number. The treatment/randomization number identifies the 
participant for all procedures occurring after treatment randomization. Once a 
treatment /randomization number is assigned to a participant, it can never be re -assigned to 
another participant.
08WCSH
PRODUCT:   MK-8591A  70
PROTOCOL/AMENDMENT NO.:   017 -09
MK-8591A -017-09 FINAL PROTOCOL 26-MAR -2024
A single participant cannot be assigned more than 1 treatment /randomization number.
8.1.8 Study Intervention Administrati on
Study intervention will be provided as per Table 2and dispensed through the IRT system at 
visits indicated in the SoA ( Section 1.3.1).
Study intervention should begin within 24 hours ofrandomization.
[IP_ADDRESS] Timing of Do se Administration
Group 1
Participants in G roup 1 will take 1 tablet of DOR/ISL (unsupervised at their home) at 
approximately the same time each day without regard to food .If more than 1 bottle is 
dispensed, the participant is instructed to use all of the medication in the 1 bottle before 
opening another bottle.
Group 2
Day 1 to Wee k 48: Participants will take baseline ART as per approved label.
After Week 48: Participants will take 1 tablet of DOR/ISL (unsupervised at their home) 
at approximately the same time each day without regard to food .If more than 1 bottle is 
dispensed, the participant is instructed to use all of the medication in the 1 bottle before 
opening another bottle.
Note: Those participants in Group 2 who become pregnant prior to Week 48 and consent 
to continue baseline ART will not switch to DOR/ISL (Section 8.11. 6).
If a participant misses a dose of DOR/ISL, the following guidance should be followed:
If ≤12 hours from the missed dose, the missed dose should be taken, and the normal 
dosing schedule resumed.
If >[ADDRESS_916858] an Early Discontinuation visit performed per SoA (Section 1.3 )and be 
encouraged to continue to be followed as outlined in Section 8.11.3.
08WCSH
PRODUCT:   MK-8591A  71
PROTOCOL/AMENDMENT NO.:   017 -09
MK-8591A -017-09 FINAL PROTOCOL 26-MAR -2024
When a participant withdraws from participation in the study, all applicable activities 
scheduled for the Early Discontinuation visit should be performed (at the time of 
withdrawal). Any AEs that are present at the time of withdrawal should be followed in 
accordance with the safety requirements outlined in Section 8.4.
Participants who discontinue study intervention for decreases in CD4+ T -cell counts and/or 
total lymphocyte counts or who dis continue study intervention for any other reason and are 
noted to have a >10% decrease from average baseline value in their CD4+ T -cell and/or total 
lymphocyte counts or have decreases in CD4+ T- cell and/or total lymphocyte counts that 
meet ECI criteria at the Early Discontinuation of Treatment Visit should be managed per 
Section 8.11.5 until the counts recover .
[IP_ADDRESS] Withdrawal From Future Biomedical Resear ch
Participants may withdraw their consent for future biomedical research. Participants may 
withdraw consent at any time by [CONTACT_111954]. If medical 
records for the main study are still available, the investigator will contact [CONTACT_111955] (clinical.specimen.management@ MSD .com). Subsequently, the 
participant's consent for future biomedical research will be withdrawn. A letter will be sent 
from the Sponsor to the investigator confirming the withdrawal. It is the responsibility of the 
investigator to inform the participant of completion of withdrawal. Any analyses in progress 
at the time of request for withdrawal or already performed prior to the request being received 
by [CONTACT_180630]. 
No new analyses would be generated after the request is received.
In the event that the medical records for the main study are no longer available (eg, if the 
investigator is no longer required by [CONTACT_180631]) 
or the specimens have been completely anony mized, there will no longer be a link between 
the participant’s personal information and their specimens. In this situation, the request for 
specimen withdrawal cannot be processed.
8.1.10 Participant Blinding/Unblindi ng
This is an open -label study; there is no blinding for this study.
8.1.11 Calibration of Equipme nt
The investigator or qualified designee has the responsibility to ensure that any device or 
instrument used for a clinical evaluation/test during a clinica l study that provides information 
about inclusion/exclusion criteria and/or safety or efficacy parameters shall be suitably 
calibrated and/or maintained to ensure that the data obtained are reliable and/or reproducible. 
Documentation of equipment calibration must be retained as source documentat ion at the 
study site .
08WCSH
PRODUCT:   MK-8591A  72
PROTOCOL/AMENDMENT NO.:   017 -09
MK-8591A -017-09 FINAL PROTOCOL 26-MAR -2024
8.1.12 Administration of Patient Questionnaires
Participants will complete 3 PRO questionnaires at Day 1, Week 4, Week 12, Week 48, and 
Week 96 and/or the Early Discontinuation visit. Participants are to complete the 
questionnaires on their own at the site on paper during the appropriate study visit (see SoA) 
prior to being seen by [CONTACT_093], discussing any medical conditions with the study 
personnel, or receiving any medi cal results. The questionnaires will not be administered to 
participants if native language translations are not available for all questionnaires .
The participant responses to questionnaires will be entered into the appropriate eCRF by [CONTACT_180633].
8.2 Efficacy Assessmen ts
8.2.1 HIV -1 RNA
Plasma HIV -1 RNA quantification will be performed at the central laboratory using a real 
time PCR assay with a lower limit of detection of 40 copi[INVESTIGATOR_014]/mL.
8.2.2 Management of Study Participants W ith Viremia
When viremia (HIV -1 RNA ≥ 50 copi[INVESTIGATOR_014]/mL) is detected (Section [IP_ADDRESS].2), the investigator 
should query the participant regarding adherence to study intervention, intercurrent illness, or 
recent immunization. All cases of viremia must be confirmed, and the participant should 
continue to take the full assigned dosage of study intervent ion while awaiting 
confirmation .
[IP_ADDRESS] Viremia Confirmation
Confirmation of viremia requires 2 consecutive plasma HIV -1 RNA results of ≥ 50copi[INVESTIGATOR_014]/mL 
(Section [IP_ADDRESS].2) with the secon d sample collected at a “Viremia Confirmation” visit at 
least 2 week sbut not more than 4 weeks from the date of the initial sample. This timeframe 
may be extended if study intervent ion is interrupted for 1 of the following circumstances:
Intercurrent illness : redraw 2 to 4 weeks following resolution of the illness, during 
which time the participant should continue to receive the assigned dosage of study 
intervent ion(s)without interruption ;
Immunization :redraw at least 4 weeks following a ny immunization, during which time 
the participant should continue to receive the assigned dosage of study interven tion(s)
without interruption ;
Toxicity management, noncompliance, or other reason : redraw 2 to 4 weeks following 
resuming the assigned dosage of study intervention (s).
08WCSH
PRODUCT:   MK-8591A  73
PROTOCOL/AMENDMENT NO.:   017 -09
MK-8591A -017-09 FINAL PROTOCOL 26-MAR -2024
[IP_ADDRESS] Participants W ith Clinically Significant Viremia ( ≥200 Copi[INVESTIGATOR_014]/mL)
Study participants with confirmed HIV -1 RNA of ≥200 copi[INVESTIGATOR_014]/mL will be assessed for 
development of viral drug resistance (Section [IP_ADDRESS]) and discontinuation from study 
intervention (Section 7.1). Once it is determined that study intervention discontinuation is 
appropriate, Early Discontinuation of Treatment and End of Treatment Follow -up visit 
procedures should be completed (Sections 1.3.2 and 8.11.3) and the parti cipant managed by 
[CONTACT_180634] -of-care.
[IP_ADDRESS] Participants With Low -level Viremia ( ≥50and <200 Copi[INVESTIGATOR_014]/mL)
Study participants with confirmed HI V-1 RNA of ≥50 and <200 copi[INVESTIGATOR_014]/mL should continue 
study intervention and all regularly scheduled study visits during which HIV-1 RNA levels 
will be monitored per SoA (approximately every 3 months). Additional visits may be 
conducted to monitor HIV -1 RNA levels more frequently than every 3 months, if 
appropriate, after discussion with the Sponsor. Participants with confirmed low -level viremia 
at Week 48 will not be automatically discontinued from study intervention but will be 
included in the virologic fai lure rate calculated for the purposes of the primary analyses 
(Section 9.6.1).
Investigators should use their clinical judgment regarding the most appropriate clinical 
management of participants, if more stringent local guidelines apply, and may contact [CONTACT_3433] e 
Sponsor’s Clinical Director to discuss questions on clinical management of individual 
participants.
[IP_ADDRESS] Viral Drug Resistance Testing
Participants with confirmed HIV-1 RNA ≥200 copi[INVESTIGATOR_014]/mL at any time during the study will 
be assessed for development of viral drug resistance. 
Samples will be collected for genotypic and phenotypic HIV-1 drug resistance testing per 
SoA (Section 1.3) and used to assess resistance -associated substitutions as applicable during 
the study.
8.2.3 T-and B -Lymphocyte and Natural Killer Cell Profile (TBNK)
A TBNK panel , including CD4+ T -cell count, will be performed at the central laboratory
(Appendix 2).
Refer to Section 8.11.5 for guidance on management of participants with decreased CD4+ 
T-cell counts and/or decreased total lymphocyte counts.
8.3 Safety Assessments
Details regarding specific safety procedures/assessments to be performed in this study are 
provided. The total amount of blood/tissue to be drawn/collected over the course of the stud y,
08WCSH
PRODUCT:   MK-8591A  74
PROTOCOL/AMENDMENT NO.:   017 -09
MK-8591A -017-09 FINAL PROTOCOL 26-MAR -2024
including approximate blood volumes drawn/collected by [CONTACT_180635], can be found in Appendix 2 .
Planned time points for all safety assessments are provided in the SoA.
8.3.1 Physical Examinations
A complete physical examination wi ll be conducted by [CONTACT_88696] (consistent with local requirements) as per institutional standard .The full physical 
examination will include examination of body systems including , but not limited to, general 
appearance, skin, neck, eyes, ears, nose, throat, breast, lungs, heart, abdomen, back, lymph 
nodes, extremities, and nervous system .
Height will also be measured and recorded at the visits specified in the SoA .Height 
measurements should be taken using a stadiometer (recommended but not required) . 
Participants should remove their shoes and stand as tall and straight as possible .
A brief directed physical examination will be conducted by [CONTACT_113803] (consistent with local requirements) per institutional standard. This 
examination will be sign- and symptom -directed and based on the participant’s condition and 
circumstances. The investigator should note any changes in the participant’s condition (body 
systems) since the last examination, not precluding examination of any body system(s) as 
clinically indicated.
Investigators should pay special attention to clinical signs related to previous serious 
illnesses.
[IP_ADDRESS] Weight
Weight will be measured and recorded at the visits specified in the SoA. Participants should 
remove their shoes and wear a single layer of clothing at each measurement.
8.3.[ADDRESS_916859] olic and diastolic blood pressure.
Note: Oral temperatures are preferred but not required.
8.3.3 Electrocardiograms
A local 12-lead ECG will be obtained and reviewed by [CONTACT_88696] (consistent with local requirements) within [ADDRESS_916860]:   MK-8591A  75
PROTOCOL/AMENDMENT NO.:   [ADDRESS_916861] of clinical laboratory tests to be performed and t o the SoA for 
the timing and frequency.
The investigator or medically qualified designee (consistent with local requirements) 
must review the laboratory report, document this review, and record any clinically 
relevant changes occurring during the study in the AE section of the case report form 
(CRF). The laboratory reports must be filed with the source documents. Clinically 
significant abnormal laboratory findings are those which are not associated with the 
underlying disease, unless judged by [CONTACT_677707]'s condition.
All protocol -required laboratory assessments, as defined in Table 15in Appendix 2, must 
be conducte d in accordance with the laboratory manual and the SoA .
If laboratory values from nonprotocol -specified laboratory assessments performed at the 
institution’s local laboratory require a change in study participant management or are 
considered clinically si gnificant by [CONTACT_093] (eg, SAE or AE or dose 
modification), then the results must be recorded in the appropriate CRF (eg, SLAB).
For any laboratory tests with values considered clinically significantly abnormal during 
participation in the study or within 42days after the last dose of study intervention, every 
attempt should be made to perform repeat assessments until the values return to normal or 
baseline or if a new baseline is established as determined by [CONTACT_093] .
Note: Management of decreases in CD4+ T -cell and/or total lymphocyte counts is 
described in Section 8.11.5.
08WCSH
PRODUCT:   MK-8591A  76
PROTOCOL/AMENDMENT NO.:   [ADDRESS_916862] HBV (3TC, FTC , TAF, or TDF) may experience an acute 
exacerbation of HBV. Therefore, participants who have evidence of past HBV exposure 
(anti-HBc positive) and who meet enrollment criteria will be closely monitored during the 
study.
All eligible participants must be HB sAg-negative at screening. Participants who are anti -HBc 
positive and HBV DNA positive at screening are excluded. Participants who are anti -HBc 
positive but HBV DNA negative at screening are eligible to enroll. For the duration of the 
study, participants positive for anti -HBc should be monitored for possible HBV reactivation. 
Samples will be taken to monitor HBsAg and HBV DNA per the SoA (Section 1.3).
Investigators should also pay close attention to changes from baseline in ALT, AST, 
bilirubin, and alkaline phosphatase (included in chemistry laboratory assessments).
Participants in Group [ADDRESS_916863] -of-care and/or 
referred for management of their HBV infection. Participants may be allowed to continue 
study intervention if deemed medica lly appropriate upon consultation with the Sponsor.
Therapi[INVESTIGATOR_181762] (eg,adefovir, TDF, 
TAF, FTC, or 3TC )areprohibited (Section 6.5).Entecavir therapy for HBV infection is 
allowed.
8.3.7 Toba cco and Alcohol Assessments
Participants’ use of tobacco and alcohol will be obtained and recorded at Weeks 48 and 96.
8.4 Adverse Events (AEs), Serious Adverse Events (SAEs), and Other Reportable 
Safety Events
The definitions of an AE or SAE, as well as the method of recording, evaluating, and 
assessing causality of AE and SAE and the procedures for completing and transmitting AE, 
SAE, and other reportable safety event reports can be found in Appendix 3 .
Adverse events, SAEs, and other reportable safety events will be reported by [CONTACT_2299] 
(or, when appropriate, by a caregiver, surrogate, or the participant's legally authorized 
representative).
08WCSH
PRODUCT:   MK-8591A  77
PROTOCOL/AMENDMENT NO.:   [ADDRESS_916864] to seriousness, 
intensity/toxicity and causality .
8.4.[ADDRESS_916865] be reported immediately to the Sponsor 
if the event is considered related to study intervention.
For infants born to participants who be come pregnant and consent to infant safety data 
collection, SAEs (including perinatal HIV -1 infection) occurring through [ADDRESS_916866] 
be reported by [CONTACT_140235] 24 hours of learning of the event.
Investigators are not oblig ated to actively seek AE sor SAEs or other reportable safety events 
in former study participants. However, if the investigator learns of any SAE, including a 
death, at any time after a participant has been discharged from the study, and he/she 
considers th e event to be reasonably related to the study intervention or study participation, 
the investigator must promptly notify the Sponsor.
All initial and follow -up AEs, SAEs, and other reportable safety events will be recorded and 
reported to the Sponsor or de signee within the time frames as indicated in Table [ADDRESS_916867]:   MK-8591A  78
PROTOCOL/AMENDMENT NO.:   017 -09
MK-8591A -017-09 FINAL PROTOCOL 26-MAR -2024
For participants who continue in a rollover study , the collection requirements of AEs, SAEs, 
and other reportable safety events in this protocol are amended as follows:
AEs, SAEs, and other reportable safety events will be collected and recorded through the 
last study visit in this protocol.
Pregnancy outcome and infant SAEs will be captured in this protoco l, if pregnancy
exposure is reported in this protocol.
The last collection of non serious AEs (including cancer that does not meet serious 
criteria) will be at the last study visit in this protocol.
Note: All new SAEs (including those considered related to study intervention) and other 
new reportable safety events (including pregnancy exposure) that occur after the last 
study visit will be collected in the rollover study.
08WCSH
PRODUCT:   MK-8591A  79
PROTOCOL/AMENDMENT NO.:   017 -09
MK-8591A -017-09 FINAL PROTOCOL 26-MAR -2024
Table 4 Reporting Time Periods and Time Frames for A dverse Events and Other 
Reportable Safety Events
Type of EventReporting Time 
Period:
Consent to 
Randomization/ 
AllocationReporting Time 
Period:
Randomization/ 
Allocation 
through 
Protocol -specified 
Follow -up PeriodReporting Time 
Period:
After the 
Protocol -specified 
Follow -up PeriodTime Frame to 
Report Event 
and Follow- up 
Information to 
Sponsor:
Nonserious 
Adverse Event 
(NSAE)Report if:
-due to protocol -
specified intervention
-causes exclusion
-participant is 
receiving placebo 
run-in or other run-in 
treatmentReport all Not required Per data entry 
guidelines
Serious Adverse 
Event (SAE)Report if:
-due to protocol -
specified intervention
-causes exclusion
-participant is 
receiving placebo 
run-in or other run -in 
treatmentReport all Report if:
-drug/vaccine 
related.
(Follow ongoing to 
outcome)Within 24 hours 
of learning of 
event
Pregnancy/
Lactation 
ExposureReport if:
-due to intervention
-causes exclusionReport all Previously 
reported – Follow 
to completion/
termination; repor t 
outcomeWithin [ADDRESS_916868] (require 
regulatory 
reporting)Report if:
-due to intervention
-causes exclusionReport
-Potential drug -
induced liver 
injury ( DILI)
-Require 
regulatory 
reportingNot required Within [ADDRESS_916869] (d o not 
require 
regulatory 
reporting)Report if:
-due to intervention
-causes exclusionReport
-non-DILI ECIs 
and those not 
requiring 
regulatory 
reportingNot required Within 5 calendar 
days of learning 
of event
Cancer Report if:
-due to intervention
-causes exclusionReport all Not required Within 5 calendar 
days of learning 
of event
Overdose Report if:
-receiving placebo 
run-in or other run -in 
medication Report all Not required Within [ADDRESS_916870]:   MK-8591A  80
PROTOCOL/AMENDMENT NO.:   017 -09
MK-8591A -017-09 FINAL PROTOCOL 26-MAR -2024
8.4.2 Method of Detecting AE s, SAE s,and Other Reportable Safety Events
Care will be taken not to introduce bias when detecting AE sand/or SAEs and other 
reportable safety events. Open- ended and nonleading verbal questioning of the participant is 
the preferred method to inquire about AE occurrence.
8.4.3 Follow -up of AE, SAE ,and Other Reportable Safety Event Information
After the initial A E/SAE report, the investigator is required to proactively follow each 
participant at subsequent visits/contacts. All AE s, SAE s, and other reportable safety events,
including pregnancy and exposure during breastfeeding, events of clinical interest (ECI s), 
cancer, and overdose will be followed until resolution, stabilization, until the event is 
otherwise explained, or the participant is lost to follow- up (as defined in Section 7.3). In 
addition, the investigator will make every attempt to follow all nonseriou s AEs that occur in
randomized participants for outcome. Further information on follow -up procedures is given 
in Appendix 3.
8.4.4 Regulatory Reporting Requirements for SAE
Prompt notification (within 24 hours) by [CONTACT_677708] a study intervention under clinical investigation are met.
The Sponsor has a legal responsibility to notify both the local regulatory authority and other 
regulatory agencies about the safety of a study intervention under clinical investigation. The 
Sponsor will comply w ith country -specific regulatory requirements and global laws and 
regulations relating to safety reporting to regulatory authoritie s, IRB/IECs, and investigators.
Investigator safety reports must be prepared for suspected unexpected serious adverse 
reactions (S[LOCATION_003]R s) according to local regulatory requirements and Sponsor policy and 
forwarded to investigators as necessary.
An investiga tor who receives an investigator safety report describing an SAE or other 
specific safety information (eg, summary or listing of SAE) from the Sponsor will file it 
along with the I Band will notify the IRB/IEC, if appropriate according to local requirement s.
8.4.5 Pregnancy and Exposure During Breastfeeding
Although pregnancy and infant exposure during breastfeeding are not considered AEs, any 
pregnancy or infant exposure during breastfeeding in a participant (spontaneously reported to 
the investigator or their d esignee) that occurs during the study are reportable to the Sponsor.
All reported pregnancies must be followed to the completion/termination of the pregnancy. 
Pregnancy outcomes of spontaneous abortion, missed abortion, benign hydatidiform mole, 
blighted ovum, fetal death, intrauterine death, miscarriage, and stillbirth must be reported as 
serious events (Important Medical Events). If the pregnancy continues to term, the outcome 
(health of infant) must also be reported.
08WCSH
PRODUCT:   MK-8591A  81
PROTOCOL/AMENDMENT NO.:   017 -09
MK-8591A -017-09 FINAL PROTOCOL 26-MAR -2024
For infants born to participants who become pregnant and consent to infant safety data 
collection, SAEs (including perinatal HIV -1 infection) occurring through [ADDRESS_916871] 
be reported by [CONTACT_140235] 24 hours of learning of the event.
8.4.6 Disease -related Events and/or Disease -related Outcomes Not Qualifying as 
AEs or SAEs
This section is not applicable to the study.
8.4.[ADDRESS_916872] (ECI s)
Selected nonserious and SAEs are also known as ECIs and must be reported to the Sponsor.
Events of clinical interest for this study include:
1.An elevated AST or ALT lab value that is greater than or equal to 3X the upper limit of 
normal and an elevated total bilirubin lab value that is greater than or e qual to 2X the 
upper limit of normal and, at the same time, an alkaline phosphatase lab value that is less 
than 2X the upper limit of normal, as determined by [CONTACT_13149] -specified laboratory 
testing or unscheduled laboratory testing.*
*Note: These cri teria are based upon available regulatory guidance documents. The 
purpose of the criteria is to specify a threshold of abnormal hepatic tests that may require 
an additional evaluation for an underlying etiology. The study site guidance for 
assessment and f ollow -up of these criteria can be found in the Investigator Study File 
Binder (or equivalent).
2.A ≥30% decrease from average baseline** in CD4+ T -cell or total lymphocyte count 
values while on study intervention .
3.A CD4+ T -cell count of <200 cells/mm3while on study intervention from either (a) 
participants whose average baseline** CD4+ T -cell count was ≥200 cells/mm3or (b) 
participants whose average baseline CD4+ T -cell count was <200 cells/mm3and 
increased to ≥ 200 cells/mm3for 3 consecutive months while on study intervention.
** Average baseline is defined as theaverage value between screening (within [ADDRESS_916873] dose of study intervention) and Day 1.
Note : The first on -treatment value that reaches the abov e CD4+ T -cell or total lymphocyte 
criteria should be reported as an ECI.SeeSection 8.11.5 for further guidance on the 
management of participants meeting CD4+ T- cell and total lymphocyte criteria.
08WCSH
PRODUCT:   MK-8591A  82
PROTOCOL/AMENDMENT NO.:   017 -09
MK-8591A -017-09 FINAL PROTOCOL 26-MAR -2024
8.5 Treatment of Overdose
In this study, an overdose is any do se higher than the prescribed dose of study intervention.
No specific information is available on the treatment of DOR/ISL overdose. If a participant 
experiences an overdose of baseline ART, guidance in the approved label should be 
followed.
Decisions regarding dose interruptions will be made by [CONTACT_180636].
8.6 Pharmacokinetics
8.6.1 Blood Collection for Plasma ISL
Venous blood samples will be collected for measurement of ISL.Samples will be collected 
only from participants in Group 1. Sample collection, storage, and shipment instructions for 
plasma samples will be provided in the laboratory manual. Investigational PK samples will 
be collected f or both Group 1 and Group 2 beyond Week 48 as outlined in the SoA 
(Section 1.3). Analysis of these samples will be triggered by [CONTACT_25753] .
Population PK samples will be collected from all participants as outlined in Table 5 . The 
time of the doses of study interventions taken prior to the sample collection will be verbally 
reported to study staff by [CONTACT_677709].
For participants that routinely take their study intervention during the day, a predose and 
postdose sample will be taken at the Week 4 visit ( Table 5 ). Participant s that routinely take 
their study intervention in the evening should continue to do so, and only [ADDRESS_916874] dose.
For participants who become pregnant and consent to continue DOR/ISL, PK samples will be 
collected to evaluate DOR and ISL concentration levels per Table 6in Section 8.11. 6.1.
Table 5 Collection of Population PK Samples
Study Visit Time Relative to Dose
Day 1 Predose
Week 4 Predose and within 0.5 to 2 hours postdose
Week 12 Sample collected irrespective of time of dose (time of last dose and time of PK 
sampl e collection must be documented)
Week 24 Sample collected irrespective of time of dose (time of last dose and time of PK 
sample collection must be documented)
Week 48 Sample collected irrespective of time of dose (time of last dose and time of PK 
sample collection must be documented)
PK=pharmacokinetic.
08WCSH
PRODUCT:   MK-8591A  83
PROTOCOL/AMENDMENT NO.:   017 -09
MK-8591A -017-09 FINAL PROTOCOL 26-MAR -2024
8.7 Pharmacodynamics
Pharmacodynamic parameters will not be evaluated in this study.
8.8 Biomarkers
8.8.1 Planned Genetic Analysis Sample Collection
The p lanned genetic analysis sample should be drawn for planned analysis of the association 
between genetic variants in DNA and drug response. This sample will not be collected at the 
site if there is either a local law or regulation prohibiting collection, or if the IRB/IEC d oes 
not approve the collection of the sample for these purposes. If the sample is collected, 
leftover extracted DNA will be stored for FBR if the participant provides documented 
informed consent for FBR . If the planned genetic analysis is not approved, but FBR is 
approved and consent is given, this sample will b e collected for the purpose of FBR .
Sample collection, storage, and shipment instruct ionsfor planned genetic analysis samples 
will be in the Operations/ Laboratory M anual.
8.8.2 Inflammation
Blood samples will be collected to evaluate the inflammatory and thrombotic response as 
measured by [CONTACT_180638] (Section 1.3):
IL-6
D-dimer
sCD-163
hs-CRP
8.8.3 Renal Function
Urine and blood samples will be collected to evaluate renal function as measured by [CONTACT_180639], such as the following potential analytes and calculations:
Urine: albumin, protein, beta -2-microglobulin/creatinine ratio, and retinol binding 
protein/creatinine ratio
Serum: cystatin- C and creatin ine clearance
8.8.[ADDRESS_916875]:   MK-8591A  84
PROTOCOL/AMENDMENT NO.:   017 -09
MK-8591A -017-09 FINAL PROTOCOL 26-MAR -2024
Participants with diabetes mellitus (type 1 or type 2) or insulin resistance are not required to 
have the blood draw for insulin testing.
8.8.[ADDRESS_916876] (cm)/hip (cm) circumferences.
BMI will be calculated using weight and height measurements taken as specified in the SoA
(Section 1.3).
8.8.6 DEXA Assessments
DEXA images to monitor fat distribution and BMD should be collected from all 
participants/sites willing and able to have the test performed and according to country law
(Section 1.3). These participa nts will undergo total body DEXA scans for BMD of the spi[INVESTIGATOR_180573]. Participants will not be excluded from 
participation in the study if unwilling/unable to have DEXA images performed.
Only those participants who are confirmed eligible to be randomized will undergo DEXA 
images for BMD of the spi[INVESTIGATOR_180574]. For Day 1 
(baseline), DEXA images should be performed after eligibility is confirmed and may be 
performed up to 14 days after rando mization. The DEXA images at subsequent visits should 
be performed ± [ADDRESS_916877] DEXA images performed at subsequent visits as indicated in the SoA 
(Section 1.3).
DEXA images will be evaluated by a central imaging reader ; these analyses are not 
performed in real time and will not be provided to the site/participant. For clinical 
management of the participant, the DEXA images should be reviewed and interpreted locally 
by a qual ified individual . Clinically significant findings noted in the local interpretation of 
the baseline DEXA images should be recorded in the participant’s medical history. Clinically
significant findings noted in the local interpretation of the DEXA images du ring the 
treatment period should be recorded appropriately. Refer to the Site Imaging Manual for 
additional details regarding DEXA procedures including participant preparation instructions 
to be considered before DEXA imaging .
Women who become pregnant during the study will not have DEXA scans performed.
08WCSH
PRODUCT:   MK-8591A  85
PROTOCOL/AMENDMENT NO.:   017 -09
MK-8591A -017-09 FINAL PROTOCOL 26-MAR -2024
8.9 Future Biomedical Research Sample Collection
If the participant provides documented informed consent for future biomedical research, the 
following specimens will be obtained as part of f uture biomedical research :
Leftover extracted DNA for future research
Leftover main study plasma from HIV -1 RNA quantification
Leftover main study plasma from HI V drug resistance samples
Whole blood for future biomedical research
Sample collection, storage, and shipment instruction for whole blood future biomedical 
research samples will be provided in the laboratory manual. Refer to the SoA (Section 1.3) 
for timing of sample collection.
8.10 Heal th Economics Medical Resource Utilization and Health Economics
Medical Resource U tilization and Health Economics are not evaluated in this study.
8.11 Visit Requirements
Visit requirements are outlined in Section 1.3. Specific procedure -related details are provided 
inSection 8.
8.11.1 Screening /Rescreening
Screening
Prior to randomization, potential participants will be evaluated to determine that they fulfill 
the entry requirements as set forth in Section 5. Participants are expected to enroll as soon as 
possible after eligibility is confirmed. In cases of unexpected delays in receiving repeat 
screening laboratory results, a screening period of up to 45 days is allowed.
Rescreening
If the screening window has been exceeded, participants are allowed to rescreen one time 
after approval from the Sponso r. Once a participant has started the rescreening process, a 
new screening period (ie, an additional ≤45-day window) will begin, during which time 
screening procedures willbe repeated.
08WCSH
PRODUCT:   MK-8591A  86
PROTOCOL/AMENDMENT NO.:   [ADDRESS_916878] be repeated for participants who are re screened:
Vital signs, weight, and directed physical examination
Review medical history and prior/concomitant medications for new information
All laboratory assessments (includes serum β -hCG pregnancy testing for WOCBP) 
Review of AEs
If the informed consent form has been updated, participants should be reconsented before
rescreening. If no updates have been made, documented informed consent during the original 
screening period should be reviewed with the participant and a verbal recons ent to continue 
in the study should be documented. 
If a participant had a Day 1 ECG during the original screening period, it should be repeated 
(at the Day 1 visit or within 7 days prior).
If a participant had a baseline Day 1 DEXA scan during the original screening period, and 
>[ADDRESS_916879] elapsed, the Day 1 DEXA should be repeated. If <[ADDRESS_916880] elapsed since 
the DEXA it is not necessary to repeat the Day 1 DEXA scan during rescreening.
Participants ,who were previously considered screen failures because the duration of baseline 
ART was <[ADDRESS_916881] continued to receive a stable oral 
2-drug or 3- drug combination (± PK booster) with documented viral sup pression (HIV -1 
RNA <50 copi[INVESTIGATOR_014]/mL) for ≥[ADDRESS_916882] or current regimen.
8.11.2 Treatment Period
All procedures 
and their timing should be completed as per SoA (Section 1.3).
[IP_ADDRESS] Fasting
Visits at Day 1, Week 24, Week 48, and Week [ADDRESS_916883] (ie, do not 
consume any food or beverages except water) for at least 8 hours prior to the visit. The 
investigator/study coordinator are responsible to remind partic ipants to fast prior to these 
visits and to confirm with participants their fasting status in the appropriate source 
documentation.
[IP_ADDRESS] Switch
At the Week 48 visit, participants in G roup 2 will begin receiving DOR/ISL.
Those participants in Group 2 who become pregnant prior to Week 48 and consent to
continue baseline AR Twillnot switch to DOR/ISL (Section 8.11.6).
08WCSH
PRODUCT:   MK-8591A  87
PROTOCOL/AMENDMENT NO.:   017 -09
MK-8591A -017-09 FINAL PROTOCOL 26-MAR -2024
[IP_ADDRESS] Optional Nurse Visits and Telephone Visits
A visiting nurse service may be utilized (if locally available and approved for use) at any 
visit after a participant is randomized. If a visiting nurse service is utilized for any visit, the 
investigator should contact [CONTACT_180640], or as 
soon as possible to perform an investigator AE assessment . Refer to the nursing manual for 
additional details.
For visits conducted by [CONTACT_180641], whole blood for FBR samples will not be collected 
by [CONTACT_180642] e. Participants should be instructed to return to the site within 2 -4 weeks 
from the scheduled visit for collection of whole blood for FBR , when possible. If an 
unscheduled visit for collection of whole blood for FBR is not possible, the sample should be 
drawn at the next scheduled visit at the site.
[IP_ADDRESS] End of Study Week 96 Visit
Week 96 represents the end of this study.
Participants will be given 2 options at the Week 96 visit:
1.End participation in this study and resume locally available treatment of their choice. 
These participants should have an End of Treatment Follow -up visit 42 (+7) days after 
the last dose of study intervention.
2.Provide documented consent to participate in the rollover study. The rollover study will 
provide open -label DOR/ISL to participants.
Participants who are pregnant at Week 96 will be managed per Section 8.11.6.
Management of participants with decreased CD4+ T
-cell counts and/or total lymphocyte 
counts is as follows:
See Section 6.[ADDRESS_916884] 
CD4+ T- cell count and/or total lymphocyte count decreases that meet ECI criteria at their 
last study visit in this study (ie, rollover enrollment visit).
Participants not participating in the rollover study who have decreases in CD4+ T -cell 
and/or total lymphocyte counts that meet ECI criteria or are decreased by >10% of their 
average baseline value require additional follow -up monitoring of CD4+ T -cell and 
lymphocyte counts per Section 6.[ADDRESS_916885]:   MK-8591A  88
PROTOCOL/AMENDMENT NO.:   [ADDRESS_916886] both an Early Discontinuation of Treatment visit (Section [IP_ADDRESS] ) 
and an End of Treatment Follow -up visit (Section [IP_ADDRESS]) conducted. After the visit 
procedures are completed, the participant will be withdrawn from the study and managed for 
treatment of HIV -[ADDRESS_916887] -of-care.
Guidance for management of participants who discontinue study intervention due to 
confirmed decreased CD4+ T -cell counts and/or decreased total lymphocyte counts is 
provided in Section 8.11.5.
If a participant discontinues study intervention for other reasons and the CD4+ T -cell 
count and/or total lymphocyte count atthe Early Discontinuation of Treatment visit is 
decreased by >10% of their average baseline value, or meets ECI criteria ,then additional 
monitoring is required per Section 8.11.5.
[IP_ADDRESS] Early Discontinuation of Treatment
Participants who discontinue treatment early for any reason should have an Early 
Discontinuation of Treatment visit as outlined in Section 1.3.2. If early discontinuation 
occurs during the timeframe of a scheduled study visit, the assessments for the Early 
Discontinuation of Treatment visit should be conducted.
[IP_ADDRESS] End of Treatment Follow-up Visit
Participants who discontinue study intervention at any time (including at the Week 96 visit)
for any reason(s) and participants who will not continue study intervention after Week [ADDRESS_916888] a safety follow -up visit in -clinic 42(+7) days after the last dose of study 
intervention. Assessments for thisvisit are outlined in Section 1.3.2. Participants who 
complete the Week [ADDRESS_916889] an End of Treatment Follow -up visit.
Participants discontinuing study intervention with specified decreases in CD4+ T -cell and/or 
total lymphocyte counts (Section 7.1 and Section 8.4.7) will be followed for monitoring of 
CD4 T -cell and total lymphocyte counts per Section 8.11.5.
8.11.4 Viremia Confir mation
If a participant has a viral load of ≥50copi[INVESTIGATOR_014]/mL at any time during the study, a V iremia 
Confirmation visit must be conducted within 2to 4weeks of the initial HIV -1 viremia
(Section s 1.3.2 and [IP_ADDRESS]) . If a scheduled visit is to occur within the timeframe that a 
participant would return for a viremia confirmation visit, the assessments for the scheduled 
visit should be conducted, and the HIV viral drug resistance sample must be collected.
08WCSH
PRODUCT:   MK-8591A  89
PROTOCOL/AMENDMENT NO.:   017 -09
MK-8591A -017-09 FINAL PROTOCOL 26-MAR -2024
8.11.5 Management of Participants with Decreases in CD4+ T -cell Counts and/or 
Total Lymphocyte Counts
Management of participants with decreases in CD4+ T -cell counts and/or total lymphocyte 
counts is explained below.
[IP_ADDRESS] Participants Whose CD4+ T -cell Count and/or Total Lymphocyte Count 
Decreases Meet Criteria for Even ts of Clinical Interest While on Study 
Intervention
Participants whose d ecreases in CD4+ T- cell counts and/or total lymphocyte counts meet 
ECI criteria (Section 8.4.7) must have a confirmation visit in 3 to 4 weeks *.
*Note exception: Participants with an average baseline total lymphocyte count 
≥1×109cells/L and a ≥30% reduction from average baseline with the count remaining ≥1 ×
109cells/L, should have a confirmation visit in 10 to 14 weeks (or earlier if applicable) .
Upon repeat testing at the confirmation visit (Section 1.3. 4), a participant must be 
discontinued from study intervention if the discontinuation criteria are met (Section 7.1) and 
managed per Section [IP_ADDRESS].
Upon repeat testing at the confirmation visit (Section 1.3. 4), if the ECI criteria are confirmed 
but the values do not meet discontinuation criteria, the Sponsor must be consulted . 
Treatment may be continued with approval from the Sponsor. 
[IP_ADDRESS] Participants Discontinued from Study Intervention Due to Decr eased CD4+ 
T-cell Count and/or Total Lymphocyte Count
After discontinuation from study intervention, participants will be managed for treatment of 
HIV-1per local standard -of-care.
Participants discontinu edfrom study intervention due to specified decrease s in CD4+ T- cell 
and/or total lymphocyte counts s hould undergo assessments as specified for the Early 
Discontinuation of Treatment V isit and the End of Treatment Follow -up visit (Section 1.3.4 ). 
CCI
08WCSH
PRODUCT:   MK-8591A  90
PROTOCOL/AMENDMENT NO.:   017 -09
MK-8591A -017-09 FINAL PROTOCOL 26-MAR -2024
[IP_ADDRESS] Participants Discontinued from Study Intervention For Other Reason s
AND Have Decreases in CD4+ T -cell Count and/or Total Lymphocyte 
Count
8.11.6 Clinical Management of Participants Who Become Pregnant
If a participant becomes pregnant ( confirmed by a positive serum pregnancy test), the 
investigator should refer her to a local provider for appropriate obstetric (prenatal) care per 
local standard of care. All pregnancies must be followed to completion or termination of the 
pregnancy by [CONTACT_180643] 8.4.5. Severity assessment of AEs that are 
pregnancy -related complications should follow guidance provided as part of the DAIDS table 
version 2.1 “Addendum 1: Female Genital Grading Table for Use in Microbicide Studies,” 
particularly the section “Complications of Pregnancy .” 
The site will discuss with the participant:
Joining a pregnancy registry (the Antiretroviral Pregnancy Registry), which collects 
information about the outcome of the pregnancy
,
Consenting to infant safety data collection per Sections [IP_ADDRESS] and 8.11. 6.4,
Her intended breastfeeding status (Section 8.11. 6.3),
Appropriateness of continuing study intervention based on available data and local 
standard- of care guidelines (where allowed by [CONTACT_427], health authorities, and 
ethics committees) .
[IP_ADDRESS] Continuing Study Intervention
Participants who become pregnant and consent to continue study intervention 
(Section [IP_ADDRESS]) should complete all remaining protocol -specified visits and procedures
(with the exception of DEXA) per the regular schedule in the SoA (Section 1.3.1). As the 
SoA specifies study visits at least every [ADDRESS_916890]:   MK-8591A  91
PROTOCOL/AMENDMENT NO.:   017 -09
MK-8591A -017-09 FINAL PROTOCOL 26-MAR -2024
approximately during each trimester and postpartum (ie, the first visit after delivery 
[~12 weeks after the 3rdtrimester visit and ≤8 weeks after delivery]).
For participants receiving baseline ART , the investigator should refer to local product 
circulars and local guidelines to determine if study intervention can be continued or must be 
modified during pregnancy. Modifications (eg, dose adjustment) and/or regimen changes 
may be permitted, but require Sponsor approval (Section 6.6). Those participants in Group 2 
who become pregnant prior to Week 48 and consent to continue baseline AR Twill not 
switch to DOR/ ISL. The participant will continue with the protocol -specified visits (with the 
exception of DEXA and PK collection) per the reg ular schedule in the SoA (Section 1.3.1) 
for the duration of their pregnancy. 
The participant’s prenatal care should be coordinated between the investigator and the local 
obstetric care provider. The investigator (or designee) is responsible for obtaining relevant 
clinical and laboratory data from the obstetric care provider to monitor the safety and well -
being of the mother and fetus. Relevant data obtained by [CONTACT_180644]. The participant’s medical records will be 
collected and reviewed by [CONTACT_180645]:
Clinical safety laboratory assessments
Plasma HIV -1 RNA level
Results of Week 20 to 22 or second trimester ultrasound(s) providing gestational age and 
anatomic survey
Any complications a ssociated with the pregnancy
Outcome of pregnancy
Information that could indicate congenital abnormalities
For participant swho are pregnant at the last regularly scheduled study visit (TW 96) , their
visit schedule will be extended through the duration of the pregnancy to allow assessments 
through each trimester and postpartum (Section 1.3.3) . At the completion of the pregnancy, 
continued access to DOR/ISL will be offered per Section 6.7 .
For p articipants who continue DOR/ISL, PK samples will be collected at their scheduled visit 
during the 1st, 2nd, and 3rdtrimester sand postpartum to evaluate DOR and ISL concentration
levels per Table 6.These samples will be used to characterize the PK profile of DOR/ISL 
during pregnancy .
08WCSH
PRODUCT:   MK-8591A  92
PROTOCOL/AMENDMENT NO.:   017 -09
MK-8591A -017-09 FINAL PROTOCOL 26-MAR -2024
Table 6 Collection of Population PK Samples During Pregnancy and Postpartum
Study Visit Time Relative to Dose
1stTrimesteraPredose
2ndTrimester Predose AND
0.5 to 2 hours AND 4 to 6 hours postdose
3rdTrimester Predose AND 
0.5 to 2 hours AND 4 to 6 hours postdose
PostpartumbPredose
PK=pharmacokinetic.
aCollected in the 1sttrimester at a scheduled visit when a participant reports gravid status.
bThe first visit after delivery; ~12 weeks after the 3rdtrimester visit and ≤8 weeks after delivery.
[IP_ADDRESS] Discontinuing Study Intervention
Participants who become pregnant and discontinue study intervention should have an Early 
Discontinuation of Treatment visit per the SoA (Section 1.3.2). If the decision to discontinue 
study intervention occurs during the timeframe of a scheduled study visi t, the assessments for 
the Early Discontinuation of Treatment visit should be conducted at that time. In addition, 
these participants will have an End of Treatment Follow -up visit in -clinic 42 (+7) days after 
the last dose of study intervention (Section 1.3.2).
The investigator (or local HIV care provider, if not the study site) should develop a new 
treatment plan per local standard of care before discontinuing study intervention to minimize 
the risk of a gap in ART.
[IP_ADDRESS] Participants Who Choose to Breastfeed
If a participant chooses to breastfeed, she should discontinue study intervention before 
initiating breastfeeding (Section 7.1) and be followed in the study per Section 8.11.6 .2. The 
investigator (or local HIV care provider, if not the study site) should ma ke every effort to 
develop a new treatment plan (per local guidelines) withinsufficient time prior to delivery to 
minimize the likelihood of a gap in ART.
[IP_ADDRESS] Infant Safety Data Collection
For participants who become pregnant while receiving study interventio n, or within [ADDRESS_916891] ofcare.
Infant SAEs , including p erinatal HIV -1 infection, will be collected as per Section 8.4.1 and 
should be reviewed at the participant’s scheduled study visits that occ ur during this time.
Infant safety data collection will be captured in this study, if exposure during pregnancy is 
reported in this study.
08WCSH
PRODUCT:   MK-8591A  93
PROTOCOL/AMENDMENT NO.:   017 -09
MK-8591A -017-09 FINAL PROTOCOL 26-MAR -2024
[IP_ADDRESS].1 Schedule of Activities: Infant Safety Data Collection 
Timepoint At Birtha1 Year 
After Birtha,b
Visit Name N/A Infant -Follow- Up-1
Administrative and Safety Procedures
Infant i nformed consent Xc
Gestational age at birth X
Apgar score X
Length X X
Weight X X
Head Circumference X X
Directed pediatric exam ination X
Concomitant medications reviewdX X
Review infant SAEse---------------------------------- X--------------------------------
HIV=human immunodeficiency virus; SAE=serious adverse event.
aData to be collected and entered at the site within 12 weeks of each timepoint.
bIf a participant withdraws from the study, data from 1 year after birth should be collected at the time of withdrawal.
cConsent for infant safety data collection can be obtained from the mother at any time following confirmation of 
pregnancy.
dConcomitant medications taken by [CONTACT_58076] (for SAEs or HIV postpartum prophylaxis) .
eCollect SAEs, including any congenital anomalies and HIV infection in the infant , per Section 8.4.1 and review at 
participant’s regularly scheduled study visits.
9 STATISTICAL ANALYSIS PLAN
This section outlines the statistical analysis strategy and procedures for the study. If, after the 
study has begun, but prior to final database lock, changes are made to primary and/or key 
secondary hypotheses, or the statistical methods related to those hypotheses, then the 
protocol will be amended (consiste nt with ICH Guideline E9). Changes to exploratory or 
other non -confirmatory analyses made after the protocol has been finalized, but prior to final 
database lock, will be documented in a nsSAP and referenced in the CSR for the study. Post 
hoc exploratory analyses will be clearly identified in the CSR.
08WCSH
PRODUCT:   MK-8591A  94
PROTOCOL/AMENDMENT NO.:   017 -09
MK-8591A -017-09 FINAL PROTOCOL 26-MAR -2024
9.1 Statistical Analysis Plan Summary
Key elements of the statistical analysis plan are summarized below; the comprehensive plan 
isprovided in Sections 9.2 through 9.12.
Study Design 
OverviewA Phase 3 Randomized, Active- Controlled, Open -Label Clinical Study to Evaluate a 
Switch to Doravirine/Islatravir (DOR/ISL) Once -Daily in Participants With HIV -1 
Virologically Suppressed on Antiretroviral Therapy
Treatment 
AssignmentThis study will enroll approximately 578 evaluable participants with HIV- 1 who 
havebeen virologically suppressed on a stable oral 2 -drug or 3-drug combination (± 
PK booster) ART for ≥3 months . Randomization will be stratifi ed by [CONTACT_677710] (PI-containing regimens [including PI -+ InSTI -containing regimens ], 
InSTI -based regimens [non-PI-containing regimens ],and all other non -PI-and non -
InSTI -containing regimens )in a 1:1 ratio to a switch to DOR/ISL on Day 1 (Group 
1) or continue baseline ART from Day 1 to Week 48 with delayed switch to 
DOR/ISL at Week 48 (Group 2) . After 48 weeks of assigned therapy, all participants 
will receive DOR/ISL QD through Week 96. 
Analysis 
PopulationsEfficacy: FAS , PP, and Resistance Analysis Subset
Safety: APaT
Primary 
Endpoint(s)1.Percentage of participant s with HIV- 1 RNA ≥50 copi[INVESTIGATOR_014]/mL at Week 48.
2.Number of participants experiencing AEs, and discontinuing study intervention 
due to AEs
Key Secondary 
Endpoints1.Percentage of participant s with HIV -1 RNA ≥50 copi[INVESTIGATOR_014]/mL at Week 96
2.Percentage of participant s with HIV -1 RNA <40 and <50 copi[INVESTIGATOR_014]/mL at Week 48
3.Percentage of participant s with HIV -1 RNA <40and <50 copi[INVESTIGATOR_014]/mL at Week 96
4.Change from baseline in CD4+T -cell count at Week s48and 96
5.Change from baseline in fasting LDL -C and non -HDL -C at Weeks 24 and 48 
6.Change from baseline in weight at Week 48 
7.Viral resistance- associated substitutions
8.General safety and tolerability through Week 96
Statistical Methods 
for Key Efficacy/
Immunogenicity/
Pharmacokinetic 
AnalysesThe primary objective and hypothesis will be assessed using a 2-sided multiplicity -
adjusted 95% CI for the difference between treatment groups (Group 1 minus Group 
2) in the percentage of participants with HIV- 1 RNA ≥50copi[INVESTIGATOR_014]/mL at Week 48.
The CI will be based on the stratified M&N method [Miettinen, O. and Nurminen, 
M. 1985] with Cochran -Mantel -Haenszel weights (stratified by [CONTACT_677711] n:PI-containing regimens [including PI -+ InSTI -containing regimens], 
InSTI -based regimens [non -PI-containing regimens], and all other non -PI-and non -
InSTI -containing regimens ).
The FAS, which is defined as all randomized participants who take at least 1 dose of 
study intervention ,will serve as the primary analysis population for this study . The 
FDA ‘snapshot’ algorithm will be used as the primary approach to analysis ; missing 
data at the primary timepoint will be imputed as an HIV -1 RNA result ≥50 
copi[INVESTIGATOR_014]/mL for those who discontinue study interv ention prior to the Week [ADDRESS_916892] available on -treatment HIV- 1 RNA result ≥50 copi[INVESTIGATOR_014]/mL .
08WCSH
PRODUCT:   MK-8591A  95
PROTOCOL/AMENDMENT NO.:   017 -09
MK-8591A -017-09 FINAL PROTOCOL 26-MAR -2024
Statistical Methods 
for Key Safety 
AnalysesPoint estimates and 2-sided nominal 95% CIs will be provided using the unstratified
Miettinen and Nurminen method [Miettinen, O. and Nurminen, M. 1985] for the 
difference between treatment groups (Group 1 minus Group 2) for the following:
The percentage of participants in the broad AE categories (ie, Tier -2 events) 
consisting of the percentage of participants with any AE, with a drug -related 
AE, with an SAE, with a Grade 3 to 4 AE, with an AE that is both drug -related 
and serious, with an AE that is both Grade 3 to 4and drug -related, who 
discontinued study intervention due to a drug-related and non -drug-related AE, 
and with AE(s) leading to deaths.
Speci fic AEs (preferred terms), SOCs, or PDLC soccurring with an incidence 
≥4participants in either treatment group.
The percentage of participants with a cardiac SAE. 
Point estimates and 2-sided multiplicity -adjusted 95% CIs will be provided using 
ANCOVA for the difference between treatment groups (Group 1 minus Group 2) for 
the c hange from baseline in fasting LDL -C, non-HDL -C, and weight .
Interim Analyses The following interim analyses and data summaries are planned. Details are 
provided in Section 9.7.
Week 24 i nterim analysis: An interim analysis to assess futility will be 
performed by [CONTACT_180646] 40% of participants have
complete dWeek 24assessments . All available efficacy and safety data for all 
participants enrolled by [CONTACT_180647]. Treatment level results will 
be provided by [CONTACT_180648]. If the upper 
bound of the 2-sidedmultiplicity -adjusted 95% CI for the treatment difference 
(Group 1 minus Group 2 ) in the percentage of participants with Week 24 HIV -1 
RNA ≥200 copi[INVESTIGATOR_014]/mL is greater than 8 percentage point sand excludes 0 , 
consideration m aybe given to stop the study .
Week 48 efficacy and safety analyses (to be conducted by [CONTACT_677712]).
Periodic efficacy and safety reviews (eDMC reviews) to be performed every 4 
to 6months or as specified in the eDMC charter.
Multiplicity For statistical rigor, a small amount of alpha ( α =0.000 01) will be set aside for the 
futility assessment and each eDMC evaluation . An allowance will be made such that 
a total of up to 5 of the unblinded eDMC reports (including the Week 24 interim 
analysis ) may be presented prior to the evaluation of the primary efficacy 
hypotheses at Week 48.
The following hypotheses will be test edsequentially at a 1 -sided 2.5% Type 1 error 
rate adjusted for the number of eDMC reports in the following order:
1)Primary efficacy hypothesis (H1) testing non -inferiority of HIV- 1 RNA 
≥50copi[INVESTIGATOR_014]/mL between Group 1 and Group 2 at Week 48
2)Secondary safety hypothesis (H2) for testing superiority of LDL -C and non -
HDL -Cbetween Group [ADDRESS_916893], 
the overall 1- sided 2.5% Type [ADDRESS_916894]:   MK-8591A  96
PROTOCOL/AMENDMENT NO.:   017 -09
MK-8591A -017-09 FINAL PROTOCOL 26-MAR -2024
Sample Size and 
Power The planned sample size is 578 participants to be randomized in a 1:1 ratio to either 
Group 1 or Group 2 . The primary hypothesis will be assessed based on the 
percentage of participants with HIV- 1 RNA ≥50copi[INVESTIGATOR_014]/mL at Week 48. The non -
inferiority will be concluded if the upper bound of the 2-sided multiplicity -adjusted 
95% CI for the difference in the percentage of participants with HIV- 1 RNA 
≥50copi[INVESTIGATOR_014]/mL (Group 1 minus G roup 2 ) is less than 4 percentage points. Ifthe true 
rate of parti cipants with HIV -1 RNA ≥50copi[INVESTIGATOR_014]/mL at Week 48 is 2% in both 
groups, this study with 289participants per group has 85% power to demonstrate 
non-inferiority.
9.2 Responsibility for Analyses/In -house Blinding
The statistical analysis of the data obtained from this study will be the responsibility of the 
Clinical Biostatistics department of the Sponsor .
Theprimary treatment period of this study ( Day 1 through Week 48) will be conducted as a 
randomized, open -label study (ie, participants, investigators, and S ponsor personnel will be 
aware of participant treatment assignments after each participant is enrolled and treatment is 
assigned ).The secondary treatment period of this st udy is defined as the period after 
Week 48 through Week 96. Results of the secondary treatment period will be presented in a 
separate CSR from that for the primary treatment period.
The Clinical Biostatistics department will generate the randomized allocat ion schedule(s) for 
study intervention assignment. Randomization will be implemented via an IRT.
The planned interim analyses are described in Section 9.7.
9.3 Hypotheses/Estimation
Objectives and hypotheses of the study are stated in Section 3.
9.4 Analysis Endp oints
Efficacy and safety endpoints for the study , which will be evaluated for within - and/or 
between -treatment differences, are listed below, followed by [CONTACT_180650].
9.4.1 Efficacy/Pharmacokinetics Endpoints
[IP_ADDRESS] Efficacy Endpoints
An initial description of efficacy measures is provided in Section 4.
Percentage of Participants W ith HIV -1 RNA ≥50 copi[INVESTIGATOR_014]/mL
The Abbott RealTime PCR assay with a reliable lower limit of quantification of 
40copi[INVESTIGATOR_014]/mL will be used to measure the HIV- [ADDRESS_916895]:   MK-8591A  97
PROTOCOL/AMENDMENT NO.:   017 -09
MK-8591A -017-09 FINAL PROTOCOL 26-MAR -2024
with HIV- 1 RNA ≥ 50copi[INVESTIGATOR_014]/mL at Week 48. A secondary objective will acces sthe 
sustained anti retrovi ral suppression of DOR/ISL after 96 weeks of treatment in Group 1, and 
after 48 weeks of treatment in Group 2 by [CONTACT_677691]-1 RNA 
≥50copi[INVESTIGATOR_014]/mL at Week 96.
Percentage of Participants W ith HIV -1 RNA <40 copi[INVESTIGATOR_014]/mL and Percentage of 
Participants W ith HIV -1 RNA <50 copi[INVESTIGATOR_014]/mL
Asecondary objective addressing the antiretrovi ral activity following a switch to DOR/ISL
will be assessed on the basis of the percentage of participants achieving HIV -1 RNA 
<40copi[INVESTIGATOR_014]/mL at Week 48as well as the percentage of participants achieving HIV -1 RNA 
<50copi[INVESTIGATOR_014]/mL at Week 48 .
At Week 96, a secondary objective will assess the antiretrovi ral activity of DOR/ISL after 96 
week sof treatment in Group 1 and after 48 weeks of treatment in G roup 2 on the basis of the 
percentage of participants achieving HIV -1 RNA <40 copi[INVESTIGATOR_014]/mL and the percentage of 
participants with HIV -1 RNA <50 copi[INVESTIGATOR_014]/mL.
Change From Baseline in CD4+ T -cell Count
Change from baseline in CD4+ T- cell count will be estimated at each timepoint at which 
CD4+ T- cell count is collected. A secondary objective will compare the change from 
baseline in CD4+ T- cell count between treatment groups at Week 48.
At Week 96, the imm unologic effect of DOR/ISL willbeassess edvia the change from 
baseline (Day 1) to Week 96 in CD4+ T- cell count after 96 weeks of treatment in Group 1, 
the change from Week 48 to Week 96 in CD4+ T -cell count after 48 weeks of treatment in 
Group 1, and the change from Week 48 to Week 96 in CD4+ T -cell count after 48 weeks of 
treatment in Group 2.
For analysis ofchange from baseline in CD4+ T -cell count , baseline measurements are 
defined as the Day [ADDRESS_916896] non- missing assessment taken a t study Week 48 and before the switch
to DOR/ISL . This rule will also be applied to define the baseline measurements for other 
change from baseline analyses (eg, change in weight, change in laboratory test, etc.) .
Clinically Significant Confirmed Viremia
Participants with confirmed virologic rebound as defined in Section [IP_ADDRESS] .2will be 
identified.
Viral Resistance -associated Substitutions
Participants who meet the definition of confirmed virologic rebound (Section [IP_ADDRESS].2 ), or
who di scontinue study intervention for another reason and have HIV- 1 RNA ≥200copi[INVESTIGATOR_014]/mL
08WCSH
PRODUCT:   MK-8591A  98
PROTOCOL/AMENDMENT NO.:   017 -09
MK-8591A -017-09 FINAL PROTOCOL 26-MAR -2024
at the time of discontinuation, will be assessed for development of viral drug resistance .
Among such participants, those with HIV -1 RNA ≥400 copi[INVESTIGATOR_014]/mL will be included in the 
resistance analyses. In addition, anyone for whom available genotypic or phenotypic data 
show evidence of resistance, irrespective of viral load, will also be included for resistance 
analyses. The resistance analysis will count the number of participants who have evidence of 
resistance a ssociated with each study intervention and will be summarized with primary 
interest at Weeks [ADDRESS_916897] 2consecutive HIV -1 RNA values (measured at least 2 week s
apart) ≥50 copi[INVESTIGATOR_014]/mL during the study, TLOVR is the time between Day [ADDRESS_916898] of the 2 consecutive HIV -1 RNA values ≥50 copi[INVESTIGATOR_014]/mL.
For participants who sustain HIV- 1 RNA < 50 copi[INVESTIGATOR_014]/mL, TLOVR is censored at the time of 
the last available measurement.
[IP_ADDRESS] Pharmacokinetic Endpoint
PKsamples collected from all participants as described in the SoA and Section 8.6 will be 
used to evaluate PK concentrations of ISL, and as appropriate , PK-efficacy , PK-
pharmacodynamic, and PK -AE relationships of ISL.
9.4.2 Safety Endpoints
An initial description of safety measures is provided in Section 4.
Change From Baseline in Fasting Lipi[INVESTIGATOR_677674] (LDL -C, non- HDL -C, TC, HDL -C,TGs and 
TC/HDL ratio ) will be analyzed with primary interest in LDL- C and non -HDL -C.
Adverse Events
The following clinical and laboratory AEs will be summarized: 1) participants with at least 
1AE; 2) participants with at least 1 drug- related AE; 3) participants with at least 1 SAE; 4) 
participants with at least 1 Grade 3 to 4 AE; 5 ) participants with at least 1 serious and drug -
related AE; 6) participants with at least 1 AE which is b oth Grade 3 to 4and drug- related; 7) 
participants who discontinue study intervention due to a drug -related and non -drug-related 
AE; and 8) participants with AE(s) leading to death.
Predefined Limits of Change in Laboratory Parameters
For the summaries of laboratory tests, participants must have both a baseline and 
postrandomiz ation on-treatment measurement to be included. Participants’ laboratory values 
(based on their most abnormal laboratory test values, in the direction of interest, while on 
08WCSH
PRODUCT:   MK-8591A  99
PROTOCOL/AMENDMENT NO.:   017 -09
MK-8591A -017-09 FINAL PROTOCOL 26-MAR -2024
study intervention) will be classified as to whether or not they fall outside of the PDLC and 
are worse in grade (ie, more abnormal in the direction of interest) than at baseline. The 
criteria are adapted from the DAIDS table for Grading the Seve rity of Adult and Pediatric 
Adverse Events, July 2017, v ersion 2.1 (Appendix 3) . A listing of the participants who meet 
the criteria will also be provided.
Weight , Laboratory ,and Radiological Markers
The mean change from baseline to Week s48 and [ADDRESS_916899] weight, laboratory and 
radiological markers of fasting lipid and metabolic profiles, renal function, inflammation and 
body composition will be summarized.
Change from baseline in weight will be summarized at each timepoint at which weight is 
collected. A secondary objective will compare the mean increase from baseline between
DOR/ISL andcontinued baseline ART of an InSTI -based regimen (non -PI-containing 
regimen) at Week 48.
For analyses of change from base line in weight , laboratory, and radiological parameters, 
baseline measurements are defined as the Day [ADDRESS_916900] recent screening visit will 
be used a s baseline, when available. For assessments of change from baseline in Group 2 at 
Week 96, baseline will be the Week 48 measurement (or, if the Week [ADDRESS_916901] measurement prior to the switch to DOR/ISL).
The baseline measure ment for analyses of DEXA will be defined in the sSAP. 
9.4.3 Patient -reported Outcome Endpoints
An initial description of patient -reported outcome measures is provided in Section [IP_ADDRESS].
PROs from each questionnaire at Day 1 and Weeks 4,12, 48, and 96 will be summarized for 
each treatment group.
9.5 Analysis Populations
9.5.1 Efficacy Analysis Population s
[IP_ADDRESS] Full Analysis Set
The FAS will serve as the primary population for the analysis of efficacy data in this study. 
The FAS population consists of all randomized participants who:
Receive at least 1 dose of study intervention
Have baseline data for those analyses that require baseline data
08WCSH
PRODUCT:   MK-8591A  100
PROTOCOL/AMENDMENT NO.:   017 -09
MK-8591A -017-09 FINAL PROTOCOL 26-MAR -2024
Participants will be included in the treatment group to which they are randomized for the 
analyses of efficacy data using the FAS population. 
[IP_ADDRESS] Per-Protocol Analysis Set
The secondary analysis set for the efficacy analyses is defined as the PP analysis set, which 
will include all participants in the FAS who have not committed any major protocol 
violations that could impact the assessment of efficacy , including violation of key entry 
criteria. Participants will be grouped according to the treatme nt to which they are 
randomized.
Participants meeting any of the following criteria will be excluded from the PP analysis set:
Participants who meet the exclusion criteria for receiving any ongoing prohibited 
therapi[INVESTIGATOR_180568] 3.
Nonadherence to study intervention : participants with <95% drug compliance rate.
Participants who become pregnant .
Any additional criteria resulting in exclusion from the PP analysis set will be provided in the 
sSAP and/or CSR .
The composition of the PP analysis set will vary by [CONTACT_180651], based on the 
number of participants who satisfy the PP criteria at that timepoint .
[IP_ADDRESS] Resistance Analysis Subset
The resistance analysis subset will include all participants in the FAS with confirmed HIV -1 
RNA ≥ 400 copi[INVESTIGATOR_014]/mL and any participants for whom available genotypic or phenotypic data 
show evidence of resistance, irrespective of viral load.
9.5.[ADDRESS_916902] 1 dose of DOR/ISL will be included in 
summaries and analyses from Week [ADDRESS_916903]:   MK-8591A  101
PROTOCOL/AMENDMENT NO.:   [ADDRESS_916904] ical Methods
This section describes the statistical methods that address the primary and secondary 
objectives. Methods related to PK analysis and modeling will be described in a separate 
modeling and simulation plan authored by [CONTACT_677713]. Methods related to exploratory objectives will be described in the sSAP.
Participants in Group 1 will receive DOR/ISL throughout the treatment period. Participants 
in Group 2 will continue their baseline regimen from Day 1 through Week 48 and then 
receive open -labeled DOR/ISL from Week 48 through Week 96. Between- treatment 
comparisons that address key efficacy and safety objectives will be limited to data from both 
treatment groups BEFORE the switch. Efficacy and safety data from Week 48 through Week 
96 will be summarized separately. To evaluate the effects on safety data of switch from 
baseline ART to DOR/ISL at Week 96 (G roup 2 ), the within- participant mean change from 
Week 48 to Week 96 will be analyzed. The safety data from Day 1 to Week 96 for 
participants in G roup 1 will be summar ized.
9.6.1 Statistical Methods for Efficacy Analyses
Time Window s
Table 7 lists the definition of time windows that will be used for the purposes of the 
statistical analyses and the target relative day for the scheduled visits in the study which will 
be used for all analyses by [CONTACT_11191] (with the exception of DEXA assessments) .The last 
available on-treatment measurement within a window will be used for analyses at a specific 
timepoint, unless otherwise specified. Results from additional timepoints beyond Week [ADDRESS_916905]:   MK-8591A  102
PROTOCOL/AMENDMENT NO.:   017 -09
MK-8591A -017-09 FINAL PROTOCOL 26-MAR -2024
Table 7 Definitions of Study Time Points
Treatment 
PhaseTreatment Period Visit Day-Range RulesaTarget Daya
Pretreatment Baseline Day 1 ≤1 1
Treatment Open -label 
Intervention: 
DOR/ISL or 
Baseline ART 
RegimenWeek 4 ≥2 and ≤ 56 29
Week 12 ≥57 and ≤126 85
Week 24 ≥127 and ≤210 169
Week 36 ≥211 and ≤294 253
Week 48 Group 1 : ≥295 and ≤378
Group 2: ≥295 and ≤3 50Group 1 and 
Group 2: 337
Open -label 
Intervention: 
DOR/ISLWeek 52bGroup 1: NA
Group 2: ≥351 and ≤392Group 1: NA
Group 2: 365
Week 60 Group 1: ≥379 and ≤462
Group 2: ≥393and ≤462Group 1 and 
Group 2: 421
Week 72 ≥463 and ≤546 505
Week 84 ≥547 and ≤630 589
Week 96 ≥631 and ≤ 714 673
ART=antiretroviral therapy; DOR=doravirine ; ISL=islatravir ;NA=not applicable.
aRelative days and target days are computed from the first day of study intervention .
bThe Week 52 visit applies only to participants in Group 2.
FDA Snapshot Algorithm and Missing Data Approaches
There are 3 types of missing values:
intermittent missing values due to a missed or skipped visit or due to an inadequate 
sample;
non-intermittent missing values due to premature study intervention discontinuations 
because of treatment -related reasons such as, “clinical adverse experience” (regardless of 
relationship to study drug), “laboratory adverse experience ” (regardless of relationship to 
study drug), and “withdrew based on HIV- 1 RNA results”;
non-intermittent missing values due to premature study intervention discontinuations 
because of other reasons which are not related to treatment such as “loss to follow -up”, 
“protocol violation” , “participant withdrew consent ”, etc.
08WCSH
PRODUCT:   MK-8591A  103
PROTOCOL/AMENDMENT NO.:   017 -09
MK-8591A -017-09 FINAL PROTOCOL 26-MAR -2024
Three approaches will be used to handle missing value s. The primary approach for analysis 
of the percentage of participants with HIV -1 RNA ≥50 copi[INVESTIGATOR_014]/mL is the FDA “snapshot” 
algorithm [Food and Drug Administration (CDER) 2015] . Virologic outcome will be defined 
according tothe following categories:
HIV -1 RNA <50 copi[INVESTIGATOR_014]/mL : participants who have the last available on -treatment HIV -
1 RNA measurement <50 copi[INVESTIGATOR_014]/mL within the time point of interest analysis window 
specified in Table 7 .
HIV -1 RNA ≥50 copi[INVESTIGATOR_014]/mL : this includes participants
1)Who have the last available on- treatment HIV -1 RNA measurement ≥50copi[INVESTIGATOR_014]/mL 
within the time point of interest analysis window specified in Table 7 .
2)Who do not have on -treatment HIV -[ADDRESS_916906] analysis 
window and 
a)Who discontinue study intervention prior to or in the time point of interest 
analysis window due to lack of efficacy, or
b)Who discontinue study intervention prior to or in the time point of interest 
analysis window due to reasons other than lack of e fficacy and have the last 
available on- treatment HIV -1 RNA measurement ≥50copi[INVESTIGATOR_014]/mL .
No Virologic Data in Specified Analysis Time Window : this includes participants who 
do not have on -treatment HIV -[ADDRESS_916907] analysis window 
because of the following:
1)Discontinued study intervention due to AE or death: this includes participants who 
discontinued study intervention because of an AE or death at any time point from Day 
[ADDRESS_916908] available on -treatment 
HIV-1 RNA measurement <50copi[INVESTIGATOR_014]/mL .In addition, this category will include
participants who discontinued study intervention because of an AE or death and had 
no on- treatment HIV -1 RNA measurements during the entirety of the study .
2)Discontinued study intervention for other reasons : this includes participants who 
discontinued study intervention prior to or in the time point of interest analysis 
window due to reasons other than lack of efficacy or AE/death (ie , lost to follow -up, 
noncompliance with study intervention, physician decision, protocol deviation, 
withdrawal by [CONTACT_3445], etc.) and have the last ava ilable on- treatment HIV -1 RNA 
measurement <50 copi[INVESTIGATOR_014]/mL. In addition, this category will include participants who 
discontinued study intervention due to reasons other than lack of efficacy or AE/death 
and had no on -treatment HIV -[ADDRESS_916909]:   MK-8591A  104
PROTOCOL/AMENDMENT NO.:   017 -09
MK-8591A -017-09 FINAL PROTOCOL 26-MAR -2024
3) On study intervention but missing data in window : only data in the predefined 
analysis window can be used for the statistical analysis at a given time point for 
participants remaining on study intervention. Participants with HIV- 1 RNA results 
outside this window will be classified as “on study intervention but missing data in 
window ”regardless of the out of window HI V-1 RNA results.
Forthe primary evaluation of non -inferiority based on those with HIV- 1 RNA 
≥50copi[INVESTIGATOR_014]/mL, the parameter for evaluation is the number of participants classified as 
“HIV -1 RNA ≥50 copi[INVESTIGATOR_014]/mL” according to the FDA snapshot algorithm defined above, 
divided by [CONTACT_180654]. For the secondary endpoint involving those 
with HIV- 1 RNA <50 copi[INVESTIGATOR_014]/mL, the parameter for evaluation is the number of participants 
classified as “HIV- 1 RNA <50 copi[INVESTIGATOR_014]/mL” according to the snapshot algorithm, divided by 
[CONTACT_180654]. Similar logic will also be used to define the 
percentage of participants with HIV -1 RNA <40 copi[INVESTIGATOR_014]/mL in accordance with the relevant 
secondary endpoints .
A second approach, the missing data treated as treatment failu re (M=F) approach, will be 
performed as a sensitivity analysis for the percentage of participants achieving HIV -1 RNA 
<50copi[INVESTIGATOR_014]/mL. Under this approach, participants who 1) have at least [ADDRESS_916910] available on -treatment measurement within the window <50 copi[INVESTIGATOR_014]/mL, OR 2) 
are on study intervention and have no HIV -[ADDRESS_916911] both the immediately preceding and 
immed iately subsequent on -treatment HIV -1 RNA measurements <50 copi[INVESTIGATOR_014]/mL, will be 
classified as a virologic “success” at the timepoint of interest. Participants with other reasons 
for missing data will be classified as a virologic failure at the timepoint of in terest.
A third approach, the OF approach will also be performed as a sensitivity analysis for the 
HIV-1 RNA measurement <50 copi[INVESTIGATOR_014]/mL endpoint. Under this approach, participants with 
non-intermittent missing data who prematurely discontinue study interve ntion due to lack of 
efficacy or who discontinue treatment for other reasons and are failures (HIV- 1 RNA 
≥50copi[INVESTIGATOR_014]/mL) at the time of study intervention discontinuation are considered as failures at 
timepoints thereafter. Participants who discontinue study intervention for reasons other than 
lack of efficacy and who are not failures at the time of study intervention discontinuation will 
be excluded from the analyses at subsequent timepoints. Participants with intermittent 
missing data will be considered as successes (HIV -1 RNA <50 copi[INVESTIGATOR_014]/mL) if both the 
immediately preceding and immediately subsequent on- treatment HIV -1 RNA measurements 
are <50copi[INVESTIGATOR_014]/mL; all other intermittent missing results will be imputed as failures.
The same supportive approaches as d escribed above will similarly be used for the analysis of 
the percentage of participants achieving HIV -1 RNA <40 copi[INVESTIGATOR_014]/mL.
Percentage of Participants W ith HIV -1 RNA ≥50 copi[INVESTIGATOR_014]/mL
The snapshot approach will be used as the primary approach to analysis with respect to the 
percentage of participants with HIV -1 RNA ≥50 copi[INVESTIGATOR_014]/mL. The full categorization of 
08WCSH
PRODUCT:   MK-8591A  105
PROTOCOL/AMENDMENT NO.:   017 -09
MK-8591A -017-09 FINAL PROTOCOL 26-MAR -2024
virologic outcome at a timepoint by [CONTACT_180656] 1) HIV -1 RNA 
<50copi[INVESTIGATOR_014]/mL, 2) HIV-1 RNA ≥50 copi[INVESTIGATOR_014]/mL, and 3) no virologic data in window for 
reasons of a) discontinued study intervention due to an AE/death, b) discontinued study
intervention for other reasons (includes withdraw al of consent, loss to follow- up, move, etc.), 
or c) onstudy intervention but missing data in window.
Non- inferiority of Group [ADDRESS_916912] to the percentage of 
participants with HIV -1 RNA ≥50 copi[INVESTIGATOR_014]/mL at Week 48 will be calculated using the
Miettinen and Nurminen method [Miettinen, O. and Nurminen, M. 1985] with Cochran-
Mantel- Haenszel weights (stratified by [CONTACT_677714] :PI-containing regimens 
[including PI -+ InSTI -containing regimens] , InSTI -based regimens [non -PI-containing 
regime ns], and all other non -PI-and non -InSTI -containing regimens) . For the evaluation of 
the primary hypothesis, a margin of 4 percentage points is used to define the non- inferiority 
of aswitch to DOR/ISL at Day 1 compared to the continuation of baseline ART for 48 
weeks; non- inferiority will be concluded if the upper bound of the 2-sided multiplicity -
adjusted 95% CI for the difference in the percentage of participants with HIV- 1 RNA ≥50 
copi[INVESTIGATOR_014]/mL (G roup 1 minus G roup 2 ) is less than 4 percentage points. The choice of non -
inferiority margin is driven by [CONTACT_677715]; 
with an anticipated virologic failure rate of approximately 2%, a stringent margin of 
4percentage points is clinically acce ptable.
For the summary of virologic response over time, the difference in percentages between 
treatment groups at each timepoint th rough Week 48 will also be estimated and the 
associated 2-sided nominal 95% CI will be derived in a similar fashion to that described for 
the primary efficacy analysis.
Percentage of Participants W ith HIV -1 RNA <40 copi[INVESTIGATOR_014]/mL and Percentage of 
Participants With HIV -1 RNA < 50copi[INVESTIGATOR_014] /mL
The percentage of participants achieving HIV -1 RNA <40 copi[INVESTIGATOR_014]/mL and the percentage of 
partici pants with HIV-1 RNA <50 copi[INVESTIGATOR_014]/mL will be summarized by [CONTACT_180658], with primary interest at Week [ADDRESS_916913], the difference in percentages between treatment groups (Group 1 minus 
Group 2) and the associated 2-sided nominal 95% CIwill be calculated using the Miettinen 
and Nurminen method [Miettinen, O. and Nurminen, M. 1985] with Cochran-Mantel-
Haenszel weights (stratified by [CONTACT_677714] ). A summary of virologic response 
over time for Group 1 from Day 1 through Week 96, and for Group 2 from Week 48 through 
Week 96 will be provi ded separately. The supportive analyses using the M=F and OF 
approaches (as defined above) will also be presented.
Change From Baseline in CD4+ T -cell C ount
Change from baseline in CD4 + T-cell count will be summarized by [CONTACT_677716]4 + T-cell count is collected, with primary interest at Week 48. The 
treatment difference in changes from baseline in CD4+ T -cell count at each timepoint will be 
estimated using the ANCOVA model adjusted by [CONTACT_180659]4+ T- cell count, t reatment 
08WCSH
PRODUCT:   MK-8591A  106
PROTOCOL/AMENDMENT NO.:   [ADDRESS_916914] 
to an absolute criterion for similarity. The clinical interpretation of treatment difference is 
dependent upon the absolute value at baseline and the magnitude and direction of the CD4+ 
T-cell count changes observed in each treatment arm. The DAO approach will be used to 
handle missing data for these analyses. Under the DAO approach, participants must have 
both a baseline measurement and at least 1postbaseline measurement within the timepoint of 
interest analysis window specified in Table 7 to be included in the analyses of the mean 
change from baseline in CD4+ T -cell count. Supportive analyses will also be provided using 
the LOCF and BOCF methods to account for missing data.
At Week 96, the change from baseline (Day 1) to Week 96 in Group 1, the change from 
Week 48 to Week 96 in Group 1 and the change from Week 48 to Week 96 in Group 2 will 
be evaluated. 
Clinicall y Significant Confirmed Viremia
The number of participants with confirmed virologic rebound, as defined in Section [IP_ADDRESS].2, 
will be summarized for each treatment group.
Viral Resistance -associated Substitutions
The number of participants in the resistance analysis subset with genotypic and/or phenotypic 
resistance to each study intervention will be summarized for each treatment group with 
primary interest at Weeks 48 and 96.
HBV Reactivation
If the clinical management of the HBV acute infection/reactivation requires discontinuation 
of study intervention or the HBV requires the addition of a concomitant therapy that is also 
active against HIV -1, efficacy assessments in these part icipants will be censored from that 
point forward and will be handled in the primary efficacy analyses following the FDA 
snapshot algorithm classification rules.
Participants Who Become Pregnant or Choose to Breastfeed
Efficacy assessments in participants who become pregnant and discontinu estudy 
intervention or choose to breastfeed will be censored from that point forward and will be 
handled in the primary efficacy analyses following the FDA snapshot algorithm classification 
rules. P articipants in Group 2 who become pregnant prior to Week 48 are not eligible to 
switch to DOR/IS L,but may consent to remain in the study on their baseline ART. Efficacy 
assessments for such participants will be censored from the date of Week [ADDRESS_916915]:   MK-8591A  107
PROTOCOL/AMENDMENT NO.:   017 -09
MK-8591A -017-09 FINAL PROTOCOL 26-MAR -2024
Table 8 Analysis Strategy for Key Efficacy Variables
Endpoint/Variable 
(Description, Time Point)Primary vs 
Supportive 
Approach Statistical MethodAnalysis 
PopulationMissing Data 
Approach
Primary Hypothesis
Percentage of participants with 
HIV-1 RNA ≥50 copi[INVESTIGATOR_014]/mL at 
Week 48 P M&N with CMH 
weightsFAS Snapshota
Secondary Objectives
Percentage of participants with 
HIV-1 RNA <40 and <50 
copi[INVESTIGATOR_014]/mL at Week 48 P M&N with CMH 
weightsFAS Snapshota
S M&N with CMH 
weightsFAS M=F
S M&N with CMH 
weightsPP OF
Change from baseline in CD4+ 
T-cell counts at Study Week 48P ANCOVA FAS DAO
S ANCOVA FAS LOCF
S ANCOVA FAS BOCF
BOCF=Baseline Observation Carried Forward; CMH=Cochran- Mantel -Haenszel; DAO=Data -As-Observed; FAS=Full 
Analysis Set; HIV=human immunodeficiency virus; LOCF=Last Observation Carried Forward; M=F= missing equal to 
failure; M&N=Miettinen and Nurminen; OF=Observed Failure; P=Primary approach; PP=Per -Protocol; 
RNA=ribonucleic acid; S=Supportive approach ; vs=versus .
a Number of participants meet the endpoint clinical response criteria over total FAS population. 
9.6.2 Statistical Methods for Safety Analyses
Safety and tolerability will be assessed by [CONTACT_113824], laboratory tests, and vital signs.
The analysis of safety results will follow a tiered approach (Table 9)atWeek [ADDRESS_916916] to the analyses that will be performed. AEs (specific terms as well as 
system organ class terms) and events that meet predefined limits of change in laboratory 
parameters will be classified as belonging to “Tier 2” or “Tier 3”, based on the number of 
events observed.
Tier 2 parameters will be assessed via point estimates and 2- sided nominal 95% CIs provided 
for between- treatment differences (Group 1 minus Group 2) in the percentage of participants 
with Tier 2 events; these analyses will be performed using the unstratified Miettinen and 
Nurminen method [Miettinen, O. and Nurminen, M. 1985] , an unconditional, asymptotic 
method. All between -group comparisons will only be conducted before the switch.
Membership in Tier [ADDRESS_916917] 4 events was chosen because the 95% CI for the between -
08WCSH
PRODUCT:   MK-8591A  108
PROTOCOL/AMENDMENT NO.:   [ADDRESS_916918] less than 4 events and thus, would add little to the interpretation of 
potentially meaningful difference s. Because many 95% CIs for Tier [ADDRESS_916919] categories consisting of the percentage of participants with any AE, with a drug -
related AE, with an SAE, with a Grade 3 to 4 AE, with an AE that is both drug- related and 
seriou s, with an AE that is both Grade 3 to 4 and drug- related, who discontinued study 
intervention due to a drug- related and non- drug-related AE, and with AE(s) leading to death 
will be considered Tier [ADDRESS_916920] recent screening visit will be used as baseline , 
when available . For the assessment of change from baseline in Group 2 at Week 96, baseline 
will be the Week 48 measurement (or the last measurement pri or to the switch to DOR/ISL).
The safety summari eswill be presented by [CONTACT_677717] . The post -switch 
safety data from both treatment arm swill be summarized together. In addition, for Group 1, 
the safety data from Day 1 to Week 96 will be analyzed separately.
For participants who become pregnant during the study, safety parameters assessed during 
the pregnancy period (estimated date of conception to date of conclusion of the pregnancy) 
may be summarized separately from the primary and secondary safety analyses. For 
continuous measures that are considered to be Tier 2 events, data collected after the 
estimated date of conception will be excluded from the analyses . Data collected for 
participants whose pregnancy extends beyond Week 96 will be reported separately. Infant 
safety data will be reported separately. Additional details on how pregnancy and infant data
will be handled in safety analyses will be provided in t he sSAP and/or CSR.
08WCSH
PRODUCT:   MK-8591A  109
PROTOCOL/AMENDMENT NO.:   [ADDRESS_916921] on LDL- C and non- HDL -C at Weeks 24 and 48 of a switch to DOR/ISL at Day [ADDRESS_916922] is assessing the superiority of DOR/ISL compared to a continuation of 
baseline ART for those in each strat umat Week 48.
Forthe evaluation of the secondary object iveto assess the effect on lipid profiles of a switch 
to DOR/ISL at Day 1 compared to continued baseline ART, the treatment difference (Group 
1 minus Group 2) and 2-sided nominal 95% CI for all lipid parameters will be estimated 
using ANCOVA models adjusted by [CONTACT_677718]. Separate 
ANCOVA models will be const ructed for each baseline ART strat um. Participants who 
receive lipid- lowering therapy at baseline will be excluded from the lipid -related analyses. 
Forparticipants who become pregnant, l ipid data collected after the estimated date of 
conception will also be excluded .Missing lipid data will be handled using the DAO 
approach, that is, any participant with a missing value will be excluded from the 
analyses. For participants who initiate lipid -lowering therapy during the study, the last lipid 
measu rement before initiating the lipid -lowering therapy will be carried forward.
The same ANCOVA models used to estimate the between -group differences in lipid profiles 
for each stratum will be used to evaluate the secondary hypothesis regarding the effect on 
LDL- C and non -HDL -C of a switch to DOR/ISL at Day 1 compared to the continuation of 
baseline ART for each stratum at Week 48. In accordance with the multiplicity strategy, the
hypothesis will be tested for each stratumsequentially (ie,the first stratum m ust be 
established before testing the next one, and so forth) in the order of PI -containing regimens 
(including PI -+ InSTI -containing regimens) , InSTI -based regimens ( non-PI-containing 
regimens) , and all other non -PI-and non -InSTI -containing regimens. The superiority of 
DOR/ISL compared to continuation of baseline ART ofhaving lower mean increase from 
baseline will be concluded if the upper bound of the 2 -sided multiplicity -adjusted 95% CI for 
the estimate of the treatment group difference (Group 1 minus Group 2) is less than 0. A p -
value for the comparison will also be provided.
Evaluation of Weight Gain Objective
Tier [ADDRESS_916923] on weight of a switch to DOR/ISL at Day 1 compared to continued 
baseline ART of an InSTI -based regimen (non -PI-containing regimen), the treatment 
difference (Group 1 minus Group 2) and 2- sided nominal 95% CI in the change from 
baseline will be estimated between treatment groups using ANCOVA models adjusted by 
[CONTACT_31269], sex at birth , race, the stratification factor and treatment group. For 
participants who become pregnant during the study, weight measured after the estimated date 
of conception will be excluded from the analysis. The APaT population will be used for this 
analysis, and the DAO approach will be used to handle missing data.
08WCSH
PRODUCT:   MK-8591A  110
PROTOCOL/AMENDMENT NO.:   017 -09
MK-8591A -017-09 FINAL PROTOCOL 26-MAR -2024
Table 9 Analysis Strategy for Safety Parameters
Safety Tier Safety Endpoint95% CI for 
Treatment 
DifferenceDescriptive 
Statistics
Tier 2The percentage of participants with an AE in each of 
the following categories: 1 or more AE(s); drug -related 
AE(s), serious AE(s), Grade 3 to 4AE(s), AE(s) which 
are both drug -related and serious, AE(s) which are 
both Grade 3 to 4and drug -related, AE(s) [drug-
related and non -drug-related ] leading to 
discontinuation of study intervention , and AE(s) 
leading to death
Specific AEs (preferred terms) , SOCs, or PDLCs 
occurring with an incidence ≥4 participants in either 
treatment group
The percentage of participants with a cardiac SAE
Change from baseline in lipid parameters: LDL -C, 
non-HDL -C, TC, HDL -C, TGs and TC/HDL -Cratioac
Change from baseline to Week 48 in body weighta
Change from baseline in select laboratory, and 
radiological markers of renal function, inflammation, 
and body compositionaX X
Tier 3Specific AEs (preferred terms), SOCs, or PDLCs 
occurring with an incidence <4 participants in both 
treatment groups
Change from baseline in body weight, laboratory 
measurements and vital signsbX
AE=adverse event; CI=confidence interval; HDL -C=high -density lipoprotein cholesterol; LDL -C=low -density 
lipoprotein cholesterol; PDLC= predefined limit of change; SAE=serious adverse event; SOC=System Organ Class;
TC=total cholesterol; TG=triglyceride.
aFor participants who become pregnant, data collected after the estimated date of conception will be excluded.
bIncludes only those endpoints not already prespecified as Tier -2 endpoints.
cThough classified as a Tier 2 event, p -value swill be provided for change from basel ine to Week 48 in LDL -C and non -
HDL -Cto support the evaluation of the corresponding secondary hypothes es.
9.6.3 Summaries of Baseline Characteristics, Demographic, and Other Analyses
[IP_ADDRESS] Demographic and Baseline Characteristics
The comparability of the treatment groups for each relevant demographic and baseline 
characteristic will be assessed by [CONTACT_113827]/or graphs . No statistical hypothesis 
tests will be perfo rmed on these characteristics. The number and percentage o f participants 
screened andrandomized andthe primary reasons for screening failure, and the primary 
reason for discontinuation will be displ ayed. Demographic variables (eg , age, gender, race, 
region, etc.), baseline characteristics, primary and secondary diagnoses, and prior and 
concomitant therapi[INVESTIGATOR_180575].
08WCSH
PRODUCT:   MK-8591A  111
PROTOCOL/AMENDMENT NO.:   017 -09
MK-8591A -017-09 FINAL PROTOCOL 26-MAR -2024
9.7 Interim Analyses
Study enrollment is likely to be ongoing at the time of the interim analyses.
An eDMC will serve as the primary reviewer of the results of the interim efficacy and safety 
reviews and may make recommendations for discontinuation of the study or protocol
modifications to an executive committee of the Sponsor. If the eDMC recommends 
modifications to the desig n of the protocol or discontinuation of the study, this executive 
committee (and potentially other limited Sponsor personnel) will review results at the 
treatment level in order to act on these recommendations. Additional logistical details will be 
provide d in the eDMC charter .
Once 40% of target enrollment ( n =232 participants) have completed Week 24 ,including
visit assessments , the Week 24 interim analysis will be conducted by [CONTACT_180661]. This analysis will be reviewed by [CONTACT_75342].
Futility Criteria: If the upper bound of the 2 -sided multiplicity -adjusted 95% CI for the 
difference in the percentage of participants with HIV -1 RNA ≥ 200 copi[INVESTIGATOR_014]/mL (Group 1 
minus Group 2) is greater than 8 percentage points and t he 95% CI excludes [ADDRESS_916924] 40% of target enrollment . For the 
purpose of the Week 24 interim analysis, those classified as HIV-1 RNA ≥200 copi[INVESTIGATOR_014]/mL 
includes participants:
Who have the last available on- treatment HIV -1 RNA ≥200 copi[INVESTIGATOR_014]/mL at the W eek24 
visit window specified in Table [ADDRESS_916925] confirmed viremia (Section [IP_ADDRESS].2) at the subsequent visit , 
their virologic outcome will be reassessed for the primary analyses ( Section 9.6.1) .
Who do not have on -treatment HIV -1 RNA data at Week24
oWho discontinue study intervention prior to the Week 24 visit due to lack of efficacy 
or confirmed viremia (Section [IP_ADDRESS].2), or
oWho discontinued study intervention prior to the Week [ADDRESS_916926] on -treatment HIV -1 RNA measuremen t 
≥50copi[INVESTIGATOR_014]/mL
Those participants will be included in the virologic failure rate calculated for the purposes of 
the primary analyses (Section 9.6.1).
In addition, the eDMC will review accumulating safety and efficacy data at regular intervals 
throughout the study duration, or modified intervals based on the recommendation of the 
DMC . The eDMC will recommend steps to ensure the safety of study participants and the 
integrity of the study.
08WCSH
PRODUCT:   MK-8591A  112
PROTOCOL/AMENDMENT NO.:   017 -09
MK-8591A -017-09 FINAL PROTOCOL 26-MAR -2024
If the study is stopped early, the CSR will include all available data up to and including the 
close -out visits. This approach to include all available information is in line with the ICH -E9 
guideline.
9.8 Multiplicity
As noted in Section 9.7, an eDMC will convene at routine intervals to monitor efficacy and 
safety. There is no intention of stoppi[INVESTIGATOR_180576]. Nevertheless, since unblinded summaries o fHIV-1 RNA values may be included in 
these reviews, a small amount of alpha (α=0.000 01) will be allocated for each of these looks,
purely for statistical rigor. An allowance will be made such that a total of up to 5 of these 
unblinded eDMC reports (including the futility assessment once 40% of participants have 
reached Week 24) may be presented prior to the evaluation of the primary efficacy 
hypotheses at Week 48.
The following hypotheses will be tested sequentially at a 1- sided 2.5% Type 1 error rate 
adjusted for the number of eDMC reports in the following order:
1)Primary efficacy hypothesis (H1) testing non -inferiority of HIV- 1 RNA ≥50 copi[INVESTIGATOR_014]/mL 
between Group 1 and Group 2 at Week 48.
2) Secondary safety hypothesis (H2) for testing superiority of LDL-C and non -HDL -C at 
Week 48 . Both parameters will be tested independently within each baseline ART 
stratumusing the Bonferroni approach :
a.Within a stratum, both endpoints will be test edat the 1- sided α/2 significance level .If 
superiority is demonstrated for a given endpoint , the Type 1 error rate of α/[ADDRESS_916927] fails to reach statistical significance for that endpoint. This 
methodology will be applied independently to the LDL- C and non -HDL -C 
parameters.
b.The baseline ART strata will be tested in the following orde r: PI-containing regimens 
(including PI -+ InSTI -containing regimens), InSTI -based regimens (non -PI-
containing regimens), and all other non- PI-and non -InSTI -containing regimens .
Testing will stop with the first hypothesis failing to reach statistical sig nificance, and the
subsequent test swould not be considered for statistical significance. In this way, the overall 
1-sided 2.5% Type [ADDRESS_916928]:   MK-8591A  113
PROTOCOL/AMENDMENT NO.:   017 -09
MK-8591A -017-09 FINAL PROTOCOL 26-MAR -2024
9.9 Sample Size and Power Calculations
9.9.1 Sample Size and Power for Efficacy Analyses
[IP_ADDRESS] Futility Criteria
The probability of passing the Week 24 interim analysis and the overall study power to 
demonstrate non -inferiority at Week 48 under a variety of assumptions is presented in 
Table 10.
The power calculations shown in Table 10 incorporate the Week 24 interim analy sis stoppi[INVESTIGATOR_37626]. The interim analysis for futility will be conducted when 40% of the study enrollment 
(approximately 116 participants per arm) have reached Week 24. The study may stop if the 
upper bound of the 2 -sided multiplicity -adjusted 95% CI for th e difference in the percentage 
of participants with HIV -1 RNA ≥ 200 copi[INVESTIGATOR_014]/mL (G roup 1minus G roup 2 ) is greater than 8 
percentage points and the 95% CI excludes 0. Of interest is the likelihood that the study 
would meet the stoppi[INVESTIGATOR_180577] 24 for a variety of assumed Week 24 response rates 
and also whether the non -inferiority criteria at Week 48 would be met.
Table 10 Probability of Passing the Interim Analysis and the Overall Study Power for 
Various Underlying True Response R atesAssuming Futility Assessed at 40% 
Enrollment
Group 1:
True Rate for Week 24 | 
True Rate for Week 48Group 2:
True Rate for Week 24 | 
True Rate for
Week 48Probability of 
Passing Interim 
Analysis (40% of 
Enrollment at 
Week 24)Probability of 
Demonstrating Non -
Inferiority at Week 48 
(Overall Study Power)
0.75% | 1.5% 1%| 2% 99.6% 95.4%
1% | 2% 1%| 2% 99.0% 82.8%
1.25% | 2.5% 1%| 2% 97.9% 64.0%
1.5% | 3% 1%| 2% 96.7% 42.2%
1.75% | 3.5% 1%| 2% 95.1% 25.6%
2% | 4% 1%| 2% 93.1% 13.5%
2.5% | 5% 1%| 2% 88.4% 2.8%
HIV=human immunodeficiency virus.
Rate for Week 24 is the percentage of participants at Week 24 with HIV- 1 RNA ≥200 copi[INVESTIGATOR_014]/mL. Rate for Week 48 is 
the p ercentage of participants at Week 48 with HIV -1 RNA ≥50 copi[INVESTIGATOR_014]/mL.
For example, if the true rate of participants at Week 24 with HIV -1 RNA ≥200 copi[INVESTIGATOR_014]/mL is 
1% in both groups, and the true rate of participants at Week 48 with HIV -1 RNA 
≥50copi[INVESTIGATOR_014]/mL is 2% in both groups, there is a 9 9.0% chance of not meeting the futility 
criteria at Week 24. The overall study power for that scenario is 82. 8%.
08WCSH
PRODUCT:   MK-8591A  114
PROTOCOL/AMENDMENT NO.:   017 -09
MK-8591A -017-09 FINAL PROTOCOL 26-MAR -2024
[IP_ADDRESS] Evaluation of the Primary Hypothesis
This section presents a fuller description of the power calculations for the primary analysis of 
non-inferiority at Week 48. In contrast to the power shown in Table 10, the power 
calculations shown here do not account for the futility analysis and instead assume the futility 
criteria are not met and the study continues through Week 48.
As described in Section 9.8, the alpha level used in the final analysis (corresponding to the 
multiplicity -adjusted 95% CI) will account for the actual number ofeDMC evaluations 
conducted in the study. For the purposes of the power calculations, 5 eDMC evaluations are 
assumed, leaving α=0.0249 5 (1- sided) available for the final analysis. Non -inferiority will be 
concluded if the upper bound of the 2 -sided multiplicity -adjusted 95% CI for the difference 
in the percentage of participants with HIV- 1 RNA ≥50 copi[INVESTIGATOR_014]/mL (G roup 1 minus G roup 2 ) 
is less than 4 percentage points. The choice of non -infer iority margin is driven by [CONTACT_180663]; with an anticipated virologic failure rate of 
approximately 1.5% to 2%, a stringent margin of 4percentage points is clinically acceptable. 
The power calculations are simulated based on an asymptotic method proposed by [CONTACT_180664] [Miettinen, O. and Nurminen, M. 1985] and were carried out using SAS 
version 9.4.
Table 11 summari zes the power for the primary comparison under various assumptions for 
the control response rate and underlying difference in response
 rate (the percentage of 
participants with HIV -1 RNA ≥50 copi[INVESTIGATOR_014]/mL). For example, if the true rates are 1.5% in both 
groups, this study has approximately 91% power to demonstrate non -inferiority. If the true 
rates are 2.0% in both groups, this study has approximately 85% power to demonstrate the 
primary h ypothesis that G roup 1 is non- inferior to G roup 2 at 48 weeks.
Table 11 Power (%) to Establish Non -Inferiority Under Various Response Rate 
Assumptions (289 Participants Per Group)
True Response Rate 
in Group 2True Difference in Response Rates (G roup 1 minus Group 2 )
-1.0 
Percentage 
Points-0.5 
Percentage 
Points0.0 
Percentage 
Points0.5 
Percentage 
Points1.0 
Percentage 
Points
1.5% 100 98 91 77 59
2.0% 99 95 85 71 54
2.5% 97 91 80 65 49
CI=confidence interval; NI=non -inferiority.
Note: Non-inferiority margin=4% and Type 1error=0.02 495 (1-sided). To establish NI: upper bound of the 2 -sided 
multiplicity -adjusted 95% CI must be <4 percentage points for G roup 1 minus Group 2 . The 95% CI used for the power 
calculations is based on the unstratified Miettinen & Nurminen method [Miettinen, O. and Nurminen, M. 1985] and 
power wasassessed via simulation.
08WCSH
PRODUCT:   MK-8591A  115
PROTOCOL/AMENDMENT NO.:   017 -09
MK-8591A -017-09 FINAL PROTOCOL 26-MAR -2024
9.9.2 Sample Size and Power for Safety Analyses
[IP_ADDRESS] Evaluation of Adverse Event
The probability of observing at least 1 of a particular type of AE in this study depends on the 
number of participants treated and the underlying percenta ge of participants with that AE in 
the study population.
If the underlying incidence of a particular AE is 1%, there is a 94.5% chance of observing at 
least 1 AE among 289 part icipants in a treatment group. If no AE of that type is observed 
among the 289 participants in a treatment group, this study will provide 97.5% confidence 
that the underlying percentage of participants with that particular AE is <1.27% (1 out of 
every 78 participants).
The estimate of, and the upper bound of the 2-sided nominal 95% CI for, the underlying 
percentage of participants with an AE given various hypothetical observed number of 
participants with the AE within each treatment group are provided in Table 12. These 
calculations are based on the exact binomial method proposed by [CONTACT_93325]
[Clopper, C. J. and Pearson, E. S. 1934] .
Table 12 Estimate of Incidence of AEs and 95% Upper Confidence Bound Based on 
Hypothetical Numbers of Participants With AEs (289 Participants Per Group)
Table 13 gives the difference in the incidence of an AE (Group 1 minus G roup 2 ) that can be 
ruled out with different power levels and 95% confidence when there are 289 participants in 
each group. The underlying incidence of the AE is assumed to be the same for the 
2treatment groups. For example, f or a reasonably common AE which occurs in 20% of 
participants in both group s, the study has 80% power to declare with 95% confidence that the 
true difference between the treatment groups is no more than 10.1percentage points. The 
calculations are based on an asymptotic method proposed by [CONTACT_240865]
[Miettinen, O. and Nurminen, M. 1985] .Hypothetical Number of 
Participants With Adverse Event Estimate of Incidence95% Upper Confidence 
Bounda
0 0.0% 1.0%
5 1.7% 4.0%
10 3.5% 6.3%
15 5.2% 8.4%
20 6.9% 10.5%
25 8.7% 12.5%
30 10.4% 14.5%
AE=adverse event; CI=confidence interval.
aBased on the 2-tailed exact CIfor a binomial proportion (Clopper and Pearson method [Clopper, C. J. and Pearson, E. S. 
1934] ).In the 0 event case, the 95% CI is 1-sided (α=0.05 all in the upper tail).
08WCSH
PRODUCT:   MK-8591A  116
PROTOCOL/AMENDMENT NO.:   017 -09
MK-8591A -017-09 FINAL PROTOCOL 26-MAR -2024
Table 13 Difference in Incidence of AEs (Group 1minus G roup 2 ) That Can Be Ruled Out 
With 289 Participants i n Each Group
Target 
PowerUnderlying AE Incidence Rate
1% 5% 10% 20% 30% 40% 50%
80% 4.0 6.4 8.1 10.1 11.1 11.6 11.6
85% 4.4 6.9 8.7 10.8 11.9 12.4 12.3
90% 4.9 7.6 9.5 11.8 12.9 13.4 13.3
95% 5.8 8.7 10.8 13.2 14.4 14.9 14.8
AE=adverse event; CI=confidence interval.
Note: The upper bound of the 2-sided nominal 95% CI(unstratified Miettinen and Nurminen method
[Miettinen, O. and Nurminen, M. 1985] )for the difference in AE incidences (G roup 1 minus G roup 2 ) 
assuming the incidences are the same. 
[IP_ADDRESS] Evaluation of Change from Baseline in Lipid Profile s
Because it is unknown at this time how many participants will be enrolled into each baseline 
ART stratum, and among those, how many will be on lipid -lowering therapy at baseline and 
will be excluded from the lipid- related an alyses, there is uncertainty in the number of 
participants available for the evaluation of the lipid -related hypothesis. In addition, the 
Bonferroni approach will be used to test LDL -C and non- HDL -C parameters independently
for each sequential stratum . As such, Table [ADDRESS_916929] deviations, number of 
participants in each treatment group , and at an alpha level of 0.0125 .
For example, if the between- treatment difference in the mean change in fasting LDL -C is 
10mg/dL with a standard deviation of 15 m g/dL ,50 participants in each treatment group , 
andanalpha level of 0.0125, then this study has approximately 85% power to demonstrate 
the secondary hypothesis that Group [ADDRESS_916930]:   MK-8591A  117
PROTOCOL/AMENDMENT NO.:   017 -09
MK-8591A -017-09 FINAL PROTOCOL 26-MAR -2024
Table 14 Power (%) to Establish Superiority in the Mean Change from Baseline in LDL -
C/non -HDL -C Under Various Assumed Treatment Differences, Standard 
Deviations, and Number of Participants in Each Treatment Group
α = 0.0125 (1- sided)
Assumed between- treatment difference in the mean change from base line=10 mg/dL
Standard Deviation of Change in Lipi[INVESTIGATOR_677675] 15 mg/dL 17 mg/dL 20 mg/dL 25 mg/dL
30 61% 50% 36% 23%
40 76% 64% 48% 32%
50 85% 75% 59% 39%
80 97% 93% 82% 61%
90 99% 95% 86% 66%
Assumed between -treatment difference in the mean change from baseline =13 mg/dL
Standard Deviation of Change in Lipi[INVESTIGATOR_677675]15 mg/dL 17 mg/dL 20 mg/dL 25 mg/dL
30 85% 74% 59% 39%
40 94% 87% 73% 52%
50 98% 94% 83% 63%
80 >99% 99% 97% 85%
90 >99% >99% 98% 89%
Assumed between- treatment difference in the mean change from baseline =16 mg/dL
Standard Deviation of Change in Lipi[INVESTIGATOR_677675]15 mg/dL 17 mg/dL 20 mg/dL 25 mg/dL
30 96% 91% 79% 57%
40 99% 97% 90% 72%
50 >99% 99% 95% 82%
80 >99% >99% 99% 96%
90 >99% >99% >99% 98%
Non-HDL -C=non -high-density -lipoprotein -cholesterol; LDL -C=low -density lipoprotein cholesterol.
Note: The power calculations are computed by [CONTACT_78718] 9.4.
08WCSH
PRODUCT:   MK-8591A  118
PROTOCOL/AMENDMENT NO.:   [ADDRESS_916931] (with a nominal 95% Miettinen and Nurminen 
CI unadjusted for stratification factors) for the primary endpoint and the key seco ndary 
endpoint s (HIV-1 RNA <50 copi[INVESTIGATOR_014]/mL and HIV -1 RNA <40 copi[INVESTIGATOR_014]/mL endpoint to aid in 
the EU review) before the switch will be calculated for the following classification variables:
Age category ( <50years of age , ≥50years of age )
Sex at birth
Gender identity
Region (North America, South America, Europe, Asia, Africa, etc.) 
Race ( White , Black , Asian, Other)
Ethnicity (Hispanic/Latino, not Hispanic/Latino)
Chronic h epatitis C status (HCV -infected, HCV -uninfected)
Baseline NRTI backbone (TAF, TDF , other )
ART class used in baseline regimen ( PI-containing regimens [including PI -+ InSTI -
containing regimens], InSTI -based regimens [non -PI-containing regimens], all other non-
PI-and non -InSTI -containing regimens)
Duration of ART regimen prior to enroll ment ( ≥1 year, <1 year)
The snapshot approach will be used to handle missing values in these subgroup analyses.
9.11 Compliance (Medication Adherence)
In this study, as part of the routine recording of the amount of study intervention taken by 
[CONTACT_181809], the number of tablets remaining in study 
packaging will be counted and reviewed at regular intervals. These results will be used to 
calculate participan t compliance.
For the main analysis of compliance in this study, a day within the study will b e considered 
an“On-Therapy ” day if the participant takes at least 1 tablet from any bottle provided for this 
study.
The “Number of Days Should be On-Therapy” is the total number of days from Day [ADDRESS_916932] dose of study intervention for eac h participant. As such, the “Number of Days 
Should be On -Therapy” will be the number of days from Day [ADDRESS_916933]:   MK-8591A  119
PROTOCOL/AMENDMENT NO.:   017 -09
MK-8591A -017-09 FINAL PROTOCOL 26-MAR -2024
For participants who discon tinue study intervention early (ie ,prior to completion of the study 
at Week 96), the “Number of Days Should be On -Therapy” will be the number of days from 
Day 1 to the date of discontinuation of study intervention. For each participant, percent 
compliance will then be calculated using the following formula:
Summary statistics will be provided on percent compliance by [CONTACT_180666]. 
9.12 Extent of Exposure
The extent of exposure to study intervention for all randomized and treated participants will 
be summarized for participants in Group 1 only . The number of participants exposed to 
various dose s(actual total daily dose) for defined periods of time will be listed, along with a 
summary of the mean (ra nge) duration participants were exposed to various doses.
08WCSH
PRODUCT:   MK-8591A  120
PROTOCOL/AMENDMENT NO.:   017 -09
MK-8591A -017-09 FINAL PROTOCOL 26-MAR -2024
10 SUPPORTING DOCUMENTATION AND OPERATIONAL 
CONSIDERATIONS
10.1 Appendix 1: Regulatory, Ethical, and Study Oversight Considerations
10.1.[ADDRESS_916934] for Clinical Trials
[COMPANY_006] Sharp & Dohme LLC, Rahway, NJ, [LOCATION_003] (MSD )
Code of Conduct for Interventional Clinical Trials
I. Introduction
A.Purpose
MSD, through its subsidiaries, conducts clinical trials worldwide to evaluate the safety and effectiveness of our 
products. As such, we are committed to des igning, implementing, conducting, analyzing ,and reporting these trials 
in compliance with the highest ethical and scientific standards. Protection of participant s inclinical trials is the 
overriding concern in the design and conduct of clinical trials . In all cases, M SD clinical trials will be conducted 
in compliance with local and/or national regulations , and International Council for Harmonisation Good Clinical 
Practice ( ICH-GCP) ,and also in accordance with the ethical principles that have their origi n in the Declaration of 
Helsinki.
B.Scope
Highest ethical and scientific standards shall be endorsed for all clinical interventional investigations sponsored by 
[CONTACT_19481] (parties) employed for their execution (e.g. , contract research organizations, 
collaborative research efforts). This Code is not intended to apply to trials that are observational in nature, or 
which are retrospective. Further, this Code does not apply to investigator -initiated trials , which are not under the 
full cont rol of M SD.
II.Scientific Issues
A.Trial Conduct
1.Trial Design
Except for pi[INVESTIGATOR_19354], clinical trial protocols will be hypothesis -driven to assess safety, efficacy 
and/or pharmacokinetic or pharmacodynamic indices of M SD or comparator products. Alternatively, M SD
may conduct outcomes research trials, trials to assess or validate various endpoint measures, or trials to 
determine patient preferences, etc.
The design (i.e. , participant population, duration, statistical power) mu st be adequate to address the specific
purpose of the trial. P articipants must meet protocol entry criteria to be enrolled in the trial. 
2.Site Selection
MSD selects investigative sites based on medical expert[INVESTIGATOR_18700], access to appropriate participants, adequacy of 
facilities and staff, previous performance in clinical trials, as well as budgetary considerations. Prior to trial 
initiation, sites are evaluated by M SD personnel (or individuals acting on behalf of MSD) to assess the ability 
to successfully conduct the trial.
3.Site Monitoring/Scientific Integrity
Investigative trial sites are monitored to assess compliance with the trial protocol and Good Clinical Pr actice
(GCP). MSD reviews clinical data for accuracy, completeness, and consistency. Data are verified versus 
source documentation according to standard operating procedures. Per M SD policies and procedures, if fraud, 
08WCSH
PRODUCT:   MK-8591A  121
PROTOCOL/AMENDMENT NO.:   017 -09
MK-8591A -017-09 FINAL PROTOCOL 26-MAR -2024
scientific/research misc onduct or serious GCP -non-compliance is suspected, the issues are investigated. 
When necessary, the clinical site will be closed, the responsible regulatory authorities and ethics review 
committees notified .
B. Publication and Authorship
Regardless of trial outc ome, MSD commits to publish theprimary and secondary results of its registered trials of 
marketed products in which treatment is assigned, according to the pre -specified plans for data analysis. To the 
extent scientifically appropriate, M SDseeks to publi sh the results of other analyses it conducts that are important 
to patients, physicians, and payers. Some early phase or pi[INVESTIGATOR_26346] -generating rather 
than hypothesis testing ;in such cases, publication of results may not be appropriate since the trial may be 
underpowered and the analyses complicated by [CONTACT_19482].
MSD’s policy on authorship is consistent with the re commendations published by [CONTACT_26399] ( ICMJE). In summary, authorship should reflect significant contribution to the design and 
conduct of the trial, performance or interpretation of the analysis, and/or writing of the manuscript. All named 
authors must be able to defend the trial results and c onclusions. M SD funding of a trial will be acknowledged in 
publications.
III.Participant Protection
A. Regulatory Authority and Ethics Committee Review (Institutiona lReview Board [I RB]/Independent Ethics 
Committee [IEC])
All protocols and protocol amendments will be submitted by [CONTACT_88708]/authorization prior to implementation of the trial or amendment, in compliance with local and/or 
national regulations.
The protocol, protocol amendment(s), informed consent fo rm, investigator’s brochure, and other relevant trial 
documents must be reviewed and approved by [CONTACT_2717]/IEC before being implemented at each site, in compliance 
with local and/or national regulations. Changes to the protocol that are required urgently to e liminate an 
immediate hazard and to protect participant safety may be enacted in anticipation of ethics committee approval.  
MSD will inform regulatory authorities of such new measures to protect participant safety, in compliance with 
local and/or national regulations.
B. Safety
The guiding principle in decision -making in clinical trials is that participant welfare is of primary importance. 
Potential participants will be informed of the risks and benefits of, as well as alternatives to, trial participation. At 
a minimum, trial designs will take into account the local stand ard of care.
All participation in M SD clinical trials is voluntary. Participants enter the trial only after informed consent is 
obtained . Participants may withdraw from a n MSD trial at any time, without any influence on their access to, or 
receipt of, medical care that may otherwise be available to them.
C. Confidentiality
MSD is committed to safeguarding participant confidentiality, to the greatest extent possible. Unless required by 
[CONTACT_2371], o nly the investigator, Sponsor ( or individuals acting on behalf of MSD), ethics committee, and/or regulatory 
authorities will have access to confidential medical records t hat might identify the participant by [CONTACT_2300].
D. Genomic Research
Genomic research will only be conducted in accordance with a protocol and informed consent authorized by [CONTACT_63544] c ommittee.
08WCSH
PRODUCT:   MK-8591A  122
PROTOCOL/AMENDMENT NO.:   017 -09
MK-8591A -017-09 FINAL PROTOCOL 26-MAR -2024
IV. Financial Considerations
A. Payments to Investigators
Clinical trials are time -and labor -intensive. It is M SD’s policy to compensate investigators (or the sponsoring 
institution) in a fair manner for the work performed in support of M SD trials. M SD does not pay incentives to 
enroll participants in its trials. However, when enrollment is particularly challenging, additional pa yments may be 
made to compensate for the time spent in extra recruiting efforts.
MSD does not pay for participant referrals. However, M SDmay compensate referring physicians for time spent 
on chart review and medical evaluation to identify potentially elig ible participants.
B.Clinical Research Funding
Informed consent forms will disclose that the trial is sponsored by M SD,and that the investigator or sponsoring 
institution is being paid or provided a grant for performing the trial. However, the local ethics committee may 
wish to alter the wording of the disclosure statement to be consistent with financial practices at that institution. As 
noted above, all publications resulting from M SD trials will indicate M SD as a source of funding.
C. Funding for Travel and Other Requests
Funding of travel by [CONTACT_19488] (e.g. , to scientific meetings, investigator meetings, etc.) will be 
consistent with local guidelines and practices .
V. Investigator Commitment
Investigators will be expected to review M SD’s Code of Conduct as an appendix to the trial protocol, and in signing the 
protocol, agree to support these et hical and scientific standards .
10.1.2 Financial Disclosure
Financial Disclosure requirements are outlined in the US Food and Drug Administration 
Regulations, Financial Disclosure by [CONTACT_6230] (21 CFR Part 54). It is the 
Sponsor's responsibility to determine, based on these regulations, whether a request for 
Financial Disclosure information is required. It is the investigator's/subi nvestigator's 
responsibility to comply with any such request.
The investigator/subinvestigator(s) agree, if requested by [CONTACT_19489] 21 
CFR Part 54, to provide his/her financial interests in and/or arrangements with the Sponsor to 
allow for the submission of complete and accurate certification and disclosure statements. 
The investigator/subinvestigator(s) further agree to provide this information on a 
Certification/Disclosure Form, commonly known as a financial disclosure form, provided b y 
the Sponsor. The investigator/subinvestigator(s) also consent to the transmission of this 
information to the Sponsor in the [LOCATION_002] for these purposes. This may involve the 
transmission of information to countries that do not have laws protecting p ersonal data.
10.1.3 Data Protection
Participants will be assigned a unique identifier by [CONTACT_1034]. Any participant records or 
datasets that are transferred to the Sponsor will contain the identifier only; participant names 
or any information that would make the participant identifiable will not be transferred.
08WCSH
PRODUCT:   MK-8591A  123
PROTOCOL/AMENDMENT NO.:   [ADDRESS_916935] be informed that his/her personal study -related data will be used by [CONTACT_19490]. The level of disclosure must also be 
explained to the participant. 
The participant must be informed that his/her medical records may be examined by [CONTACT_88710] S ponsor, by 
[CONTACT_6667]/IEC members, and by [CONTACT_618289].
[IP_ADDRESS] Confidentiality of Data
By [CONTACT_12570], the investigator affirms to the Sponsor that information furnished to 
the investigator by [CONTACT_19492], and such information will 
be divulged to the IRB , IEC ,or similar or expert committee; affiliated institution and 
employees, only under an appropriate understanding of confidentiality with such board or 
committee, affiliated institution and employees. Data generated by [CONTACT_677719], except to the extent that it is included in a 
publication as provided in the Publications section of this protocol.
[IP_ADDRESS] Confidentiality of Participant Records
By [CONTACT_12570], the investigator agrees that the Sponsor (or Sponsor representative), 
IRB/IEC, or regulatory authority representatives may consult and/or copy study documents to 
verify worksheet/ CRF data. By [CONTACT_17317], the participant agrees to this 
process. If study documents will be photocopi[INVESTIGATOR_88648]/ CRF information, the participant will be identified by [CONTACT_19494]; full 
names/initials will be masked prior to transmission to the Sponsor.
By [CONTACT_12570], the investigator agrees to treat all participa nt data used and 
disclosed in connection with this study in accordance with all applicable privacy laws, rules 
and regulations.
[IP_ADDRESS] Confidentiality of IRB/IEC Information
The Sponsor is required to record the name [CONTACT_19525]/IEC that reviews and 
approves this study. The Sponsor is also required to document that each IRB/IEC meets 
regulatory and ICH GCP requirements by [CONTACT_26389]/IEC members and to make these records available for 
regulatory agency review upon request by [CONTACT_19496] .
10.1.4 Committees Structure
[IP_ADDRESS] Executive Oversight Committee
The EOC is comprise d of members of Sponsor Senior Management. The EOC will receive 
and decide upon any recommendations made by [CONTACT_677720] s tudy.
08WCSH
PRODUCT:   MK-8591A  124
PROTOCOL/AMENDMENT NO.:   017 -09
MK-8591A -017-09 FINAL PROTOCOL 26-MAR -2024
[IP_ADDRESS] External D ata Monitoring Committee
To supplement the routine study monitoring outlined in this protocol, an external DMC will 
monitor the interim data from this study. The voting members of the committee are external 
to the Sponsor. The members of the DMC must not be involved with the study in any other 
way (eg, they cannot be study investigators) and must have no competing interests that could 
affect their roles with respect to the study.
The DMC will make recommendations to the EOC regarding steps t o ensure both participant 
safety and the continued ethical integrity of the study. Also, the DMC will review interim 
study results, consider the overall risk and benefit to study participants ( Section 9. 7 [Interim 
Analysis] ) and recommend to the EOC whethe rthe study should continue in accordance with 
the protocol.
Specific details regarding composition, responsibilities, and governance, including the roles 
and responsibilities of the various members and the Sponsor protocol team ; meeting 
facilitation; the study governance structure; and requirements for and proper documentation 
of DMC reports, minutes, and recommendations will be described in the DMC charter that is 
reviewed and approved by [CONTACT_63548].
[IP_ADDRESS] Scientific Advisory Committee (SAC)
This study was developed in collaboration with a SAC . The SAC is comprise d of both 
Sponsor and non -Sponsor scientific experts who provide input with respect to study design, 
interpretation of study results, and subsequent peer -reviewed scientific publicati ons.
10.1.[ADDRESS_916936] (FDAAA) of 2007 
and the European Medicines Agency (EMA) clinical trial Directive 2001/20/EC, the Sponsor 
of the study is solely responsible for determining whether the study and its results are subject
to the requirements for submission to http://www.clinicaltrials.gov, 
08WCSH
PRODUCT:   MK-8591A  125
PROTOCOL/AMENDMENT NO.:   [ADDRESS_916937] the study in an efficient and 
diligent manner and in conformance with this protocol; generally accepted standards of G CP
(eg, International Conference on Harmoni sation of Technical Requirements for Registration 
of Pharmaceuticals for Human Use GCP : Consolidated Guideline and other generally 
accepted standards of GCP ); and all applicable federal, state and local laws, rules and 
regulations relating to the conduct of the clinical study.
The Code of Conduct, a collection of goals and considerations that govern the ethical and 
scientific conduct of clinical investigations sponsored by [CONTACT_19487], is provided i n this appendix 
under the Code of Conduct for Clinical Studies.
The investigator agrees not to seek reimbursement from participants, their insurance 
providers, or from government programs for procedures included as part of the study 
reimbursed to the inves tigator by [CONTACT_1034].
The investigator will promptly inform the Sponsor of any regulatory authority inspection 
conducted for this study.
The investigator agrees to provide the Sponsor with relevant information from inspection 
observations/findings to all ow the Sponsor to assist in responding to any citations resulting 
from regulatory authority inspection and will provide the Sponsor with a copy of the 
proposed response for consultation before submission to the regulatory authority. 
Persons debarred from conducting or working on clinical studies by [CONTACT_19500]’s studies. The investigator 
will immediately disclose in writing to the Sponsor if any person who is involved in 
conducting the study is debarred or if any proceeding for debarment is pending or, to the best 
of the investigator’s knowledge, threatened .
08WCSH
PRODUCT:   MK-8591A  126
PROTOCOL/AMENDMENT NO.:   017 -09
MK-8591A -017-09 FINAL PROTOCOL 26-MAR -2024
10.1.8 Data Quality Assurance
All participant data relating to the study will be recorded on printed or electronic CRF unless 
transmitted to the Sponsor or designee electronically (eg, laboratory data). The investigator 
or qualified designee is responsible for verifying that data entries are accurate and correct by 
[CONTACT_1189].
Detailed information regarding Data Management procedures for this protocol will be 
provided separately.
The investigator must maintain accurate documentation (source data) that supports the 
information entered in the CRF.
The investigator must permit study- related monitoring, audits, IRB/IEC review, and 
regulatory agency inspections and provide direct access to source data documents.
Study documentation will be promptly and fully disclosed to the Sponsor by [CONTACT_677721] e study site upon request for inspection, 
copying, review, and audit at reasonable times by [CONTACT_19502]. The investigator agrees to promptly take any reasonable steps that are 
requested by [CONTACT_88713] a result of an audit or inspection to 
cure deficiencies in the study documentation and worksheets/CRFs .
The Sponsor or designee is responsible for the data management of this study including 
quality checking of the data.
Study mo nitors will perform ongoing source data review and verification to confirm that data 
entered into the CRF by [CONTACT_1191], complete, and verifiable from 
source documents; that the safety and rights of participants are being protec ted; and that the 
study is being conducted in accordance with the currently approved protocol and any other 
study agreements, ICH GCP, and all applicable regulatory requirements.
Records and documents, including participants’ documented informed consent, p ertaining to 
the conduct of this study must be retained by [CONTACT_1732] 15 years after study 
completion unless local regulations or institutional policies require a longer retention period. 
No records may be destroyed during the retention period wi thout the written approval of the 
Sponsor. No records may be transferred to another location or party without written 
notification to the Sponsor .
10.1.9 Source Documents
Source documents provide evidence for the existence of the participant and substantiate the 
integrity of the data collected. The investigator/institution should maintain adequate and 
accurate source documents and study records that include al lpertinent observations on each 
of the site’s participants. Source documents and data should be attributable, legible, 
contemporaneous, original, accurate, and complete. Changes to source data should be 
08WCSH
PRODUCT:   MK-8591A  127
PROTOCOL/AMENDMENT NO.:   017 -09
MK-8591A -017-09 FINAL PROTOCOL 26-MAR -2024
traceable, should not obscure the original entry, and should be explained if necessary (eg, via 
an audit trail). Source documents are filed at the investigator’s site.
Data reported on the CRF or entered in the eCRF that are transcribed from source documents 
must be consistent with the source documents or th e discrepancies must be explained. The 
investigator /institution may need to request previous medical records or transfer records, 
depending on the study. Also, current medical records must be available .
10.1.10 Study and Site Closure
The Sponsor or its designee ma y stop the study or study site participation in the study for 
medical, safety, regulatory, administrative, or other reasons consistent with applicable laws, 
regulations, and GCP.
In the event the Sponsor prematurely terminates a particular study site, the Sponsor or 
designee will promptly notify that study site’s IRB/IEC as specified by [CONTACT_88714](s) .
08WCSH
PRODUCT:   MK-8591A  128
PROTOCOL/AMENDMENT NO.:   017 -09
MK-8591A -017-09 FINAL PROTOCOL 26-MAR -2024
10.2 Appendix 2: Clinical Laboratory Tests
Thetests detailed in Table 15will be performed by [CONTACT_281140] .
Local laboratory results are only required in the event central laboratory results are not 
available in time for either study intervention administration and/or response evaluation. 
If a local sample is required, it is important that the sample for central analysis is 
obtained at the same time. Additionally, if the local laboratory results are used to make 
either a study intervention decision or response evaluation, the results must be entered 
into the CRF.
Protocol -specific requirements for inclusion or exclusion of participants are detailed in 
Section 5 of the protocol.
Additional tests may be performed at any time during the study as determined necessary 
by [CONTACT_11006].
Pregnancy Testing
Pregnancy testing requirements for study inclusion are described in Section 5.1
Additional serum or urine pregnancy tests may be performed, as determined necessary by 
[CONTACT_31837], to establish the absence of pregnancy at 
any time during the subject’s participation in the study , where appropriate .
08WCSH
PRODUCT:   MK-8591A  129
PROTOCOL/AMENDMENT NO.:   017 -09
MK-8591A -017-09 FINAL PROTOCOL 26-MAR -2024
Table 15 Protocol -Require d Laboratory Assessments
Laboratory 
AssessmentsParameters
Hematology Platelet Count RBC Indices:
Mean corpuscular volume ( MCV )
Mean corpuscular hemoglobin
(MCH )
MCH Concentration
Red Cell Distribution Width 
(RDW)White Blood Cell (WBC)
count with Differential:
Neutrophils
Lymphocytes
Monocytes
Eosinophils
BasophilsRed Blood Cell 
(RBC) Count
Hemoglobin
Hematocrit
CD4+ T -cell 
Count/TBNK panelT-cell, B -cell,and Natural Killer cell profile that includes but is not limited to :
CD3+ Percent 
CD3+ Value/Absolute Count 
CD3+CD4+ Percent 
CD3+CD4+ Value/Absolute Count 
CD3+CD8+ Percent 
CD3+CD8+ Value/Absolute Count 
CD3 -CD19+ Percent 
CD3 -CD19+ Value/Absolute Count 
CD16+CD56+ Percent 
CD16+CD56+ Value/Absolute Count 
CD3+CD4+CD8+ Percent 
CD3+CD4+CD8+ Value/Absolute Count 
CD4/CD8 Ratio
Coagulation Prothrombin Time/ international normalized ratio ( INR)
Chemistry 
(non-fasting)Blood Urea 
Nitrogen 
(BUN)Potassium Aspartate Amino -
transferase
(AST )Total bilirubin 
Direct bilirubin
Indirect bilirubin
Albumin Bicarbonate Chloride Phosphorous
Creatinine Sodium Alanine Amino -
transferase
(ALT )Total Protein
Glucose 
(non-fasting)Calcium Alkaline 
phosphataseCreatinine Clearance
Creatine 
kinaseLipase Amylase Magnesium
Additional c hemistry
at fasting visits
(fasting for at least 
8 h)Glucose (fasting)
High -density lipoprotein (HDL -C)
Low-density lipoprotein (LDL -C)
Triglycerides (TGs)
Total Cholesterol (TC)
Non-HDL -C
Insulina
Homeostatic Model Assessment of Insulin Resistance (HOMA -IR)(calculation)
08WCSH
PRODUCT:   MK-8591A  130
PROTOCOL/AMENDMENT NO.:   017 -09
MK-8591A -017-09 FINAL PROTOCOL 26-MAR -2024
Laboratory 
AssessmentsParameters
Routine UrinalysisSpecific gravity
pH, glucose, protein, blood, ketones, bilirubin, urobilinogen, nitrite, 
leukocyte s
Pregnancy testingSerum and urine β human chorionic gonadotropin (β -hCG) pregnancy test (for a 
woman/women of childbearing potential [ WOCBP ])
Urinary analysis Albumin
Protein
Beta-2-microglobulin/creatinine ratio (B -2M/Cr)
Retinol binding protein/creatinine ratio (RBP/Cr)
Renal function Estimated glomerular filtration rate (eGFR) by [CONTACT_180668] (MDRD )equation
Hepatitis screening 
and monitoringbHepatitis B virus surface antigen (HBsAg)
Hepatitis B virus (HBV) surface antibody 
Anti-HBc (hepatitis B core antibody)
HBV DNA
Hepatitis C antibody (if positive perform plasma hepatitis C virus quantitative test) 
(at screening only)
Human immune-
deficiency virus -1 
(HIV -1) serologyHIV 1/[ADDRESS_916938]
Virology HIV-1 viral ribonucleic acid (RNA) quantification (Real time polymerase chain 
reaction [PCR])
HIV-1 viral resistance
Inflammatory markers D-Dimer
Inerleukin -6 (IL -6)
Soluble CD-163 (sCD -163)
High -sensitivity C -reactive protein (hs -CRP)
Blood for Renal 
BiomarkersCystatin -C
Pharmacokinetics 
(PK)Islatravir (ISL) PK (For Group 1 participants only)
Investigational PK samples will be collected for both Group 1 and Group 2 beyond 
Week 48. Analysis of these samples will be triggered by [CONTACT_25753].
ISL and DOR PK (For female participants on DOR/ISL who become pregnant 
during the study) 
aParticipants with diabetes mellitus (type 1 or type 2) or insulin resistance are not required to have the blood draw for 
insulin testing.
b All participants will be screened for HBsAg, HBV surface antibody, anti -HBc and HBV DNA. Participants that are anti -
HBc positive ,but HBV DNA negative will have HBsAg and HBV DNA monitored for the duration of the study .
The investigator (or medically qualified designee) must document their review of each 
laboratory safety report.
08WCSH
PRODUCT: MK-8591A  131
PROTOCOL/AMENDMENT NO.: 017-09
MK-8591A -017-09 FINAL PROTOCOL 26-MAR -2024
Table 16 Blood Volumes
Study Period Screening InterventionViremia 
Confirm -
ationCD4+ T -Cell/
Lymphocyte 
ConfirmEarly 
Discon of 
Treat -
mentCD4+ T -Cell/
Lymphocyte 
MonitorEOT 
F-U
Scheduled Day/Week
Screening
Day 1
Week 4
Week 12
Week 24
Week 36
Week 48
Week 52b
Week 60
Week 72
Week 84
Week 96
Unscheduled
Unscheduled Unscheduled
Unscheduled
UnscheduledBlood Parameter Approximate Blood Volume (mL)
Plasma HIV -1 RNA Quantification 
(Real Time PCR)6 6 6 6 6 6 6 6 6 6 6 6 6 6 6
CD4+ T -cell Count /TBNK Panel 6 6 6 6 6 6 6 6e6 6e6
HIV-1 Drug Resistance Testing 18 15 15 15 15 15 15 15 15 15 15 15 15 15
HIV-1 & -2 and Hepatitis Screena4 4 4 4 4 4 4 4 4 4 4 4
HIV Confirmation Geenius 1
HBV DNAa6 6 6 6 6 6 6 6 6 6 6 6
Chemistry (Includes Serum Pregnancy 
at Screening and Early 
Discontinuation)6 6 6 6 6 6 6 6 6 6 6 6 6
Hematology 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
Fasting Lipi[INVESTIGATOR_805] 2 2 2 2
Fasting Insulin 1 1 1 1
PT/INR 2.7
Blood for Inflammatory Biomarkers 10.7 10.7 10.7 10.7
Cystatin -C 2 2 2 2
PK Blood Sample Collection Group 1 
participants only)4 8 4 4 4
Blood (Plasma) for Investigational PKc4 4 4 4 4 4 4 4 4
Blood (Plasma) for DOR and ISL PK 
During Pregnancy<-------------------------------- Xd-------------------------------- >
08WCSH
PRODUCT: MK-8591A  132
PROTOCOL/AMENDMENT NO.: 017-09
MK-8591A -017-09 FINAL PROTOCOL 26-MAR -2024
Study Period Screening InterventionViremia 
Confirm -
ationCD4+ T -Cell/
Lymphocyte 
ConfirmEarly 
Discon of 
Treat -
mentCD4+ T -Cell/
Lymphocyte 
MonitorEOT 
F-U
Scheduled Day/Week
Screening
Day 1
Week 4
Week 12
Week 24
Week 36
Week 48
Week 52b
Week 60
Week 72
Week 84
Week 96
Unscheduled
Unscheduled Unscheduled
Unscheduled
UnscheduledBlood Parameter Approximate Blood Volume (mL)
Blood for Genetic Analysis 8.5
Whole Blood for FBR 8 8 8 8 8 8 8
Total Blood Volume per Visit (mL)d33.7 84.2 47 43 72.7 43 72.7 43 43 57 49 72.7 33 8 47 8 33
anti-HBc=hepatitis B core antibody; Discon=discontinuation; DNA=deoxyribonucleic acid; FBR=future biomedical research; HBsAg=hepatitis B surface antigen; HBV=hepatitis B virus; HIV -
1=human immunodeficiency virus -1; INR=international normalized ratio; PCR=polymerase chain reaction; PK=pharmacokinetic(s) PT=prothrombin time; RNA=ribonucl eic acid ; TBNK=T -and B -
lymphocyte and natural killer cell profile . 
aAll participants will have hepatitis screening and HBV DNV drawn at screening. At subsequent visits, only anti -HBc positive participants will have HBsAg and HBV DNA monitored.
bWeek 52 sample collectio ns are only for participants in Group 2
cInvestigational PK samples will be collected for both Group 1 and Group 2 beyond Week 48. Analysis of these samples will be t riggered by [CONTACT_25753] .
dPK samples collected during pregnancy will be collected per Section 8.11. 6.1. During the 1sttrimester and postpartum study visits, 4 mL of blood will be collected for PK sampling. During the 2ndand 
3rdtrimester study visits, 12 mL of blood will be coll ected for PK sampling.
eBlood volumes collected at the CD4+ T- cell count/Lymphocyte count Monitoring Visit represent single monitoring visits.
08WCSH
PRODUCT: MK-8591A  133
PROTOCOL/AMENDMENT NO.: 017-[ADDRESS_916939] scheduled 
study visit (ie, Week 96) and whose visit schedule will be extended through the duration of 
the pregnancy to allow assessments thr ough each trimester and postpartum.
Table 17 Blood Volumes : Participants Whose Pregna ncy or Postpartum Visit(s) Extends 
Beyond Week 96
Visit Number 13 14 15 16
Scheduled Week
Week 108
Week 120
Week 132 Week 144Blood Parameter Approximate Blood Volume (mL)
Plasma HIV -1 RNA Quantification (Real 
Time PCR)6 6 6 6
CD4+ T -cell Count /TBNK Panel 6 6 6 6
Plasma for HIV Viral Drug Resistance 
Testing 15 15 15 15
HBsAg and HBV DNA 6 6 6 6
Chemistry 6 6 6 6
Hematology 2 2 2 2
Blood (Plasma) for DOR and ISL PK ----------------------- Xa---------------------
Whole Blood for FBR 8 8 8 8
Approximate Blood Volume per Visit 
(mL)a 61 61 61 61
DNA=deoxyribonucleic acid; DOR=doravirine; FBR=future biomedical research; HBsAg=hepatitis B surface antigen; 
HBV=hepatitis B virus; HIV -1=human immunodeficiency virus Type 1; ISL=islatravir; mL=milliliter ; PCR=polymerase 
chain reaction; PK=pharmacokinetic(s) ;RNA=ribonucleic acid; TBNK=T- and B -lymphocyte and natural killercell 
profile .
aPK samples collected during pregnancy will be collected per Section 8.11. 6.1. During the 1sttrimester and postpartum 
study visits, [ADDRESS_916940]: MK-8591A  134
PROTOCOL/AMENDMENT NO.: 017-09
MK-8591A -017-09 FINAL PROTOCOL 26-MAR -2024
10.3 Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow -up, and Reporting
10.3.1 Definition of AE
AE definition
An AE is any untoward medical occurrence in a clinical study participant, temporally 
associated with the use of study intervention, whether or not considered related to the 
study intervention.
NOTE: An AE can therefore be any unfavorable and unintended si gn (including an 
abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally 
associated with the use of a study intervention.
NOTE: For purposes of AE definition, study intervention (also referred to as Sponsor’s 
product) includes any pharmaceutical product, biological product, vaccine, diagnostic 
agent, or protocol specified procedure whether investigational or marketed (including 
placebo, active comparator product, or run -in intervention) , manufactured by, licensed 
by, provided by, or distributed by [CONTACT_63553].
Events meeting the AE definition
Any abnormal laboratory test results (hematology, clinical chemistry, or urinalysis) or 
other safety assessments (eg, ECG, radiological scans, vital signs measurem ents), 
including those that worsen from baseline ,considered clinically significant in the medical 
and scientific judgment of the investigator.
Exacerbation of a chronic or intermittent pre -existing condition including either an 
increase in frequency and/ or intensity of the condition.
New conditions detected or diagnosed after study intervention administration even 
though it may have been present before the start of the study.
Signs, symptoms, or the clinical sequelae of a suspected drug -drug interaction .
Signs, symptoms, or the clinical sequelae of a suspected overdose of either study 
intervention or a concomitant medication.
For all reports of overdose (whether accidental or intentional) with an associated AE, the 
AE term should reflect the clinical symptoms or abnormal test result. An overdose 
without any associated clinical symptoms or abnormal laboratory results is reported using 
the terminology “accidental or intentional overdose without adverse effect.”
•Any new cancer or progression of existing cancer.
08WCSH
PRODUCT: MK-8591A  135
PROTOCOL/AMENDMENT NO.: 017-09
MK-8591A -017-09 FINAL PROTOCOL 26-MAR -2024
Events NOT meeting the AE d efinition
Medical or surgical procedure (eg, endoscopy, appendectomy): the condition that leads to 
the procedure is the AE.
Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospi[INVESTIGATOR_307]).
Anticipated day -to-day fluctuations of pre -existing disease(s) or condition(s) present or 
detected at the start of the study that do not worsen.
Surgery planned prior to informed consent to treat a pre -existing condi tion that has not 
worsened.
Refe r to Section 8.4.[ADDRESS_916941] medical o ccurrence that, at any dose:
a.Results in death
b.Is life -threatening
The term “ life-threatening ”in the definition of “serious” refers to an event in which 
the participant was at risk of death at the time of the event. It does not refer to an 
event, which hypothetically might have caused death, if it were more severe.
c.Requires inpatient hospi[INVESTIGATOR_1081]
Hospi[INVESTIGATOR_19357], regardless of length of stay, even 
if the hospi[INVESTIGATOR_2138] a precautionary measure for continued observation. (Note: 
Hospi[INVESTIGATOR_19358] a pre -existing condition that has not 
worsened is not an SAE. A pre -existing condition is a clinical condition that is 
diagnosed prior to the use of an MSD product and is documented in the participant’s 
medical history.
08WCSH
PRODUCT: MK-8591A  136
PROTOCOL/AMENDMENT NO.: 017-09
MK-8591A -017-09 FINAL PROTOCOL 26-MAR -2024
d.Results in persistent or significant disability/incapacity
The term disability means a substantial disruption of a person’s ability to conduct 
normal life functions.
This definition is not intended to include experiences of relatively minor medical 
significance such as uncomplicated headache, nausea, vomiting, diarrhea, influenza, 
and accidental trauma (eg, sprained ankle) that may interfere with or prevent 
everyday life fu nctions but do not constitute a substantial disruption.
e.Is a congenital anomaly/birth defect
In offspring of participant taking the product regardless of time to diagnosis.
f.Other important medical events
Medical or scientific judgment should be exercised in deciding whether SAE 
reporting is appropriate in other situations such as important medical events that may 
not be immediately life -threatening or result in death or hospi[INVESTIGATOR_63474] 1 
of the other outcomes listed in the above definition. These events should usually be 
considered serious.
Examples of such events include invasive or malignant cancers, intensive treatment in 
an emergency room or at home for allergic bronchospasm, blood dyscrasias or 
convulsions that do not result in hospi[INVESTIGATOR_059], or development of drug dependency 
or drug abuse.
10.3.3 Additional Events Reported
Additional events that require r eporting
In addition to the above criteria, AEs me eting either of the below criteria, although not 
serious per ICH definition, are reportable to the Sponsor.
Is a cancer
Is associated with an overdose
08WCSH
PRODUCT: MK-8591A  137
PROTOCOL/AMENDMENT NO.: 017-09
MK-8591A -017-09 FINAL PROTOCOL 26-MAR -2024
10.3.4 Recording AE and SAE
AE and SAE r ecording
When an AE/SAE occurs, it is the responsibility of the investi gator to review all 
documentation (eg, hospi[INVESTIGATOR_1088], laboratory, and diagnostics reports) related to 
the event.
The investigator will record all relevant AE/SAE information on the AE 
CRFs /worksheets at each examination.
It is not acceptable for the investigator to send photocopi[INVESTIGATOR_10914]’s medical 
records to the Sponsor in lieu of completion of the AE C RF page.
There may be instances when copi[INVESTIGATOR_88650]. In this case, all participant identifiers, with the exception of the participant 
number, will be blinded on the copi[INVESTIGATOR_63476].
The investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical information. In such cases, the diagnosis (not the 
individual signs/symptoms) will be documented as the AE/ SAE.
Assessment of i ntensity /toxicity
An event is defined as “serious” when it meets at least 1 of the predefined outcomes as 
described in the definition of an SAE, not when it is rated as severe.
The investigator will make an assessment of intensity for each AE and SAE (and other 
reportable safety event) by [CONTACT_111970], version 2.1. Any AE which 
changes DAIDS grade over the course of a gi ven epi[INVESTIGATOR_19362]/worksheets.
-Grade 1 Mild event : Mild symptoms causing no or minimal interference with usual 
social and functional activities with intervention not indicated.
-Grade 2 Moderate event : Moder ate symptoms causing greater than minimal 
interference with usual social and functional activities with intervention indicated.
-Grade 3 Severe event: Severe symptoms causing inability to perform usual social and 
functional activities with intervention or hospi[INVESTIGATOR_374].
-Grade 4 Potentially life -threatening event: Potentially life -threatening symptoms 
causing inability to perform basic self -care funtions with intervention indicated to 
prevent permanent impairment, persistent disability, or death.
-Grade 5 Death: Deaths related to an AE.
08WCSH
PRODUCT: MK-8591A  138
PROTOCOL/AMENDMENT NO.: 017-09
MK-8591A -017-09 FINAL PROTOCOL 26-MAR -2024
Assessment of c ausality
Did the Sponsor ’s product cause the AE?
The determination of the likelihood that the Sponsor ’s product caused the AE will be 
provided by [CONTACT_19427] a qualified physician. The investigator’s signed/dated 
initials on the source document or worksheet that supports the causality noted on the AE 
form, ensures that a medically qualified assessment of causality was done. This initialed 
document must be retained for the required regula tory time frame. The criteria below are 
intended as reference guidelines to assist the investigator in assessing the likelihood of a 
relationship between the test product and the AE based upon the available information.
The following components are to be used to assess the relationship between the 
Sponsor ’s product and the AE ; the greater the correlation with the components and 
their respective elements (in number and/or intensity), the more likely the Sponsor ’s 
product caused the AE:
-Exposure: Is there e vidence that the participant was actually exposed to the 
Sponsor ’s product such as: reliable history, acceptable compliance assessment (pi[INVESTIGATOR_9650], diary, etc.), expected pharmacologic effect, or measurement of drug/metabolite 
in bodily specimen?
-Time Cou rse:Did the AE follow in a reasonable temporal sequence from 
administration of the Sponsor ’s product? Is the time of onset of the AE compatible 
with a drug -induced effect (applies to studies with investigational medicinal product)?
-Likely Cause: Is the AE not reasonably explained by [CONTACT_19511], other drug(s)/vaccine(s), or other host or environmental factors.
-Dechallenge: Was the Sponsor ’s product discontinued or dose/exposure/frequency 
reduced?
oIf yes, did the AE resolve or improve?
oIf yes, this is a positive dechallenge.
oIf no, this is a negative dechallenge.
(Note: This criterion is not applicable if: (1) the AE resulted in death or permanent 
disability; (2) the AE resolved/improved despi[INVESTIGATOR_55530] ’s 
product; (3) the study is a single -dose drug study; or (4) Sponsor ’s product(s) is/are 
only used 1 time.)
08WCSH
PRODUCT: MK-8591A  139
PROTOCOL/AMENDMENT NO.: 017-09
MK-8591A -017-09 FINAL PROTOCOL 26-MAR -2024
-Rechallenge: Was the participant re -exposed to the Sponsor ’s product in this study?
oIf yes, did the AE recur or worsen?
oIf yes, this i s a positive rechallenge.
oIf no, this is a negative rechallenge.
(Note: This criterion is not applicable if: (1) the initial AE resulted in death or 
permanent disability, or (2) the study is a single -dose drug study; or (3) Sponsor ’s 
product(s) is/are us ed only 1 time.)
NOTE: IF A RECHALLENGE IS PLANNED FOR AN AE THAT WAS SERIOUS AND 
MAY HAVE BEEN CAUSED BY [CONTACT_26370] ’S PRODUCT, OR IF RE -EXPOSURE 
TO THE SPONSOR ’S PRODUCT POSES ADDITIONAL POTENTIAL SIGNIFICANT 
RISK TO THE PARTICIPANT THEN THE RECHALLENGE MUST BE APPROVED IN 
ADVANCE BY [CONTACT_93333], AND IF REQUIRED, THE 
IRB/IEC .
Consistency with study intervention profile: Is the clinical/pathological presentation of 
the AE consistent with previous knowledge regarding the Sponsor ’s product or drug class 
pharmacology or toxicology?
The assessment of relationship will be reported on the case report forms/worksheets by 
[CONTACT_19427] a qualified physician according to his/her best clinical judgment, 
including consideration of the above elements.
Use the following scale of criteria as guidance (not all criteria must be present to be 
indicative of a Sponsor ’s product relationship).
-Yes, there is a reasonable possibility of Sponso r’s product relationship:
oThere is evidence of exposure t o the Sponsor ’s product. The temporal sequence of 
the AE onset relative to the administration of the Sponsor ’s product is reasonable. 
The AE is more likely explained by [CONTACT_1034] ’s product than by [CONTACT_5748].
-No, there is not a re asonable possibility of Sponsor’ s product relationship:
oParticipant did not receive the Sponsor ’s product OR temporal sequence of the 
AE onset relative to administration of the Sponsor ’s product is not reasonable OR 
the AE is more likely explained by [CONTACT_26372]’s product. 
(Also entered for a participant with overdose without an associated AE.)
For each AE/SAE, the investigator must document in the medical notes that he/she has 
reviewed the AE/SAE and has provided an assessment of c ausality.
08WCSH
PRODUCT: MK-8591A  140
PROTOCOL/AMENDMENT NO.: 017-09
MK-8591A -017-09 FINAL PROTOCOL 26-MAR -2024
There may be situations in which an SAE has occurred and the investigator has minimal 
information to include in the initial report to the Sponsor. However, it is very important 
that the investigator always make an assessment of causality for eve ry event before the 
initial transmission of the SAE data to the Sponsor.
The investigator may change his/her opi[INVESTIGATOR_9242] -up 
information and send an SAE follow -up report with the updated causality assessment.
The causality asse ssment is 1 of the criteria used when determining regulatory reporting 
requirements.
Follow -up of AE and SAE
The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as medically indicated or as r equested by [CONTACT_19514]/or causality of the AE or SAE as fully as possible. This may 
include additional laboratory tests or investigations, histopathological examinations, or 
consultation with other health care professionals.
New o r updated information will be recorded in the CRF.
The investigator will submit any updated SAE data to the Sponsor within 24 hours of 
receipt of the information.
10.3.5 Reporting of AE s, SAE s, and Other Reportable Safety Events to the Sponsor
AE, SAE, and o ther reportable safety event reporting to Sponsor via electronic d ata 
collection t ool
The primary mechanism for reporting to the Sponsor will be the electronic data collection 
(EDC) tool.
-Electronic reporting procedures can be found in the EDC data entry guidelines (or 
equivalent).
-If the electronic system is unavailable for more than 24 hours, then the site will use 
the paper AE Reporting form.
Reference Section 8.4.1 for reporting time requirements.
The site will enter the SAE data into the electronic system as soon as it becomes 
available.
After the study is completed at a given site, the EDC tool will be taken off -line to prevent 
the entry of new data or changes to existing data.
08WCSH
PRODUCT: MK-8591A  141
PROTOCOL/AMENDMENT NO.: 017-09
MK-8591A -017-09 FINAL PROTOCOL 26-MAR -2024
If a site receives a report of a new SAE from a study parti cipant or receives updated data 
on a previously reported SAE after the EDC tool has been taken off -line, then the site can 
report this information on a paper SAE form or by [CONTACT_756] (see next section).
Contacts for SAE reporting can be found in the Inves tigator Study File Binder (or 
equivalent).
SAE reporting to the Sponsor via paper CRF
If the EDC tool is not operational, facsimile transmission or secure e -mail of the SAE 
paper CRF is the preferred method to transmit this information to the Sponsor.
Inrare circumstances and in the absence of facsimile equipment, notification by 
[CONTACT_9337] a copy of the SAE data collection tool sent by [CONTACT_19515].
Initial notification via telephone does not replace the need for the investigator to 
complete and sign the SAE CRF pages within the designated reporting time frames.
Contacts and instructions for SAE reporting and paper reporting procedures can be found 
in the Investigator Study File Binder (or equivalent) .
08WCSH
PRODUCT: MK-8591A  142
PROTOCOL/AMENDMENT NO.: 017-09
MK-8591A -017-09 FINAL PROTOCOL 26-MAR -2024
10.4 Appendix 4: Device Events, Adverse Device Events, and Medical Device 
Incidents: Definition s, Collection, and Documentation
Not applicable.
08WCSH
PRODUCT: MK-8591A  143
PROTOCOL/AMENDMENT NO.: 017-09
MK-8591A -017-09 FINAL PROTOCOL 26-MAR -2024
10.5 Appendix 5: Contraceptiv e Guidance
10.5.1 Definitions
Women of Childbearing Potential (WOCBP)
A woman (including a transgender man who is assigned female gender at birth and is 
transitioning toward maleness) is considered fertile following menarche and until becoming 
postmenopausal unless permanently sterile (see below):
If fertility is unclear (eg, amenorrhea in adole scents or athletes) and a menstrual cycle cannot 
be confirmed before first dose of study intervention, additional evaluation should be 
considered.
Women in the following categories are not considered WOCBP:
Transgender women (assigned male gender at birth and transitioning toward femaleness).
Premenarchal
Premenopausal female with 1 of the following:
-Documented hysterectomy
-Documented bilateral salpi[INVESTIGATOR_1656]
-Documented bilateral oophorectomy
For individuals with permanent infertility due to an alternate medical cause other than the 
above (eg, Mullerian agenesis, androgen insensitivity), investigator discretion should be 
applied to determining study entry.
Note: Documentation can come from the site personnel’s review of the participant’s 
medical records, medical examination, or medical history interview.
Postmenopausal female
-A postmenopausal state is defined as no menses for [ADDRESS_916942]: MK-8591A  144
PROTOCOL/AMENDMENT NO.: 017-[ADDRESS_916943] discontinue HRT to allow 
confirmation of postmenopausal status before study enrollment.
Women of Nonchildbearing Potential (WONCBP)
Women in the following categories are considered WONCBP:
•Premenopausal female with 1 of the following:
oDocumented hysterectomy
oDocumented bilateral salpi[INVESTIGATOR_677676]
•Forindividuals with permanent infertility due to an alternate medical cause other than the 
above (eg, Mullerian agenesis, androgen insensitivity), investigator discretion should be 
applied to determining study entry.
Note: Documentation can come from the site personnel’s review of the participant’s 
medical records, medical examination, or medical history interview.
•Postmenopausal female
oA postmenopausal state is defined as no menses for 12 months without an alternative 
medical cause. 
◦A high FSH level in the postmenopausal range may be used to confirm a 
postmenopausal state in women not using hormonal contraception or HRT. 
However, in the absence of [ADDRESS_916944]: MK-8591A  145
PROTOCOL/AMENDMENT NO.: 017-09
MK-8591A -017-09 FINAL PROTOCOL 26-MAR -2024
10.5.2 Contraception Requirements
Contraceptives allowed during the study includea:
Highly Effective Contraceptive Metho ds That Have Low User Dependencyb
Failure rate of <1% per year when used consistently and correctly.
 Progestogen -only contraceptive implantc
 IUSd
 Nonhormonal IUD
 Bilateral tubal occlusion
 Azoospermic partner (vasectomized or secondary to medical cause)
This is a highly effective contraception method provided that the partner is the sole male sexual partner of the 
WOCBP and the absence of sperm has been confirmed. If not, an additional highly effective method of contraception 
should be used. A sper matogenesis cycle is approximately 90 days.
Note: Documentation of azoospermia can come from the site personnel’s review of the participant’s medical records, 
medical examination, or medical history interview.
Highly Effective Contraceptive Methods That Are User Dependentb
Failure rate of <1% per year when used consistently and correctly.
 Combined (estrogen -and progestogen -containing) hormonal contraceptionc
 Oral
 Intravaginal
 Transdermal
 Injectable
 Progestogen -only hormonal contraceptionc
 Oral
 Injectable
Sexual Abstinence
 Sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual intercourse 
during the entire period of risk associated with the study intervention. The reliability of sexual abstinence needs to be 
evaluated in relation to the duration of the study and the preferred and usual lifestyle of the participant.
Acceptable Contraceptive Methods
Failure rate of >1% per year when used consistently and correctly.
 Progesterone -only hormonal contraception where inhibition of ovulation is not the primary mode of action
 Male or female condom with or without spermicide
 Cervical cap, diaphragm, or sponge with spermicide
 A combination of male condom with either cervical cap, diaphragm, or sponge with spermicide (double barrier 
methods)e
a. Contraceptive use by [CONTACT_93339].
b. Typi[INVESTIGATOR_63485] -use failure rates (ie, when used consistently and correctly).
c. If locally required, in accordance with CTFG guidelines, acceptable contraceptive implants are limited to those 
which inhibit ovulation.
d. IUS is a progestin releasing IUD.
e. A combination of male condom with either cap, diaphragm, or sponge with spermicide are considered 
acceptable, but not highly effective, birth control methods.
Note: The following are not acceptable methods of contraception:
- Periodic abstinence (calendar, symptothe rmal, post -ovulation methods), withdrawal (coitus interruptus), 
spermicides only, and LAM.
- Male and female condom should not be used together (due to risk of failure with friction).
08WCSH
PRODUCT: MK-8591A  146
PROTOCOL/AMENDMENT NO.: 017-09
MK-8591A -017-09 FINAL PROTOCOL 26-MAR -2024
10.6 Appendix 6: Collection and Management of Specimens for Future Biomedical 
Research
1.Definitions
a.Biomarker: A biological molecule found in blood, other body fluids, or tissues that is 
a sign of a normal or abnormal process or of a condition or disease. A biomarker may 
be used to see how well the body responds to a treat ment for a disease or condition.1
b.Pharmacogenomics: The investigation of variations of DNA and RNA characteristics 
as related to drug/vaccine response.2
c.Pharmacogenetics: A subset of pharmacogenomics, pharmacogenetics is the influence 
of variations in DNA sequence on drug/vaccine response.2
d.DNA: Deoxyribonucleic acid.
e.RNA: Ribonucleic acid.
2.Scope of Future Biomedical Research
The specimens consented and/or collected in this study as outlined in Section 8. 9will be 
used in various experiments to understand:
The biology of how drugs/vaccines work
Biomarkers responsible for how a drug/vaccine enters and is removed by [CONTACT_10489]
Other pathways with which drugs/vaccines may interact
The biology of disease
The specimen(s) may be used for future assay development an d/or drug/vaccine 
development.
It is now well recognized that information obtained from studying and testing clinical 
specimens offers unique opportunities to enhance our understanding of how individuals 
respond to drugs/vaccines, enhance our understanding of human disease and ultimately 
improve public health through development of novel treatments targeted to populations 
with the greatest need. All specimens will be used by [CONTACT_63558].
08WCSH
PRODUCT: MK-8591A  147
PROTOCOL/AMENDMENT NO.: 017-09
MK-8591A -017-09 FINAL PROTOCOL 26-MAR -2024
3.Summary of Procedures for Fut ure Biomedical Research.
a.Participants for Enrollment
All participants enrolled in the clinical study will be considered for enrollment in 
future biomedical research.
b.Informed Consent
Informed consent for specimens (ie, DNA, RNA, protein, etc.) will be obtained 
during screening for protocol enrollment from all participants or legal guardians, at a 
study visit by [CONTACT_63559] d esignate. Informed consent for future 
biomedical r esearch should be presented to the participants on the visit d esignated in 
the SoA. If delayed, present consent at next possible Participant Visit. Consent forms 
signed by [CONTACT_88723].
A template of each study site’s approved info rmed consent will be stored in the 
Sponsor’s clinical document repository.
c.eCRF Documentation for Future Biomedical Research Specimens
Documentat ion of participant consent for future biomedical research will be captured 
in the eCRFs . Any specimens for whic h such an informed consent cannot be verified 
will be destroyed.
d.Future Biomedical Research Specimen(s)
Collection of specimens for future biomedical r esearch will be performed as outlined 
in the SoA. In general, if additional blood specimens ar e being collected for future 
biomedical r esearch, these will usually be obtained at a time when the participant is 
having blood drawn for other study purposes.
4.Confidential Participant Information for Future Biomedical Research
In order to optimize the resea rch that can be conducted with future biomedical r esearch 
specimens, it is critical to link participant' clinical information with future test results. In 
fact little or no research can be conducted without connecting the clinical study data to 
the specimen. The c linical data allow specific analyses to be conducted. Knowing 
participant characteristics like gender, ag e, medical history and intervention outcomes are 
critical to understanding clinical context of analytical results.
To maintain privacy of information c ollect ed from specimens obtained for future 
biomedical r esearch, the Sponsor has developed secure policies and procedures. All 
specimens will be single -coded per ICH E15 guidelines as described below.
08WCSH
PRODUCT: MK-8591A  148
PROTOCOL/AMENDMENT NO.: 017-09
MK-8591A -017-09 FINAL PROTOCOL 26-MAR -2024
At the clinical study site, unique codes will be placed on the future biomedical r esearch 
specimens. This code is a random number which does not contain any personally 
identifying information embedded within it. The link (or key) between participant 
identifiers and this unique code will be held at the study si te. No personal identifiers will 
appear on the specimen tube.
5.Biorepository Specimen Usage
Specimens obtained for the Sponsor will be used for analyses using good scientific 
practices. Analyses utilizing the future biomedical r esearch specimens may be perf ormed 
by [CONTACT_1034], or an additional third party (eg, a university investigator) designated by 
[CONTACT_1034]. The investigator conducting the analysis will follow the Sponsor’s privacy 
and confidentiality requirements. Any contracted third party analyses w ill conform to the 
specific scope o f analysis outlined in future biomedical research protocol and consent. 
Future biomedical r esearch specimens remaining with the third party after specific 
analysis is performed will be reported to the Sponsor.
6.Withdrawal From Future Biomedical Research
Participants may withdraw their consent for future biomedical r esearch and ask that thei r 
biospecimens not be used for future biomedical r esearch. Participants may withdraw 
consent at any time by [CONTACT_111954]. If medical records 
for the main study are still available, the investigator will contact [CONTACT_111972] (clinical.specimen.management@ MSD .com). Subsequently, the 
participant's specimens will be flagged in the b iorepository and restricted to main study 
use only. If specimens were collected from study participants specifically for future 
biomedical r esearch, these specimens will be removed from the biorepository and 
destroyed. Documentation will be sent to the inv estigator confirming withdrawal and/or 
destruction, if applicable. It is the responsibility of the investigator to inform the 
participant of completion of the withdrawal and/or destruction, if applicable. Any 
analyses in progress at the time of request for withdrawal/destruction or already 
performed prior to the request being received by [CONTACT_259711]. No new analyses would be generated 
after the request is received.
In the event that the medical records for the main study are no longer available (eg, if the 
investigator is no longer required by [CONTACT_111974]) or the specimens have been completely anonymized, there will no longer be a 
link between the participant’s personal information and their specimens. In this situation, 
the request for withdrawal of consent and/or destruction cannot be processed.
7.Retention of Specimens
Future biomedical r esearch specimens will be stored in the biorepository for potential 
analysis for up to [ADDRESS_916945]: MK-8591A  149
PROTOCOL/AMENDMENT NO.: 017-[ADDRESS_916946] results are accessible only to the 
authorized Spo nsor representatives and the designated study administrator research 
personnel and/or collaborators. Database user authentication is highly secure, and is 
accomplished using network security policies and practices based on international 
standards to protec t against unauthorized access.
9.Reporting of Future Biomedical Research Data to Participants
No information obtained from exploratory laboratory studies will be reported to the 
participant, family, or physicians. Principle reasons not to inform or return re sults to the 
participant include: Lack of relevance to participant health, limitations of predictive 
capability, and concerns regarding misinterpretation.
If important research findings are discovered, the Sponsor may publish results, present 
results in na tional meetings, and make results accessible on a public website in order to 
rapi[INVESTIGATOR_88651]. Participants will not be 
identified by [CONTACT_557459].
10. Future Biomedical Research Study Population
Every effort will be made to recruit all participants diagnosed and treated o n Sponsor 
clinical studies for f uture biomedical r esearch.
11.Risks Versus Benefits of Future Biomedical Research
For future biomedical research, risks to the participant have been mini mized and are 
described in the future biomedical r esearch informed consent.
The Sponsor has developed strict security, policies, and procedures to address participant 
data privacy concerns. Data privacy risks are largely limited to rare situations involving 
possible breach of confidentiality. In this highly unlikely situation, there is risk that the 
information, like all medical information, may be misused.
08WCSH
PRODUCT: MK-8591A  150
PROTOCOL/AMENDMENT NO.: 017-09
MK-8591A -017-09 FINAL PROTOCOL 26-MAR -2024
12.Questions
Any questio ns related to the future biomedical research should be e mailed directly to 
clinical.specimen.management@ MSD .com.
13.References
1.National Cancer Institute [Internet]: Available from 
https://www.cancer.gov/publications/dictionaries/cancer -terms?cdrid=[ZIP_CODE]
2.Inter national Council on Harmoni sation [Internet]: E15: Definitions for Genomic 
Biomarkers, Pharmacogenomics, Pharmacogenetics, Genomic Data and Sample 
Coding Categories. Available from 
http://www.ich.org/products/guidelines/efficacy/efficacy -single/article/def initions -
for-genomic -biomarkers- pharmacogenomics -pharmacogenetics -genomic -data-and-
sample -cod.html 
3.Industry Pharmacogenomics Working Group [Internet]: Understanding the Intent, 
Scope and Public Health Benefits of Exploratory Biomarker Research: A Guide fo r 
IRBs/IECs and Investigational Site Staff. Available at http://i -pwg.org/ 
4.Industry Pharmacogenomics Working Group [Internet]: Pharmacogenomics 
Informational Brochure for IRBs/IECs and Investigational Site Staff. Available at 
http://i- pwg.org/
08WCSH
PRODUCT: MK-8591A  151
PROTOCOL/AMENDMENT NO.: 017-09
MK-8591A -017-09 FINAL PROTOCOL 26-MAR -2024
10.7 Appendix 7: Country -specific Requirements
10.7.[ADDRESS_916947] for Japan
The baseline ART taken by [CONTACT_257671] 2 until Week 48 will be considered 
NIMPin Japan ,asthe ART will be a continuation of prestudy treatment (ie, the best 
therapy available to each participant) . These medications will be provided by [CONTACT_677722].
Changes to the protocol required per Japanese local regulation are documented in the 
translated version of the protocol that is filed locally.
10.7.[ADDRESS_916948] for Russia
Standard -of-care baseline ART taken by [CONTACT_257671] 2 until Week  48 is 
considered to be NIMPin Russia .
If a participant becomes pregnant (has a positive serum pregnancy test), DOR/ISL
must be dis continued and the participant’s HIV- [ADDRESS_916949] of care. Therefore, the following sections of the protocol 
are not applicable for participants receiving DOR/ISL :
oSection 4.2.7: Rationale for Continuing Study Intervention During Pregnancy
oSection [IP_ADDRESS]: Consent for Continuation of Study Intervention During 
Pregnancy
oSection 8.11.6 .1: Continuing Study Intervention
10.7.[ADDRESS_916950] for Canada
The baseline ART taken by [CONTACT_257671] 2 until We ek 48 will be considered 
NIMP in Canada , as the ART will be a continuation of prestudy treatment .
Participants who become HBsAg or HBV DNA positive after randomization must be 
discontinued from study intervention. This was included in a country- specific 
amendment (MK -8591A -017-01).
10.7.[ADDRESS_916951] for the [LOCATION_002]
[IP_ADDRESS] Plasma/PBMC PK Substudy
Aplasma/PBMC PK substudy will be conducted at selected sites in the [LOCATION_002] to 
measure ISL in plasma and ISL-TP in PBMCs to evaluate steady -state levels in participants
with HIV- [ADDRESS_916952]: MK-8591A  152
PROTOCOL/AMENDMENT NO.: 017-09
MK-8591A -017-09 FINAL PROTOCOL 26-MAR -2024
Participation in the substudy is optional (as described in Section [IP_ADDRESS].1) .
Approximately 12 DOR/ISL participants who provide documented informed consent willbe 
enrolled in the plasma/PBMC PK substudy. These participants may be enrolled from any of 
the 3 Phase 3 studies (MK- 8591A -017, - 018, and -033).
The b lood samples will be collected from the consented participant 20 to 24 hours after the ir
previous dose of DOR/ISL Table 18. Site staff will instruct participants to delay the
DOR/ISL dose to be taken on the day of this visit until after the blood sample sfor the 
substudy are collected .Site staff will record the date and time of the participants’ last dose of 
study intervention and the date and time of the blood sample collection in the appropriate 
eCRF.
Sample collection can occur at a scheduled or unscheduled visit. Site staff must follow the 
operations/laboratory manual for sample collection and handling.
[IP_ADDRESS].1 Consent to Participate in the Optional Plasma/PBMC PK Substudy
The investigator or medically qualified designee will explain the optional plasma/PBMC PK 
substudy to the participant, or the participant’s legally acceptable representative, answer all 
of his/her questions, and obtain documented informed consent before pe rforming any 
procedure related to the plasma/PBMC PK substudy . A copy of the documented informed 
consent will be given to the participant. After documented informed consent is obtained, the 
participant will have additional blood sample collection performed ,as described in 
Section [IP_ADDRESS].2. 
[IP_ADDRESS].2 Plasma/PBMC PK Substudy Procedures
Participants who provide documented informed consent to participate in the plasma/PBMC
PK substudy will have the procedures performed as described in Table 18andTable 19.
Table 18 Schedule of Activities for Participants in the Plasma/PBMC PK Substudy
Study Period Plasma/PBMC PK Substudy Notes
Visit NumberParticipant’s Next Routine Study Visit 
or Unscheduled
Scheduled Day/Week Plasma/PBMC PKSubstudy
Visit Window NA
Administrative Procedures
Informed Consent to Participate in the
Optional Plasma/PBMC SubstudyXSeeSection [IP_ADDRESS] .
1.
Pharmacokinetics 
Blood (Plasma) forISL PK X SeeSection [IP_ADDRESS].
Blood (PBMC) for ISL -TP PK X
ISL=islatravir; ISL-TP=islatravir- triphosphate; NA=not applicable; PBMC=peripheral blood mono nuclear cell; 
PK=pharmacokinetics.
08WCSH
PRODUCT: MK-8591A  153
PROTOCOL/AMENDMENT NO.: 017-09
MK-8591A -017-09 FINAL PROTOCOL 26-MAR -2024
Table 19 Blood Volumes: Plasma/PBMC PK Substudy
Visit Participant’s Next Routine Study Visit or 
Unscheduled
Sample Collection Timing Predose
Blood Parameter Approximate Blood Volume (mL)
Blood (Plasma) for ISL PK 3
Blood (PBMC) for ISL -TP PK 16
Overall Approximate Blood Volume for the Substudy 19
ISL=islatravir; ISL-TP=islatravir- triphosphate; PBMC=peripheral blood mono nuclear cell; PK=pharmacokinetics.
08WCSH
PRODUCT: MK-8591A  154
PROTOCOL/AMENDMENT NO.: 017-09
MK-8591A -017-09 FINAL PROTOCOL 26-MAR -2024
10.8 Appendix 8: Calculation of Creatinine Clearance
Cockcroft -Gault equations:
If male:
If female:
08WCSH
PRODUCT: MK-8591A  155
PROTOCOL/AMENDMENT NO.: 017-09
MK-8591A -017-09 FINAL PROTOCOL 26-MAR -2024
10.9 Appendix 9: Abbreviations
Abbreviation Expanded Term
β-hCG Beta human chorionic gonadotropin
3TC lamivudine
AE adverse event 
AIDS acquired immunodeficiency syndrome
ALT alanine aminotransferase
Anti-HBc hepatitis B core antibody
ANCOVA analysis of covariance
APaT All Participants as Treated
ART antiretroviral therapy
AST aspartate aminotransferase
AUC area under the curve
BMD bone mineral density
BMI body mass index
BOCF baseline observation carried forward
C24 concentration after 24 hours
CD4+ CD4 -positive
CI confidence interval
CONSORT Consolidated Standards of Reporting Trials
Cmax maximum (peak) observed drug plasma concentration
Crcl creatinine clearance
CRF Case Report Form 
CSR Clinical Study Report
CTFG Clinical Trial Facilitation Group 
Ctrough lowest concentration reached by a drug before the next dose is administered
DAIDS The Division of AIDS
DAO Data -As-Observed
DDI drug-drug interaction
DEXA Dual X -ray Absorptiometry
DMC Data Monitoring Committee 
DNA deoxyribonucleic acid 
DOR doravirine
ECG electrocardiogram 
ECI event of clinical interest
eCRF electronic Case Report Form
EDC electronic data collection 
eDMC External Data Monitoring Committee
EFV efavirenz
EMA European Medicines Agency
EOC Executive Oversight Committee 
EQ-5D-5L EuroQol 5-dimensional descriptive system, 5level version
EU European Union
FAS Full Analysis Set
FBR Future Biomedical Research
FDA Food and Drug Administration
FDAAA Food and Drug Administration Amendments Act
FDC fixed dose combination
FSH Follicle stimulating hormone 
FTC emtricitabine
GCP Good Clinical Practice 
H hypothesis
08WCSH
PRODUCT: MK-8591A  156
PROTOCOL/AMENDMENT NO.: 017-09
MK-8591A -017-09 FINAL PROTOCOL 26-MAR -2024
Abbreviation Expanded Term
HBc hepatitis B core
HBsAg hepatitis B surface antigen
HBV hepatitis B virus
HCV hepatitis C virus
HDL -C high-density lipoprotein cholesterol
HIV human immunodeficiency virus
HIV SDM Human Immunodeficiency Virus Symptom Distress Module
HIV-SI Human Immunodeficiency Virus Symptom Index
HIVTSQ Human Immunodeficiency Virus Treatment Satisfaction Questionnaire
HOMA -IR Homeostatic Model Assessment of Insulin Resistance
HRQoL health -related quality of life
HRT hormone replacement therapy
hs-CRP high-sensitivity C -reactive protein
HTA Health Technology Assessment
IB Investigator’s Brochure 
IC50 concentration of drug needed to inhibit 50% of viral growth
ICF Informed Consent Form 
ICH International Co uncil for Harmonisation of Technical Requirements for 
Pharmaceuticals for Human Use
IEC Independent Ethics Committee
IL-[ADDRESS_916953]
M=F missing data treated as treatment failure
NIMP Non-Investigational Medicinal Product
NK natural killer
NNRTI non-nucleoside reverse transcriptase inhibitor 
NRTI nucleoside analog reverse transcriptase inhibitor
NRTTI nucleoside reverse transcriptase translocation inhibitor
OF Observed Failure
PBMC peripheral blood mono nuclear cell
PCR polymerase chain reaction
PDLC predefined limit of change
PI [INVESTIGATOR_677677]-Protocol
PrEP preexposure prophylaxis
PRO patient -reported outcome
QD once daily
RNA ribonucleic acid
SAC Scientific Advisory Committee
SAE serious adverse event 
sCD-[ADDRESS_916954]: MK-8591A  157
PROTOCOL/AMENDMENT NO.: 017-09
MK-8591A -017-09 FINAL PROTOCOL 26-MAR -2024
Abbreviation Expanded Term
SoA schedule of activities
SOC System Organ Class
sSAP supplemental statistical analysis plan
S[LOCATION_003]R suspected unexpected serious adverse reaction
TAF tenofovir alafenamide
TAMs thymidine analog mutations
TBNK T-and B -Lymphocyte and Natural Killer
TC total cholesterol
TDF tenofovir disoproxil fumarate
TG triglyceride
TLOVR Time to Loss of Virologic Response
TP triphosphate
WHO World Health Organization
US [LOCATION_002]
WOCBP woman/women of childbearing potential 
WONCBP woman/women of nonchildbearing potential
08WCSH
PRODUCT: MK-8591A  158
PROTOCOL/AMENDMENT NO.: 017-09
MK-8591A -017-09 FINAL PROTOCOL 26-MAR -2024
10.10 Appendix 10: Summary of Protocol Clarification Letter
The following PCLs changes were not implemented:
Protocol PCL date Correction s not implemented in a subsequent amendment Impact
P017 03-JUN-2021 Add a reference to Appendix 3: DAIDS criteria for the 
assessment of AEs that are pregnancy -related complication.
DAIDS table version 2.1 “Addendum 1: Female Genital 
Grading Table for Use in Microbicide Studies”, particularly 
the section “Complications of Pregnancy” (found on pages 
11-12 of the Addendum): 
https://rsc.niaid.nih.gov/sites/default/files/addendum -1-
female -genital -grading -table- v1-nov-2007.pdfStudy conduct, 
assessment  of 
AEs, no 
pregnant 
participants 
continued study 
intervention
P017 29-OCT -2021 Add the following text to Section 8.2.2 “participants with 
confirmed HIV -1 RNA>200 copi[INVESTIGATOR_014]/mL  at any time during 
the study will be assessed for development of drug 
resistance”Study conduct, 
however , no 
participants 
remain on study 
intervention.
AE=adverse event ; DAIDS=Division of AIDS; HIV=Human immunodeficiency virus; PCL=protocol 
clarification letter ; RNA=  ribonucleic acid
08WCSH
PRODUCT: MK-8591A  159
PROTOCOL/AMENDMENT NO.: 017-09
MK-8591A -017-09 FINAL PROTOCOL 26-MAR -2024
11 REFERENCES
[AIDS info 2017] AIDS info. Guidelines for the use of 
antiretroviral agents in HIV -1-Infected adults 
and adolescents [Internet]. Rockville, MD: 
AIDS info; 2017. Available from: 
http://aidsinfo.nih.gov/guidelines.[04LV4N]
[Baker, J. V., et al 
2011]Baker JV, Neuhaus J, Duprez D, Kul ler LH, 
Tracy R, Belloso WH, De Wit S. et al. Changes 
in inflammatory and coagulation biomarkers: a 
randomized comparison of immediate versus 
deferred antiretroviral therapy in patients with 
HIV infection. J Acquir Immune Defic Syndr. 
2011 Jan 1;56(1):36 -43.[04MWL0]
[Burger, D., et al 
2005]Burger D, van der Heiden I, la Porte C, van der 
Ende M, Groeneveld P, Richter C, et al. 
Interpatient variability in the pharmacokinetics 
of the HIV non -nucleoside reverse transcriptase 
inhibitor efavirenz: the effect o f gender, race, 
and CYP2B6 polymorphism. Br J Clin 
Pharmacol. 2005;61(2):148 -54.[057GSX]
[Cahn, P., et al 2019] Cahn P, Madero JS, Arribas JR, Antinori A, 
Ortiz R, Clarke AE, et al. Dolutegravir plus 
lamivudine versus dolutegravir plus tenofovir 
disoprox il fumarate and emtricitabine in 
antiretroviral -naive adults with HIV -1 infection 
(GEMINI -1 and GEMINI -2): week 48 results 
from two multicentre, double -blind, 
randomised, non- inferiority, phase 3 trials. 
Lancet. 2019 Jan 12;393:143- 55.[054KXQ]
[Carr, A., et al 1998] Carr A, Samaras K, Burton S, Law M, Freund 
J, Chisholm DJ, et al. A syndrome of peripheral 
lipodystrophy, hyperlipi[INVESTIGATOR_677678]. AIDS 1998;12(7):F51 -F58.[03Q6RY]
[Centers for Dis ease 
Control (CDC) 1992]Centers for Disease Control (CDC). 1993 
Revised classification system for HIV infection 
and expanded surveillance case definition for 
AIDS among adolescents and adults. MMWR 
1992;41(RR -17):1- 17.[03RH6J]
08WCSH
PRODUCT: MK-8591A  160
PROTOCOL/AMENDMENT NO.: 017-09
MK-8591A -017-09 FINAL PROTOCOL 26-MAR -2024
[Centers for Disease 
Control and 
Prevention 2019]Centers for Disease Control and Prevention. 
HIV and transgender communities. Atlanta 
(GA): U.S. Department of Health and Human 
Services (HHS); 2019 Apr; 4 p.[05BCMG]
[Charpentier, C., et al 
2014]Charpentier C, Choque t M, Joly V, Yeni P, 
Visseaux B, Caseris M, et al. Virological 
outcome at week [ADDRESS_916955];69(10):2819- 25.[04PYMQ]
[Clopper, C. J. and
Pearson, E. S. 1934]Clopper CJ, Pearson ES. The use of confidence 
or fiducial limits illustrated in the case of the 
binomial. Biometrika 1934;26(4):404- 13.[00V5VX]
[Department of 
HIV/AIDS 2015]Department of HIV/AIDS. Transgender people 
and HIV. Geneva (Switzerland): World Health 
Organization (WHO); 2015 Jul. 32 p.[05BDGP]
[European AIDS 
Clinical Society 2016]European AIDS Clinical Society (EACS). 
Guidelines - Version 8.1 October 2016 
[Internet]. Brussels, Belgium; 2016. Available 
from: 
http://www.ea csociety.org/files/guidelines_8.1 -
english.pdf.[04MN4Z]
[Food and Drug 
Administration 
(CDER) 2015]Food and Drug Administration (CDER). 
Human Immunodeficiency Virus -1 Infection: 
Developi[INVESTIGATOR_677679] [Internet]. Silver Spring, 
MD: U.S. Department of Health and Human 
Services; 2015. Available from: 
https://www.fda.gov/downloads/drugs/guidanc
ecomplianceregulatoryinformation/guidances/u
cm355128.pdf.[04MT4V]
[Hill, A., et al 2019] Hill A, Waters L, Pozni ak A. Are new 
antiretroviral treatments increasing the risks of 
clinical obesity? J Virus Erad. 2019;5:41 -3.[058G5N]
08WCSH
PRODUCT: MK-8591A  161
PROTOCOL/AMENDMENT NO.: 017-09
MK-8591A -017-09 FINAL PROTOCOL 26-MAR -2024
[Joint United Nations 
Programme on 
HIV/AIDS 2017]Joint United Nations Programme on HIV/AIDS 
(UNAIDS). Ending AIDS: progress towards 
the 90- 90-90 targets. Slides presented at: 9th 
International AIDS Society (IAS) Conference 
on HIV Science; 2017 Jul 23 -26; Paris 
([LOCATION_009]).[058SY8]
[Knudsen, T. B., et al 
2016]Knudsen TB, Ertner G, Petersen J, Moller HJ, 
Moestrup SK, Eugen -Olsen J. et al. Pl asma 
Soluble CD163 Level Independently Predicts 
All-Cause Mortality in HIV -1-Infected 
Individuals. J Infect Dis. [ADDRESS_916956] 
15;214(8):1198- 204.[04MWL7]
[Llibre, J. M., et al 
2018]Llibre JM, Hung CC, Brinson C, Castelli F, 
Girard PM, Kahl LP, et al. Effica cy, safety, and 
tolerability of dolutegravir -rilpi[INVESTIGATOR_677680]- 1: phase 3, randomised, non-
inferiority SWORD -[ADDRESS_916957] -2 studies. 
Lancet. 2018 Mar 3;391:839 -49. Erratum in: 
Lancet. 2018 Feb 1.[0528SS]
[Michailidis E 2014] Michailidis E, et al. 4- Ethynyl -2-fluoro-2-
deoxyadenosine (EFdA) Inhibits HIV -1 
Reverse Transcriptase with Multiple 
Mechanisms. J Biol Chem 2014; 
289(35):[ZIP_CODE] -[ZIP_CODE].[04PXGP]
[Miettinen, O. and 
Nurminen, M. 1985]Miettinen O, Nurminen M. Comparative 
analysis of two rates. Statist Med 1985;4:213-
26.[00W9P2]
[Molina, J. M., et al 
2018]Molina JM, Squires K, Sax PE, Cahn P, 
Lombaard J, DeJesus E, et al. Doravirine 
versus ritonavir -boosted darunavir in 
antiretroviral -naive adults with HIV -1 
(DRIVE -FORWARD): 48 -week results of a 
randomised, double -blind, phase 3, non -
inferiority trial. Lancet HIV. In press 2018.[04WHL3]
08WCSH
PRODUCT: MK-8591A  162
PROTOCOL/AMENDMENT NO.: 017-09
MK-8591A -017-09 FINAL PROTOCOL 26-MAR -2024
[Orkin, C., et al 2018] Orkin C, Squires KE, Molina JM, Sax PE, 
Wong WW, Sussmann O, et al. 
Doravi rine/lamivudine/tenofovir disoproxil 
fumarate is non- inferior to 
efavirenz/emtricitabine/tenofovir disoproxil 
fumarate in treatment -naive adults with human 
immunodeficiency virus- 1 infection: week [ADDRESS_916958] 
Dis. In pr ess 2018.[050SC7]
[Panel on 
Antiretroviral 
Guidelines for Adults 
and Adolescents 
2018]Panel on Antiretroviral Guidelines for Adults 
and Adolescents. Guidelines for the use of 
antiretroviral agents in adults and adolescents 
living with HIV: Oct 2018. Was hington (DC): 
U.S. Department of Health and Human 
Services (HHS); [last updated: [ADDRESS_916959] 25]. 
331 p.[053CRN]
[Panel on Treatment 
of Pregnant Women 
with HIV Infection 
and Prev 2018]Panel on Treatment of Pregnant Women with 
HIV Infection and Prevention of Perinatal 
Transmission. Recommendations for the use of 
antiretroviral drugs in pregnant women with 
HIV infection and interventions to reduce 
perinatal HIV transmission in the United 
States: Dec 2018. Washington (DC): 
Department of Health and Human Services 
(HHS). [Last updated: 2018 Dec 7]. 365 p.[05BXZW]
[Poteat, T., et al 2016] Poteat T, Scheim A, Xavier J, Reisner S, Baral 
S. Global epi[INVESTIGATOR_181767]. 
J Acquir Immune Defic Syndr. 2016 Aug 
15;72(suppl 3):S210- 9.[05BDHN]
[Ribaudo, H. J., et al 
2013]Ribaudo HJ, Smith KY, Robbins GK, Flexner 
C, Haubrich R, Chen Y, et al. Racial 
differences in response to antiretroviral therapy 
for HIV infection: an AIDS Clinical Trials 
Group (AC TG) study analysis. Clin Infect Dis. 
2013 Dec 1;57(11):1607 -17.[057GSZ]
08WCSH
PRODUCT: MK-8591A  163
PROTOCOL/AMENDMENT NO.: 017-09
MK-8591A -017-09 FINAL PROTOCOL 26-MAR -2024
[Trickey, A., et al 
2017]Trickey A, May MT, Vehreschild JJ, Obel N, 
Gill MJ, Crane HM, et al. Survival of HIV -
positive patients starting antiretroviral therapy 
between 1996 and 2013 : a collaborative 
analysis of cohort studies. Lancet HIV. 2017 
Aug;4:e349- 56.[055HR8]
[U.S. Prescribing 
Information 2017]U.S. Prescribing Information: SUSTIVA 
(efavirenz) capsules for oral use; SUSTIVA 
(efavirenz) tablets for oral use: Oct 2017.[04VGFN]
[U.S. Prescribing 
Information 2019]U.S. Prescribing Information: VIREAD 
(tenofovir disoproxil fumarate) tablets, for oral 
use; VIREAD (tenofovir disoproxil fumarate) 
powder, for oral use: Apr 2019.[057N3H]
[Vandenhende, M. A., 
et al 2015]Vandenhende MA, Ingle S, May M, Chene G, 
Zangerle R, Van Sighem A, et al. Impact of 
low-level viremia on clinical and virological 
outcomes in treated HIV -1-infected patients. 
AIDS. 2015;29(3):373 -83.[056V0P]
[Vazquez- Carrera, M. 
2016]Vazquez -Carrera M. Unraveling the effects of 
PPARbeta/delta on insulin resistance and 
cardiovascular disease. Trends Endocrinol 
Metab. 2016 May;27(5):319 -34.[058MZ6]
[Wang, H., et al 2016] Wang H, Lu X, Yang X, Xu N. The efficacy 
and safety of tenofovir alafenamide versus 
tenofovir disoproxil fumarate in antiretroviral 
regimens for HIV -1 therapy: Meta -analysis. 
Medicine (Baltimore). [ADDRESS_916960];95(41):e5146.[04MWLQ]
[Weintrob, A. C., et al 
2009]Weintrob AC, Grandits GA, Agan BK, 
Ganesan A, Landrum ML, Crum -Cianflone NF, 
et al. Virologic response differences between 
African Americans and European Americans 
initiating highly active antiretroviral therapy 
with equal access to care. J Acquir Immune 
Defic Syndr. 2009 Dec 15;52(5):574- 80.[0576P6]
08WCSH
PRODUCT: MK-8591A  164
PROTOCOL/AMENDMENT NO.: 017-09
MK-8591A -017-09 FINAL PROTOCOL 26-MAR -2024
[World Health 
Organization 2016]World Health Organization (WHO). 
Consolidated guidelines on the use of 
antiretroviral drugs for treating and preventing 
HIV infection 2016: recommendations for a 
public health approach, second edition 2016 
[Internet]. Geneva, Switzerland: WHO; 2016. 
Available from: 
http://apps.who.int/iris/bitstream/[ZIP_CODE]/208825
/1/9789241549684_eng.pdf.[04MN5R]
08WCSH